
<html lang="en"     class="pb-page"  data-request-id="d5519db0-9164-4f14-b5e3-71b051a0491b"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";requestedJournal:journal:jmcmar;journal:journal:jmcmar;page:string:Article/Chapter View;ctype:string:Journal Content;article:article:10.1021/jm200682b;wgroup:string:ACHS website Group;website:website:acspubs;issue:issue:10.1021/jmcmar.2011.54.issue-18;pageGroup:string:Publication Pages;subPage:string:Full Text"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="dc.Title" content="Design and Synthesis of Novel Arylpiperazine Derivatives Containing the Imidazole Core Targeting 5-HT2A Receptor and 5-HT Transporter" /></meta><meta name="dc.Creator" content="Hee Jeong  Seo" /></meta><meta name="dc.Creator" content="Eun-Jung  Park" /></meta><meta name="dc.Creator" content="Min Ju  Kim" /></meta><meta name="dc.Creator" content="Suk Youn  Kang" /></meta><meta name="dc.Creator" content="Suk Ho  Lee" /></meta><meta name="dc.Creator" content="Hyun Jung  Kim" /></meta><meta name="dc.Creator" content="Ki Nam  Lee" /></meta><meta name="dc.Creator" content="Myung Eun  Jung" /></meta><meta name="dc.Creator" content="MinWoo  Lee" /></meta><meta name="dc.Creator" content="Mi-Soon  Kim" /></meta><meta name="dc.Creator" content="Eun-Jung  Son" /></meta><meta name="dc.Creator" content="Woo-Kyu  Park" /></meta><meta name="dc.Creator" content="Jeongmin  Kim" /></meta><meta name="dc.Creator" content="Jinhwa  Lee" /></meta><meta name="dc.Description" content="Serotonin antagonist reuptake inhibitor (SARI) drugs that block both 5-HT2 receptors and the serotonin transporters have been developed. The human 5-HT2A/2C receptor has been implicated in several ..." /></meta><meta name="Description" content="Serotonin antagonist reuptake inhibitor (SARI) drugs that block both 5-HT2 receptors and the serotonin transporters have been developed. The human 5-HT2A/2C receptor has been implicated in several ..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="August 23, 2011" /></meta><meta name="dc.Type" content="research-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/jm200682b" /></meta><meta name="dc.Language" content="EN" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="Â© 2011 American Chemical Society" /></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Fjm200682b" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Fjm200682b" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Fjm200682b" /></link>
        
    
    

<title>Design and Synthesis of Novel Arylpiperazine Derivatives Containing the Imidazole Core Targeting 5-HT2A Receptor and 5-HT Transporter | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/jm200682b" /></meta><meta property="og:title" content="Design and Synthesis of Novel Arylpiperazine Derivatives Containing the Imidazole Core Targeting 5-HT2A Receptor and 5-HT Transporter" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-18/jm200682b/production/images/large/jm-2011-00682b_0022.jpeg" /></meta><meta property="og:description" content="Serotonin antagonist reuptake inhibitor (SARI) drugs that block both 5-HT2 receptors and the serotonin transporters have been developed. The human 5-HT2A/2C receptor has been implicated in several neurological conditions, and potent selective 5-HT2A/2C ligands may have therapeutic potential for treatment of CNS diseases such as depression. An imidazole moiety usually provides good pharmacokinetic properties as a drug substance, and thus considerable efforts have been devoted to develop imidazole derivatives into drug candidates. The imidazole series of compounds was evaluated against 5-HT2A/2C and serotonin reuptake inhibition. A few of the compounds in the series showed promising IC50 values and antidepressant-like effect in in vivo forced swimming test (FST). On the basis of these results, further lead optimization studies resulted in identifying promising compounds potentially for therapeutic use." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/jm200682b"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/jm200682b">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=âtrueâ></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=âtrueâ></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=âtrueâ></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=âtrueâ></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-15/achre4.2021.54.issue-15/20210803/achre4.2021.54.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-7/amrcda.2021.2.issue-7/20210723/amrcda.2021.2.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-7/aabmcb.2021.4.issue-7/20210719/aabmcb.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-7/aaembp.2021.3.issue-7/20210727/aaembp.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-7/aaemcq.2021.4.issue-7/20210726/aaemcq.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-30/aamick.2021.13.issue-30/20210804/aamick.2021.13.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-7/aanmf6.2021.4.issue-7/20210723/aanmf6.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-14/accacs.2021.11.issue-14/20210716/accacs.2021.11.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-7/acscii.2021.7.issue-7/20210728/acscii.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-7/acbcct.2021.16.issue-7/20210716/acbcct.2021.16.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-4/achsc5.2021.28.issue-4/20210726/achsc5.2021.28.issue-4.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-15/acncdm.2021.12.issue-15/20210804/acncdm.2021.12.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-7/aesccq.2021.5.issue-7/20210715/aesccq.2021.5.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-6/afsthl.2021.1.issue-6/20210716/afsthl.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-7/amlccd.2021.10.issue-7/20210720/amlccd.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-8/amlcef.2021.3.issue-8/20210802/amlcef.2021.3.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-7/ancac3.2021.15.issue-7/20210727/ancac3.2021.15.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-30/acsodf.2021.6.issue-30/20210803/acsodf.2021.6.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-7/apchd5.2021.8.issue-7/20210721/apchd5.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-7/ascefj.2021.6.issue-7/20210723/ascefj.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-30/ascecg.2021.9.issue-30/20210802/ascecg.2021.9.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-7/asbcd6.2021.10.issue-7/20210716/asbcd6.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-30/ancham.2021.93.issue-30/20210803/ancham.2021.93.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-30/bichaw.2021.60.issue-30/20210803/bichaw.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-7/bcches.2021.32.issue-7/20210721/bcches.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-28/cgeabj.2021.99.issue-28/20210802/cgeabj.2021.99.issue-28.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-7/crtoec.2021.34.issue-7/20210719/crtoec.2021.34.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-14/chreay.2021.121.issue-14/20210728/chreay.2021.121.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-14/cmatex.2021.33.issue-14/20210727/cmatex.2021.33.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-8/cgdefu.2021.21.issue-8/20210804/cgdefu.2021.21.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-14/enfuem.2021.35.issue-14/20210715/enfuem.2021.35.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-15/esthag.2021.55.issue-15/20210803/esthag.2021.55.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-30/iecred.2021.60.issue-30/20210804/iecred.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-15/inocaj.2021.60.issue-15/20210802/inocaj.2021.60.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-7/jaaucr.2021.1.issue-7/20210726/jaaucr.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-30/jafcau.2021.69.issue-30/20210804/jafcau.2021.69.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-7/jcisd8.2021.61.issue-7/20210726/jcisd8.2021.61.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/jmcmar.2021.64.issue-14/20210722/jmcmar.2021.64.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-7/jnprdf.2021.84.issue-7/20210723/jnprdf.2021.84.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-14/joceah.2021.86.issue-14/20210716/joceah.2021.86.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-29/jpcafh.2021.125.issue-29/20210729/jpcafh.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-29/jpcbfk.2021.125.issue-29/20210729/jpcbfk.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-29/jpccck.2021.125.issue-29/20210729/jpccck.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-29/jpclcd.2021.12.issue-29/20210729/jpclcd.2021.12.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-30/jacsat.2021.143.issue-30/20210804/jacsat.2021.143.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-8/jamsef.2021.32.issue-8/20210804/jamsef.2021.32.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-30/langd5.2021.37.issue-30/20210803/langd5.2021.37.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-14/mamobx.2021.54.issue-14/20210727/mamobx.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-8/mpohbp.2021.18.issue-8/20210802/mpohbp.2021.18.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-14/nalefd.2021.21.issue-14/20210728/nalefd.2021.21.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-14/orlef7.2021.23.issue-14/20210716/orlef7.2021.23.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-7/oprdfk.2021.25.issue-7/20210716/oprdfk.2021.25.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-14/orgnd7.2021.40.issue-14/20210726/orgnd7.2021.40.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Fjm200682b&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Fjm200682b&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/jm200682b&amp;href=/doi/10.1021/jm200682b" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2011</span><span class="cit-fg-volume">, 54</span><span class="cit-fg-issue">, 18</span><span class="cit-fg-pageRange">, 6305-6318</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/54/18" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/jm200662c" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Article</span><a href="/doi/10.1021/jm200692n" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Design and Synthesis of Novel Arylpiperazine Derivatives Containing the Imidazole Core Targeting 5-HT<sub>2A</sub> Receptor and 5-HT Transporter</span></h1><ul class="loa non-jats-loa"><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Hee+Jeong++Seo">Hee Jeong Seo</a></span><span class="author-xref-symbol author-aff-symbol"><sup>â </sup></span></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Eun-Jung++Park">Eun-Jung Park</a></span><span class="author-xref-symbol author-aff-symbol"><sup>â </sup></span></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Min+Ju++Kim">Min Ju Kim</a></span><span class="author-xref-symbol author-aff-symbol"><sup>â </sup></span></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Suk+Youn++Kang">Suk Youn Kang</a></span><span class="author-xref-symbol author-aff-symbol"><sup>â </sup></span></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Suk+Ho++Lee">Suk Ho Lee</a></span><span class="author-xref-symbol author-aff-symbol"><sup>â </sup></span></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Hyun+Jung++Kim">Hyun Jung Kim</a></span><span class="author-xref-symbol author-aff-symbol"><sup>â </sup></span></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Ki+Nam++Lee">Ki Nam Lee</a></span><span class="author-xref-symbol author-aff-symbol"><sup>â </sup></span></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Myung+Eun++Jung">Myung Eun Jung</a></span><span class="author-xref-symbol author-aff-symbol"><sup>â </sup></span></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=MinWoo++Lee">MinWoo Lee</a></span><span class="author-xref-symbol author-aff-symbol"><sup>â </sup></span></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Mi-Soon++Kim">Mi-Soon Kim</a></span><span class="author-xref-symbol author-aff-symbol"><sup>â </sup></span></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Eun-Jung++Son">Eun-Jung Son</a></span><span class="author-xref-symbol author-aff-symbol"><sup>â </sup></span></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Woo-Kyu++Park">Woo-Kyu Park</a></span><span class="author-xref-symbol author-aff-symbol"><sup>â¡</sup></span></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Jeongmin++Kim">Jeongmin Kim</a></span><span class="author-xref-symbol author-aff-symbol"><sup>â </sup></span></span></li><span class="comma-separator">,Â andÂ </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Jinhwa++Lee">Jinhwa Lee</a></span><span class="author-xref-symbol "><sup>*</sup></span><span class="author-xref-symbol author-aff-symbol"><sup>â </sup></span></span></li><span class="comma-separator"></span></ul><div class="affiliations"><div class="view-affs"><span class="title">View Author Information</span><i class="caret-icon icon-angle-down"></i></div><div class="all-aff-infos hlFld-Affiliation"><div class="aff-info" id="aff1"><span class="aff-text">Research Center, Green Cross Corporation, 303 Bojeong-dong, Giheung-gu, Yongin 446-770, Korea</span></div><div class="aff-info" id="aff2"><span class="aff-text">Pharmacology Research Center, Korea Research Institute of Chemical Technology, 100 Jang-Dong, Yuseong-Gu, Daejeon 305-343, Korea</span></div><div class="corresp-info">Phone: +82-31-260-9892. Fax: +82-31-260-9020. E-mail: <a href="/cdn-cgi/l/email-protection#650f0c0b0d120409000025021700000b06170a16164b060a08"><span class="__cf_email__" data-cfemail="d1bbb8bfb9a6b0bdb4b491b6a3b4b4bfb2a3bea2a2ffb2bebc">[emailÂ protected]</span></a></div></div></div><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Fjm200682b&amp;href=/doi/10.1021%2Fjm200682b" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2011</span></span><span class="cit-volume">, 54</span><span class="cit-issue">, 18</span><span class="cit-pageRange">, 6305â6318</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">August 8, 2011</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>30 May 2011</li><li><span class="item_label"><b>Published</b> online</span>23 August 2011</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 22 September 2011</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/jm200682b" title="DOI URL">https://doi.org/10.1021/jm200682b</a></div><div class="article_header-article-copyright"><strong>Copyright Â© 2011 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D6305%26pageCount%3D14%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DHee%2BJeong%2BSeo%252C%2BEun-Jung%2BPark%252C%2BMin%2BJu%2BKim%252C%2Bet%2Bal%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D54%26issueNum%3D18%26contentID%3Djm200682b%26title%3DDesign%2Band%2BSynthesis%2Bof%2BNovel%2BArylpiperazine%2BDerivatives%2BContaining%2Bthe%2BImidazole%2BCore%2BTargeting%2B5-HT2A%2BReceptor%2Band%2B5-HT%2BTransporter%26numPages%3D14%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D6318%26publicationDate%3DSeptember%2B2011">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/jm200682b"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">2202</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val"><a href="#citeThis" class="internalNav">27</a></div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/jm200682b" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Design and Synthesis of Novel Arylpiperazine Derivatives Containing the Imidazole Core Targeting 5-HT2A Receptor and 5-HT Transporter&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Hee&quot;,&quot;last_name&quot;:&quot;Jeong Seo&quot;},{&quot;first_name&quot;:&quot;Eun-Jung&quot;,&quot;last_name&quot;:&quot;Park&quot;},{&quot;first_name&quot;:&quot;Min&quot;,&quot;last_name&quot;:&quot;Ju Kim&quot;},{&quot;first_name&quot;:&quot;Suk&quot;,&quot;last_name&quot;:&quot;Youn Kang&quot;},{&quot;first_name&quot;:&quot;Suk&quot;,&quot;last_name&quot;:&quot;Ho Lee&quot;},{&quot;first_name&quot;:&quot;Hyun&quot;,&quot;last_name&quot;:&quot;Jung Kim&quot;},{&quot;first_name&quot;:&quot;Ki&quot;,&quot;last_name&quot;:&quot;Nam Lee&quot;},{&quot;first_name&quot;:&quot;Myung&quot;,&quot;last_name&quot;:&quot;Eun Jung&quot;},{&quot;first_name&quot;:&quot;MinWoo&quot;,&quot;last_name&quot;:&quot;Lee&quot;},{&quot;first_name&quot;:&quot;Mi-Soon&quot;,&quot;last_name&quot;:&quot;Kim&quot;},{&quot;first_name&quot;:&quot;Eun-Jung&quot;,&quot;last_name&quot;:&quot;Son&quot;},{&quot;first_name&quot;:&quot;Woo-Kyu&quot;,&quot;last_name&quot;:&quot;Park&quot;},{&quot;first_name&quot;:&quot;Jeongmin&quot;,&quot;last_name&quot;:&quot;Kim&quot;},{&quot;first_name&quot;:&quot;Jinhwa&quot;,&quot;last_name&quot;:&quot;Lee&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2011&quot;,&quot;month&quot;:&quot;08&quot;,&quot;day&quot;:&quot;23&quot;,&quot;issue&quot;:&quot;18&quot;,&quot;volume&quot;:&quot;54&quot;,&quot;pages&quot;:&quot;6305-6318&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/jm200682b&quot;},&quot;abstract&quot;:&quot;Serotonin antagonist reuptake inhibitor (SARI) drugs that block both 5-HT2 receptors and the serotonin transporters have been developed. The human 5-HT2A/2C receptor has been implicated in several neurological conditions, and potent selective 5-HT2A/2C ligands may have therapeutic potential for treatment of CNS diseases such as depression. An imidazole moiety usually provides good pharmacokinetic properties as a drug substance, and thus considerable efforts have been devoted to develop imidazole derivatives into drug candidates. The imidazole series of compounds was evaluated against 5-HT2A/2C and serotonin reuptake inhibition. A few of the compounds in the series showed promising IC50 values and antidepressant-like effect in in vivo forced swimming test (FST). On the basis of these results, further lead optimization studies resulted in identifying promising compounds potentially for therapeutic use.&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Fjm200682b&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=jm200682b" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Fjm200682b&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=jm200682b" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Fjm200682b&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=jm200682b" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Fjm200682b&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=jm200682b&amp;href=/doi/10.1021/jm200682b" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/jm200682b" /></input><a href="/doi/pdf/10.1021/jm200682b" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (2 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/jm200682b&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Fjm200682b%26sid%3Dliteratum%253Aachs%26pmid%3D21823597%26genre%3Darticle%26aulast%3DSeo%26date%3D2011%26atitle%3DDesign%2Band%2BSynthesis%2Bof%2BNovel%2BArylpiperazine%2BDerivatives%2BContaining%2Bthe%2BImidazole%2BCore%2BTargeting%2B5-HT2A%2BReceptor%2Band%2B5-HT%2BTransporter%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D54%26issue%3D18%26spage%3D6305%26epage%3D6318%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div><div class="article_header-suppInfo pull-left"><i class="icon-supporting-info"></i><span class="article_header-suppInfo-text">Supporting Info (1)</span><span class="article_header-suppInfo-arrow">Â»</span><a href="#" data-slide-target=".tab__pane-suppInfo" title="Supporting Information" class="article_header-suppInfo-link-mobile hidden-sm hidden-md hidden-lg w-slide__btn">Supporting Information
                </a><a href="#article_content-right" title="Supporting Information" data-scrollDuration="1000" class="article_header-suppInfo-link internalNav hidden-xs">Supporting Information
                </a></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=292461" title="Neurophysiology">Neurophysiology</a>,</li><li><a href="/action/doSearch?ConceptID=292464" title="Rodent models">Rodent models</a>,</li><li><a href="/action/doSearch?ConceptID=291793" title="Inhibition">Inhibition</a>,</li><li><a href="/action/doSearch?ConceptID=292253" title="Imidazoles">Imidazoles</a>,</li><li><a href="/action/doSearch?ConceptID=292186" title="Receptors">Receptors</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/54/18" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-18/jmcmar.2011.54.issue-18/production/jmcmar.2011.54.issue-18.largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="f_tgr1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-18/jm200682b/production/images/medium/jm-2011-00682b_0022.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-18/jm200682b/production/images/large/jm-2011-00682b_0022.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm200682b&amp;id=f_tgr1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">Serotonin antagonist reuptake inhibitor (SARI) drugs that block both 5-HT<sub>2</sub> receptors and the serotonin transporters have been developed. The human 5-HT<sub>2A/2C</sub> receptor has been implicated in several neurological conditions, and potent selective 5-HT<sub>2A/2C</sub> ligands may have therapeutic potential for treatment of CNS diseases such as depression. An imidazole moiety usually provides good pharmacokinetic properties as a drug substance, and thus considerable efforts have been devoted to develop imidazole derivatives into drug candidates. The imidazole series of compounds was evaluated against 5-HT<sub>2A/2C</sub> and serotonin reuptake inhibition. A few of the compounds in the series showed promising IC<sub>50</sub> values and antidepressant-like effect in in vivo forced swimming test (FST). On the basis of these results, further lead optimization studies resulted in identifying promising compounds potentially for therapeutic use.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li><li><i class="icon-supporting-info"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i1">Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_10757" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_10757" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Depression, especially major depression, is an extremely serious disease affecting about 121 million people and is one of the leading causes of disability worldwide. And unipolar depression is predicted to be the second main cause of disability in 2020 by the World Health Organization.<a onclick="showRef(event, 'ref1 ref2'); return false;" href="javascript:void(0);" class="ref ref1 ref2">(1, 2)</a> Over the past several decades, the synaptic actions of monoamine neurotransmitters such as norepinephrine (NE) and serotonin (SER, 5-HT) were considered as important indications to psychiatric disease, including anxiety and depression.<a onclick="showRef(event, 'ref3 ref4'); return false;" href="javascript:void(0);" class="ref ref3 ref4">(3, 4)</a> Various psychotropic drugs which are associated with these neurotransmitters have been individually developed. Selective serotonin reuptake inhibitors (SSRIs) are a relatively newer class of antidepressants for treating depression. SSRIs such as fluoxetine, sertraline, paroxetine, and citalopram have been the most widely prescribed antidepressants since 1980s.<a onclick="showRef(event, 'ref5'); return false;" href="javascript:void(0);" class="ref ref5">(5)</a> All SSRIs strongly and selectively inhibit 5-HT reuptake by the presynaptic neuron, thus increasing 5-HT concentration at the synapse. Although SSRIs offer a more favorable profile, they also have some side adverse effects including anxiety, sedation, headache, tremor, insomnia, and sexual dysfunction. More importantly, there are troublesome facts that SSRIs are generally effective only for less than two-third patients and have undesirably long therapeutic onset time.<a onclick="showRef(event, 'ref6'); return false;" href="javascript:void(0);" class="ref ref6">(6)</a> Recently, there has been the achievement of an important development of an antidepressant which interacts with dual or multiple targets.<a onclick="showRef(event, 'ref7'); return false;" href="javascript:void(0);" class="ref ref7">(7)</a></div><div class="NLM_p">5-HT<sub>1</sub> autoreceptors are widely distributed in the brain, and also serotonin transporters (SERT) are known to have a major role in the control of synaptic 5-HT levels.<a onclick="showRef(event, 'ref8'); return false;" href="javascript:void(0);" class="ref ref8">(8)</a> Blockade of 5-HT<sub>1A/B/D</sub> autoreceptors, with or without concomitant SERT inhibition, rapidly increases brain 5-HT levels and consequently might be able to provide a fast onset of antidepressant/anxiolytic action relative to current therapies.<a onclick="showRef(event, 'ref9'); return false;" href="javascript:void(0);" class="ref ref9">(9)</a> Arylpiperazine is a core fragment of a good number of active compounds displaying various pharmacological effects. The most frequently studied of arylpiperazine derivatives, so-called long-chain arylpiperazines, have been found as serotonin receptor ligands, especially 5-HT<sub>1A</sub> and 5-HT<sub>2A</sub> ones. Their general chemical structure contains an alkyl chain attached to the N4 atom of the piperazine moiety and a terminal amide or an imide fragment.<a onclick="showRef(event, 'ref10'); return false;" href="javascript:void(0);" class="ref ref10">(10)</a></div><div class="NLM_p">Because numerous side effects are associated with nonselective binding at postsynaptic 5-HT receptors, addition of 5-HT receptor antagonistic component to 5-HT reuptake inhibitor has been proposed.<a onclick="showRef(event, 'ref11 ref12 ref13'); return false;" href="javascript:void(0);" class="ref ref11 ref12 ref13">(11-13)</a> The level of synaptic 5-HT was expected to increase with this approach and thus eventually achieve rapid onset time. Along the line, various compounds have been proposed and developed as potential antidepressant with dual activity (Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a>). For instance, Eli Lillyâs LY367265 (1-[2-[4-(6-fluoro-1<i>H</i>-indol-3-yl)-3,6-dihydro-1(2<i>H</i>)-pyridinyl]ethyl]-5,6-dihydro-1<i>H</i>,4<i>H</i>-[1,2,5]thiadiazolo[4.3.2-ij]quinoline-2,2,-dioxide, <b>1</b>) shows excellent binding affinities (<i>K</i><sub>i</sub> = 2.3 nM for SERT; <i>K</i><sub>i</sub> = 0.81 nM for 5-HT<sub>2A</sub>).<a onclick="showRef(event, 'ref14'); return false;" href="javascript:void(0);" class="ref ref14">(14)</a> Yamanouchi has also discovered YM992 ((<i>S</i>)-2-((7-fluoro-2,3-dihydro-1<i>H</i>-inden-4-yloxy)methyl)morpholine monohydrochloride, <b>2</b>) as an antidepressant with moderate affinities for SERT/5-HT<sub>2A</sub> (<i>K</i><sub>i</sub> = 21 and 86 nM, respectively).<a onclick="showRef(event, 'ref15'); return false;" href="javascript:void(0);" class="ref ref15">(15)</a> Bristol-Myers Squibbâs nefazodone (1-(3-(4-(3-chlorophenyl)piperazin-1-yl)propyl)-3-ethyl-4-(2-phenoxyethyl)-<i>1H</i>-1,2,4-triazol-5(4<i>H</i>)-one, <b>3</b>) has been described as having a similar mode of action with an improved side effect profile.<a onclick="showRef(event, 'ref16'); return false;" href="javascript:void(0);" class="ref ref16">(16)</a><b>3</b> had advantages over other antidepressants, including reduced possibility to disturb sleep or sexual dysfunction and ability to treat patients who did not respond properly to other antidepressant drugs. However, Bristol-Myers Squibb discontinued the sale in 2004 with adverse hepatic events including liver failure.<a onclick="showRef(event, 'cit16c cit16d'); return false;" href="javascript:void(0);" class="ref cit16c cit16d">(16c, 16d)</a> More recently, aripiprazole (7-(4-(4-(2,3-dichlorophenyl)piperazin-1-yl)butoxy)-3,4-dihydroquinolin-2(1<i>H</i>)-one, <b>4</b>),<a onclick="showRef(event, 'ref17 ref18'); return false;" href="javascript:void(0);" class="ref ref17 ref18">(17, 18)</a> which had been approved for the treatment of atypical antipsychotics, was also approved by the FDA as an adjunct to treat major depressive disorder in adults. Unlike other FDA-approved atypical antipsychotics antagonizing the <i>D</i><sub><i>2</i></sub> receptor, <b>4</b> appears as a 5-HT<sub>1A</sub> partial agonist, 5-HT<sub>2A</sub> antagonist, and 5-HT<sub>2C</sub> partial agonist. In addition, it has moderate affinity for the serotonin transporter. However, it also has a number of side effects including headache, nausea, constipation, anxiety, restlessness, insomnia, nervousness, and so on. In this regard, there are still urgent unmet medical needs on the development of novel drugs with better developability characteristics, i.e. improved pharmacologic properties and reduced side effects.</div><figure id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-18/jm200682b/production/images/medium/jm-2011-00682b_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-18/jm200682b/production/images/large/jm-2011-00682b_0002.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Chemical structures of representative antidepressant compounds.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-18/jm200682b/production/images/large/jm-2011-00682b_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm200682b&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">We have previously reported a series of arylpiperazine-containing heteroaryl derivatives targeting serotonin 5-HT<sub>2A</sub>, 5-HT<sub>2c</sub>, and the serotonin transporter as a potential antidepressant.<a onclick="showRef(event, 'ref19'); return false;" href="javascript:void(0);" class="ref ref19">(19)</a> The pyrrole series showed outstanding in vitro activity profiles and in vivo antidepressant-like activity on a forced swimming test, but it also suffered from a relatively strong <i>h</i>ERG channel inhibition and false positive effects measured via spontaneous locomotor activity.<a onclick="showRef(event, 'cit19a cit19b'); return false;" href="javascript:void(0);" class="ref cit19a cit19b">(19a, 19b)</a> On the other hand, the pyrimidine series showed the favorable spontaneous locomotor activity as well as improved <i>h</i>ERG channel inhibition profile but tended to exhibit diminished binding affinity against 5-HT<sub>2A</sub>, 5-HT<sub>2c</sub>, and the serotonin transporter.<a onclick="showRef(event, 'cit19c'); return false;" href="javascript:void(0);" class="ref cit19c">(19c)</a> On the basis of these earlier data, we embarked on exploring imidazole series, hoping that we would be able to collect only positive aspects out of the above pyrrole and pyrimidine series. With this in mind, the general structure of target compounds <b>A</b> can be readily prepared by typical amide coupling of imidazole 4-carboxylic acid <b>B</b> with arylpiperazinyl alkyl amine <b>C</b> at the final stage as shown in Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a>. As a continuation of our investigation, we wish to describe the design, synthesis, and biological evaluation of novel arylpiperazine-containing imidazole 4-carboxamide derivatives targeting serotonin 5-HT<sub>2A</sub>, 5-HT<sub>2C</sub>, and the serotonin transporter as a potential antidepressant.</div><figure id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-18/jm200682b/production/images/medium/jm-2011-00682b_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-18/jm200682b/production/images/large/jm-2011-00682b_0003.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Preparation of target compounds using peptide bond formation.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-18/jm200682b/production/images/large/jm-2011-00682b_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm200682b&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">Chemistry</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_84530" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_84530" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">The first approach toward a key imidazole intermediate is described in Scheme <a class="ref internalNav" href="#sch1" aria-label="1">1</a>. Thus, ethyl acetoacetate (<b>5</b>) was subjected to a reaction with sodium nitrite in acetic acid to give ethyl 2-(hydroxyimino)-3-oxobutanoate (<b>6</b>) in 70% yield. The compound <b>6</b> was reacted with an anhydride such as acetic anhydride (<b>7</b>) in the presence of a reducing agent such as hydrogen and a catalyst such as Pd on carbon (Pd/C) in EtOH to give an amide <b>8</b>.<a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(20)</a> The amide <b>8</b> was reacted with aniline <b>9</b> in acetonitrile under microwave irradiation to produce an imidazole derivative <b>10</b> in 76% yields. Hydrolysis of ester <b>10</b> with lithium hydroxide produced compound <b>11</b> as shown in Scheme <a class="ref internalNav" href="#sch1" aria-label="1">1</a>.</div><figure id="sch1" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-18/jm200682b/production/images/medium/jm-2011-00682b_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-18/jm200682b/production/images/large/jm-2011-00682b_0004.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Scheme 1. <sup>a</sup></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-18/jm200682b/production/images/large/jm-2011-00682b_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm200682b&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents: (a) NaNO<sub>2</sub>, AcOH, â10 Â°C to rt, 2 h, 70%; (b) <b>7</b>, Pd/C, H<sub>2</sub>, EtOH, rt, 12 h, 86%; (c) <b>9</b>, TFA or AcOH, butyronitrile, microwave, 140 Â°C, 40 min, 76%; (d) LiOHÂ·H<sub>2</sub>O, THF/H<sub>2</sub>O(1/1), heat, 12 h, 90%.</p></p></figure><div class="NLM_p">The imidazole acid derivative <b>16</b> was synthesized by adopting a method reported by Solvay.<a onclick="showRef(event, 'ref21'); return false;" href="javascript:void(0);" class="ref ref21">(21)</a> Thus, benzonitrile (<b>12</b>) was reacted with aniline (<b>9</b>) in the presence of sodium bis(trimethylsilyl)amide (NaHMDS) to produce a corresponding arylbenzamidine <b>13</b>. Subsequent reaction of the resulting arylbenzamidine <b>13</b> with Î±-bromoketone <b>14</b> generated an intermediate ethyl 5-methyl-1,2-diphenyl-1<i>H</i>-imidazole-4-carboxylate (<b>15</b>) in 55% yield. Hydrolysis of ester <b>15</b> with lithium hydroxide produced the corresponding lithium carboxylate <b>16</b> as shown in Scheme <a class="ref internalNav" href="#sch2" aria-label="2">2</a>.</div><figure id="sch2" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-18/jm200682b/production/images/medium/jm-2011-00682b_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-18/jm200682b/production/images/large/jm-2011-00682b_0005.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Scheme 2. <sup>a</sup></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-18/jm200682b/production/images/large/jm-2011-00682b_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm200682b&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents: (a) <b>9</b>, NaHMDS, THF, rt; (b) <b>14</b>, NaHCO<sub>3</sub>, <i>i</i>-PrOH, reflux, 55%; (c) LiOHÂ·H<sub>2</sub>O, THF/H<sub>2</sub>O(1/1), heat, 12 h.</p></p></figure><div class="NLM_p">The imidazole derivative <b>22</b> was prepared by reaction of a conventional method,<a onclick="showRef(event, 'ref22'); return false;" href="javascript:void(0);" class="ref ref22">(22)</a> for example, by reacting a nitrile <b>18</b> with an aniline derivative <b>17</b> using aluminum chloride to produce <i>N</i>-(4-chlorophenyl)-butyrimidamide (<b>19</b>). Subsequent reaction of the resulting compound <b>19</b> with ethyl 3-bromo-2-oxopropanoate (<b>20</b>) provided an intermediate ethyl 1-(4-chlorophenyl)-2-propyl-1<i>H</i>-imidazole-4-carboxylate (<b>21</b>). An acid form <b>22</b> was prepared from the ester <b>21</b> using lithium hydroxide, followed by acidification, as shown in Scheme <a class="ref internalNav" href="#sch3" aria-label="3">3</a>.</div><figure id="sch3" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-18/jm200682b/production/images/medium/jm-2011-00682b_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-18/jm200682b/production/images/large/jm-2011-00682b_0006.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Scheme 3. <sup>a</sup></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-18/jm200682b/production/images/large/jm-2011-00682b_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm200682b&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents: (a) <b>18</b>, AlCl<sub>3</sub>, toluene, reflux, 5 h, 60%; (b) <b>20</b>, Na<sub>2</sub>CO<sub>3</sub>, toluene, reflux, 4 h, 37%; (c) LiOHÂ·H<sub>2</sub>O, THF/H<sub>2</sub>O(1/1), heat, 12 h, 86%.</p></p></figure><div class="NLM_p">Another approach toward imidazole intermediate is described in Scheme <a class="ref internalNav" href="#sch4" aria-label="4">4</a>. The original reaction sequence was published by F. Hoffmann-La Roche.<a onclick="showRef(event, 'ref23'); return false;" href="javascript:void(0);" class="ref ref23">(23)</a><i>N</i>-Acetylglycine (<b>23</b>) and phosphorus oxychloride are mixed, to which dimethylacetamide was added dropwise slowly at low temperature (exothermic). The reaction was then stirred and warmed at 45 Â°C. In this way, (<i>E</i>)-4-(1-(dimethylamino)ethylidene)-2-methyloxazol-5(4<i>H</i>)-one (<b>24</b>) was generated in 50% yield. Oxazolone <b>24</b> was cleaved with in situ generated ethoxide to produce (<i>E</i>)-ethyl 2-acetamido-3-(dimethylamino)but-2-enoate (<b>25</b>). Next, an amine <b>26</b> was reacted with <b>25</b> in acetic acid at room temperature overnight to give a Michael adduct <b>27</b>. The crude intermediate <b>27</b> was then refluxed together with fine powdered ammonium sulfate in hexamethyldisilazane at 145 Â°C to provide the corresponding imidazoles of structure <b>28</b> in 55â73% yields for the three steps from the oxazolone <b>24</b>. The ester <b>28</b> was hydrolyzed with sodium hydroxide to produce <b>29</b> uneventfully.</div><figure id="sch4" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Scheme 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-18/jm200682b/production/images/medium/jm-2011-00682b_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-18/jm200682b/production/images/large/jm-2011-00682b_0007.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Scheme 4. <sup>a</sup></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-18/jm200682b/production/images/large/jm-2011-00682b_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm200682b&amp;id=sch4"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents: (a) POCl<sub>3</sub>, DMA, 45 Â°C, 50%; (b) NaH, EtOH, rt, then reflux, 1 h; (c) <b>26</b>, AcOH, rt, 12 h; (d) (NH<sub>4</sub>)<sub>2</sub>SO<sub>4</sub>, AcOH, HMDS, reflux; (e) NaOH, aq MeOH, reflux.</p></p></figure><div class="NLM_p">As shown in Scheme <a class="ref internalNav" href="#sch5" aria-label="5">5</a>, the synthesis of 3-(4-(2,3-dichlorophenyl)piperazin-1-yl)propan-1-amine (<b>33</b>) and the like, wherein the alkyl chain between the piperazine and the terminal amine corresponds to two carbons through four carbons, commenced with <i>N</i>-(2-bromoethyl)phthalimide, <i>N</i>-(3-bromopropyl)phthalimide (<b>30</b>) and <i>N</i>-(4-bromobutyl)phthalimide by adopting a reported procedure.<a onclick="showRef(event, 'ref24'); return false;" href="javascript:void(0);" class="ref ref24">(24)</a> For example, <i>N</i>-(3-bromopropyl)phthalimide (<b>30</b>) was reacted with 1-(2,3-dichlorophenyl)piperazine (<b>31</b>) in the presence of potassium carbonate in a suitable solvent such as DMF at rt afforded the corresponding alkylated product <b>32</b> in 80% yield. Hydrazinolysis of <b>32</b>, followed by treatment of HCl solution, generated 3-(4-(2,3-dichlorophenyl)piperazin-1-yl)propan-1-amine as a HCl salt form (<b>33</b>) in 76% yield.</div><figure id="sch5" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Scheme 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-18/jm200682b/production/images/medium/jm-2011-00682b_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-18/jm200682b/production/images/large/jm-2011-00682b_0008.jpeg" id="gr7" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Scheme 5. <sup>a</sup></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-18/jm200682b/production/images/large/jm-2011-00682b_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm200682b&amp;id=sch5"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents: (a) K<sub>2</sub>CO<sub>3</sub>, DMF, rt, 8 h, 80%; (b) (i) H<sub>2</sub>NNH<sub>2</sub>Â·H<sub>2</sub>O, EtOH, rt, 6 h, (ii) 2 M HCl solution in diethyl ether, 76%.</p></p></figure><div class="NLM_p">To increase hydrophilicity for compounds such as 3-(4-(2,3-dichlorophenyl)piperazin-1-yl)propan-1-amine (<b>33</b>), a compound such as 1-amino-3-(4-(2,3-dichlorophenyl)piperazin-1-yl)propan-2-ol (<b>36</b>) was prepared as shown in Scheme <a class="ref internalNav" href="#sch6" aria-label="6">6</a>. Thus, commercially available <i>N</i>-(2,3-epoxypropyl)phthalimide (<b>34</b>) was treated with 1-(2,3-dichlorophenyl)piperazine (<b>31</b>) in the presence of base such as triethylamine in a suitable solvent such as THF at 80 Â°C produced the alcohol <b>35</b> in about 91% yield. Subsequently, hydrazinolysis of <b>35</b> generated 1-amino-3-(4-(2,3-dichlorophenyl)piperazin-1-yl)propan-2-ol (<b>36</b>) as a white solid in 95% yield.</div><figure id="sch6" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Scheme 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-18/jm200682b/production/images/medium/jm-2011-00682b_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-18/jm200682b/production/images/large/jm-2011-00682b_0009.jpeg" id="gr8" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Scheme 6. <sup>a</sup></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-18/jm200682b/production/images/large/jm-2011-00682b_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm200682b&amp;id=sch6"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents: (a) TEA, THF, 80 Â°C, 92%; (b) (i) H<sub>2</sub>NNH<sub>2</sub>Â·H<sub>2</sub>O, EtOH, rt, 6 h, (ii) 2 M HCl solution in diethyl ether, 95%.</p></p></figure><div class="NLM_p">Generally, a target compound was prepared by amide bond formation of acid <b>B</b> and amine <b>C</b> by use of EDCI, HOBt, and NMM in a suitable solvent such as DMF to generate <b>A</b> as shown in Scheme <a class="ref internalNav" href="#sch7" aria-label="7">7</a>.</div><figure id="sch7" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Scheme 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-18/jm200682b/production/images/medium/jm-2011-00682b_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-18/jm200682b/production/images/large/jm-2011-00682b_0010.jpeg" id="gr9" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Scheme 7. <sup>a</sup></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-18/jm200682b/production/images/large/jm-2011-00682b_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm200682b&amp;id=sch7"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents: (a) (i) EDCI, HOBt, NMM, DMF, rt, 12 h, (ii) 2 M HCl solution in diethyl ether.</p></p></figure></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i3">Results and Discussion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_47461" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_47461" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">The binding affinity of current compounds against 5-HT<sub>2A</sub>, 5-HT<sub>2C</sub> receptor, and serotonin transporter, stably expressed in CHO-K1 cells, was evaluated by displacement binding using [<sup>3</sup>H]ketanserin, [<sup>3</sup>H]mesulergine, and [<sup>3</sup>H]imipramine, respectively, as radioligands.<a onclick="showRef(event, 'ref25'); return false;" href="javascript:void(0);" class="ref ref25">(25)</a> The initial work was focused on exploration of substitution on the central imidazole moiety and the size of the linker connecting the central imidazole ring to a 2,3-dichlorophenylpiperazine moiety. We decided to use 2,3-dichlorophenylpiperazine as an initial arylpiperazine, adopting a structural motif shown in <b>4</b>. The binding affinity against 5-HT<sub>2A/2C</sub> and inhibition against SERT are shown in Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a>. Most compounds tested displayed IC<sub>50</sub> < 1 Î¼M, implying that this series of arylpiperazinyl imidazole 4-carboxamide might hold promise as a potentially viable antidepressant. Especially, 2,5-dimethyl-1-phenyl-1<i>H</i>-imidazole (<b>40</b>) or 1-(2,3-dihydrobenzo[<i>b</i>][1,4]dioxin-6-yl)-2,5-dimethyl-1<i>H</i>-imidazole (<b>57</b>) shows potent and balanced activity profiles against 5-HT<sub>2A/2C</sub> and SERT (IC<sub>50</sub> = 18.6, 12.1, and 10.2 nM for <b>40</b> vs IC<sub>50</sub> = 8.63, 14.6, and 9.17 nM for <b>57</b>, respectively). As the linker size reduces by one carbon, the activity profiles appear to become deteriorated as shown in <b>37</b> (IC<sub>50</sub> = 31, 66, and 129 nM, respectively). Most of phenyl derivatives on the 1-position of the imidazole ring appear to be tolerated. Thus, physicochemical properties can be modulated by modifying this moiety later. Also, different groups such as methyl, ethyl, <i>n</i>-propyl, or phenyl can be introduced at 2-position of the imidazole ring without hampering overall in vitro activity profiles. A methyl (<b>40</b>) or <i>n</i>-propyl group (<b>42</b>) usually appears to be more favorable than an ethyl group (<b>41</b>), but in some cases (<b>47</b>, <b>55</b>, and <b>58</b>), a <i>n</i>-propyl group on C-2 imidazole ring was observed to diminish in vitro 5-HT<sub>2A/2C</sub> and SERT, implying that increased lipophilicity at this position might disrupt binding to 5-HT<sub>2A/2C</sub> receptors.</div><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. Binding Affinity to Serotonin Receptor 5-HT<sub>2A</sub>, 5-HT<sub>2C</sub> and Serotonin Transporter (SERT) (IC<sub>50</sub>, nM)</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-18/jm200682b/production/images/medium/jm-2011-00682b_0011.gif" alt="" id="fx1" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-18/jm200682b/production/images/medium/jm-2011-00682b_0012.gif" alt="" id="fx2" /></img><div></div></div><div class="NLM_p">Some of the compounds were further evaluated with other subtypes that constitute the serotonin receptor family and dopamine receptors. The results are shown in Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a>. Interestingly, both compounds <b>37</b> and <b>40</b> proved to be highly bound to either 5-HT<sub>1A</sub> or 5-HT<sub>7</sub> as well. In particular, compound <b>40</b> showed good activity against 5-HT receptors and SERT across the board (IC<sub>50</sub> = 4.9â19 nM) except 5-HT<sub>6</sub> (IC<sub>50</sub> = 136 nM). Such compounds might have the synergistic antidepressant properties because the blockade of 5-HT<sub>7</sub> receptors has been recently proposed as an alternative therapy for depression. On the contrary, binding affinity against dopamine receptors was only marginal, thereby providing good selectivity over dopamine D<sub>2/3/4</sub> receptors while maintaining the key target interactions. Meanwhile, a radioligand binding assay for the <i>h</i>ERG potassium channel was adopted to see if our compounds may have inhibitory activity and potential cardiotoxicity.<a onclick="showRef(event, 'ref26'); return false;" href="javascript:void(0);" class="ref ref26">(26)</a> Compound <b>37</b> turned out not to be a significant inhibitor of <i>h</i>ERG channel (IC<sub>50</sub> > 10 Î¼M). But as the linker size becomes elongated (<b>38</b>), the <i>h</i>ERG profile gets slightly worse (IC<sub>50</sub> = 8.11 Î¼M) although these data are not too much problematic as shown in Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a>.</div><div class="NLM_table-wrap" id="tbl2"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 2. Profiles of Interesting Compounds via Competition Binding Assay at Serotonin Receptors, SERT, Dopamine Receptors (IC<sub>50</sub>, nM), and Properties of <i>h</i>ERG Channels (IC<sub>50</sub>, Î¼M)</div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">Â </th><th class="rowsep1 colsep0" colspan="5" align="center" char=".">serotonin (5-HT) receptor</th><th class="colsep0 rowsep0" align="center" char=".">Â </th><th class="rowsep1 colsep0" colspan="3" align="center" char=".">dopamine receptor</th><th class="colsep0 rowsep0" align="center" char=".">Â </th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compd</th><th class="colsep0 rowsep0" align="center" char=".">5-HT<sub>1A</sub></th><th class="colsep0 rowsep0" align="center" char=".">5-HT<sub>2A</sub></th><th class="colsep0 rowsep0" align="center" char=".">5-HT<sub>2C</sub></th><th class="colsep0 rowsep0" align="center" char=".">5-HT<sub>6</sub></th><th class="colsep0 rowsep0" align="center" char=".">5-HT<sub>7</sub></th><th class="colsep0 rowsep0" align="center" char=".">serotonin transpoter</th><th class="colsep0 rowsep0" align="center" char=".">D<sub>2</sub></th><th class="colsep0 rowsep0" align="center" char=".">D<sub>3</sub></th><th class="colsep0 rowsep0" align="center" char=".">D<sub>4</sub></th><th class="colsep0 rowsep0" align="center" char="."><i>h</i>ERG IC<sub>50</sub> (Î¼M)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>37</b></td><td class="colsep0 rowsep0" align="char" char=".">3.9</td><td class="colsep0 rowsep0" align="char" char=".">31</td><td class="colsep0 rowsep0" align="char" char=".">66</td><td class="colsep0 rowsep0" align="char" char=".">1682</td><td class="colsep0 rowsep0" align="char" char=".">6.8</td><td class="colsep0 rowsep0" align="char" char=".">129</td><td class="colsep0 rowsep0" align="char" char=".">908</td><td class="colsep0 rowsep0" align="char" char=".">2189</td><td class="colsep0 rowsep0" align="char" char=".">3942</td><td class="colsep0 rowsep0" align="char" char=".">>10</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>40</b></td><td class="colsep0 rowsep0" align="char" char=".">4.9</td><td class="colsep0 rowsep0" align="char" char=".">19</td><td class="colsep0 rowsep0" align="char" char=".">12</td><td class="colsep0 rowsep0" align="char" char=".">136</td><td class="colsep0 rowsep0" align="char" char=".">11</td><td class="colsep0 rowsep0" align="char" char=".">10</td><td class="colsep0 rowsep0" align="char" char=".">1369</td><td class="colsep0 rowsep0" align="char" char=".">493</td><td class="colsep0 rowsep0" align="char" char=".">>10000</td><td class="colsep0 rowsep0" align="char" char=".">8.11</td></tr></tbody></table></div></div><div class="NLM_p">Before we move on to the in vivo efficacy study, we screened our compounds particularly against spontaneous locomotor activity to identify false positives. Although several compounds in Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a> looked very good for in vitro activity, they appeared to have hyperactivity. For example, compounds <b>37</b> or <b>49</b> showed a high spontaneous locomotor activity (SLA) value (14802 Â± 3275 at 50 mg/kg for <b>37</b>; 13040 Â± 4261 at 50 mg/kg for <b>49</b>, respectively). Thus, to reduce SLA values, we decided to introduce 2,3-dimethylphenylpiperazine or 2-methyl-3-chlorophenylpiperazine which is less hydrophobic while maintain the structural motif as an approach and we also decided to keep the three-carbon distance between imidazole-amide and phenylpiperazine because they appear to provide better activity than the corresponding two-carbon linker. Also four-carbon linker was conceivable at this point, but we hesitated to explore its possibility because it looked so lengthy and too flexible that they would not be desirable from the development perspective even if they would be potent. All compounds thus designed and prepared were evaluated. The binding affinity against 5-HT<sub>2A/2C</sub> and inhibition against SERT are shown in Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a>. Notably, this modification significantly reduced intrinsic activity against 5-HT<sub>2A/2C</sub> in an order of magnitude. This phenomenon is exemplified in dimethylphenylpiperazine analogue <b>59</b> (IC<sub>50</sub> = 91 nM for 5-HT<sub>2A</sub>, IC<sub>50</sub> = 170 nM for 5-HT<sub>2C</sub>) compared to the dichlorophenylpiperazine <b>40</b> (IC<sub>50</sub> = 18.6 nM for 5-HT<sub>2A</sub>, IC<sub>50</sub> = 12.1 nM for 5-HT<sub>2C</sub>). However, its inhibition activity against SERT is not decreased but rather maintained or even increased as exemplified in <b>40</b> (IC<sub>50</sub> = 6 nM). Among the compounds demonstrating IC<sub>50</sub> < 20 nM in Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a>, compound <b>75</b> appears to have hypoactivity (SLA value =5409 Â± 3319 cm at 50 mg/kg). Replacement of the 2,3-dimethylpiperazine in <b>92</b> with 2-methyl-3-chloro-piperazine provided the compound <b>91</b> with an encouraging overall activity profile (IC<sub>50</sub> = 29 nM for 5-HT<sub>2A</sub>, IC<sub>50</sub> = 39 nM for 5-HT<sub>2C</sub>, IC<sub>50</sub> = 18 nM for SERT). Disappointingly, further investigation of the compound with SLA revealed its hyperactivity (SLA value =10189 Â± 628 cm at 50 mg/kg). Among 45 compounds in Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a>, 13 compounds show IC<sub>50</sub> < 10 nM against SERT, and 8 compounds show IC<sub>50</sub> < 20 nM against 5-HT<sub>2A</sub>, while none of the compounds show IC<sub>50</sub> < 30 nM against 5-HT<sub>2C</sub>. It is notable that replacement of 2,3-dichloropiperazine with 2,3-dimethylpiperazine boosted in vitro inhibitory activity against the serotonin transporter while maintaining binding affinity against 5-HT<sub>2A</sub>. Thus, this series appears to become more like SSRI compounds that happen to additionally block 5-HT<sub>2A</sub> at this point. There are reported studies indicating that the antidepressants which occupy 5-HT<sub>2</sub> receptors in the brain at clinical doses and block mainly 5-HT<sub>2A</sub> responses augment the clinical response to SSRIs in treatment-resistant patients.<a onclick="showRef(event, 'ref27 ref28'); return false;" href="javascript:void(0);" class="ref ref27 ref28">(27, 28)</a></div><div class="NLM_table-wrap" id="tbl3"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 3. Binding Affinity to Serotonin Receptor 5-HT<sub>2A</sub>, 5-HT<sub>2C</sub> and Serotonin Transporter (SERT) (IC<sub>50</sub>, nM)</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-18/jm200682b/production/images/medium/jm-2011-00682b_0013.gif" alt="" id="fx3" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-18/jm200682b/production/images/medium/jm-2011-00682b_0014.gif" alt="" id="fx4" /></img><div></div></div><div class="NLM_p">To decrease clogP and increase polarity and thus possibly improve solubility of the compounds in the series, we decided to introduce a hydroxyl group on the linker chain. Because introduction of a hydroxyl group might affect the overall efficacy and false positives profiles, the corresponding 2,3-dichlorophenylpiperazine analogues were also synthesized and evaluated.</div><div class="NLM_p">Introduction of hydroxyl group into the linker chain also revealed a range of interesting profiles and subtle effects on intrinsic activity as shown in Table <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a>. Hydroxyl compound <b>106</b> afforded about 2-fold drop in 5-HT<sub>2A</sub> and 5-fold drop in 5-HT<sub>2C</sub> but with slightly increased intrinsic activity at SERT compared to the corresponding deoxy analogue <b>43</b>. A 2-F-Phenyl analogue <b>122</b> afforded about a 6-fold drop in 5-HT<sub>2A</sub> and a 9-fold drop in 5-HT<sub>2C</sub> but maintained SERT affinity. 2,3-Dihydrobenzo[<i>b</i>][1,4]dioxinyl moiety on C-1 on the imidazole ring (<b>138</b>) gave the most desirable intrinsic activity profiles yet observed, maintaining high affinities at 5-HT<sub>2A</sub> and SERT but again accompanied by decreased 5-HT<sub>2C</sub> intrinsic activity. Overall, introduction of hydroxyl group into the linker led to the discovery of compounds with good SERT inhibitory activity with additional moderate 5-HT<sub>2A</sub> receptor antagonism.</div><div class="NLM_table-wrap" id="tbl4"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 4. Binding Affinity to Serotonin Receptor 5-HT<sub>2A</sub>, 5-HT<sub>2C</sub>, and Serotonin Transporter (SERT) (IC<sub>50</sub>, nM)</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-18/jm200682b/production/images/medium/jm-2011-00682b_0015.gif" alt="" id="fx5" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-18/jm200682b/production/images/medium/jm-2011-00682b_0016.gif" alt="" id="fx6" /></img><div></div></div><div class="NLM_p">Interesting compounds were further evaluated in vivo with immobility in forced swimming test (FST) on mice.<a onclick="showRef(event, 'ref29'); return false;" href="javascript:void(0);" class="ref ref29">(29)</a> Fluoxetine (<i>N</i>-methyl-3-phenyl-3-[4-(trifluoromethyl)phenoxy]propan-1-amine), venlafaxine ((<i>RS</i>)-1-[2-dimethylamino-1-(4-methoxyphenyl)-ethyl]cyclohexanol), paroxetine ((3<i>S</i>,4<i>R</i>)-3-[(2<i>H</i>-1,3-benzodioxol-5-yloxy)methyl]-4-(4-fluorophenyl)piperidine), and sertraline ((1<i>S</i>,4<i>S</i>)-4-(3,4-dichlorophenyl)-<i>N</i>-methyl-1,2,3,4-tetrahydronaphthalen-1-amine) were used as reference compounds for comparison. The results are shown in Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a>. At 50 mg/kg, des-methyl at C-5 of imidazole (<b>81</b>) showed virtually no appreciable immobility effect. This phenomenon was also observed in another des-methyl analogue <b>69</b> which is devoid of any antidepressant-like effect at 25 mg/kg. Thus, a substituent on C-5 imidazole ring appears to be minimal requirement for in vivo efficacy against FST model on mice. Compared to sertraline, which demonstrated the most impressive immobility performance among the reference compounds tested at 50 mg/kg, compounds <b>46</b>, <b>57</b>, <b>68</b>, <b>70</b>, and <b>131</b> showed superior in vivo immobility data. Among them, compounds <b>68</b>, <b>70</b>, and <b>131</b> also displayed nice dose-dependency. As oral dose reduced down from 25 to 10 mg/kg, virtually all the compounds tested showed insufficient antidepressant activity. Either <b>70</b> or <b>131</b> demonstrated merely moderate in vivo efficacy (immobility â¼80%) (see Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a>).</div><figure id="fig3" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-18/jm200682b/production/images/medium/jm-2011-00682b_0017.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-18/jm200682b/production/images/large/jm-2011-00682b_0017.jpeg" id="_i8" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Antidepressants activity immobility in forced swimming test on mice (FST, %) and spontaneous locomotor activity (SLA, cm). Effects of the drugs on immobility in forced swimming test on mice. a) Drugs (50, 25, and 10 mg/kg) were injected orally (po) 60 min before the testing, and total duration of immobility was recorded during the last 5 min of the 6-min testing period. (Values are means Â± SEM). b) Locomotor activities of the mice treated with compounds or vehicle were counted for 30 min by Activity Analyzer. Compound (50 mg/kg) or vehicle was administered orally (po) 60 min before the test. Data were expressed as mean Â± SEM of 6â7 mice.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-18/jm200682b/production/images/large/jm-2011-00682b_0017.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm200682b&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">The second in vivo test involves spontaneous locomotor activity test. The results are illustrated in Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a>. Dichlorophenylpiperazine compound <b>106</b> was observed to show obvious hyperactivity. Additional dichlorophenylpiperazine analogues <b>43</b>, <b>46</b>, and <b>138</b> also appear to have hyperactivity. At this point, it was observed that as arylpiperazine was altered from dichlorophenylpiperazine into the corresponding dimethylphenylpiperazine, some degree of spontaneous locomotor activity was decreased as exemplified in compounds <b>69</b>, <b>100</b>, and <b>103</b>. Encouragingly, 3-chloro-2-methylphenylpiperazine analogues <b>68</b>, <b>70</b>, and <b>131</b>, which we had introduced as novel arylpiperazine analogues to reduce hyperactivity with maintaining antidepressant activity, did not show hyperactivity but normal activity. </div><div class="NLM_p">In passing, an interesting observation during exploration of this series is described in Table <a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">5</a>. When hydroxyl group was introduced onto the linker chain in the molecule, it was observed that SERT affinity becomes improved in conjunction with a drop in 5-HT<sub>2A/2C</sub>. Notably, significant increases in intrinsic activity at SERT were observed for compounds with (<i>R</i>)-configuration as shown in Table <a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">5</a>. Thus, compounds <b>143</b> and <b>145</b> showed subnanomolar SERT affinities in this series for the first time (IC<sub>50</sub> = 0.64 nM, IC<sub>50</sub> = 0.75 nM, respectively). The affinity difference between (<i>R</i>)- and (<i>S</i>)-configuration is approximately an order of magnitude. However, it is noted that racemic compounds <b>104</b> or <b>124</b> rather gave the highest activity in in vivo antidepressant activity in forced swimming test on mice as shown in Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a>.</div><div class="NLM_table-wrap" id="tbl6"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 5. Binding Affinity to Serotonin Receptor 5-HT<sub>2A</sub>, 5-HT<sub>2C</sub> and Serotonin Transporter (SERT) (IC<sub>50</sub>, nM)</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-18/jm200682b/production/images/medium/jm-2011-00682b_0018.gif" alt="" id="fx9" /></img><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">Â </th><th class="colsep0 rowsep0" align="center">Â </th><th class="colsep0 rowsep0" align="center">Â </th><th class="colsep0 rowsep0" align="center">Â </th><th class="colsep0 rowsep0" align="center">Â </th><th class="colsep0 rowsep0" align="center">Â </th><th class="rowsep1 colsep0" colspan="3" align="center" char=".">in vitro</th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compd</th><th class="colsep0 rowsep0" align="center">R<sub>1</sub></th><th class="colsep0 rowsep0" align="center">R<sub>2</sub></th><th class="colsep0 rowsep0" align="center">R<sub>4</sub></th><th class="colsep0 rowsep0" align="center">R<sub>5</sub></th><th class="colsep0 rowsep0" align="center">Â </th><th class="colsep0 rowsep0" align="center" char=".">5HT<sub>2A</sub></th><th class="colsep0 rowsep0" align="center" char=".">5HT<sub>2C</sub></th><th class="colsep0 rowsep0" align="center" char=".">SERT</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>104</b></td><td class="colsep0 rowsep0" align="left">Ph</td><td class="colsep0 rowsep0" align="left">Me</td><td class="colsep0 rowsep0" align="left">Me</td><td class="colsep0 rowsep0" align="left">Me</td><td class="colsep0 rowsep0" align="left">racemic</td><td class="colsep0 rowsep0" align="char" char=".">247.6</td><td class="colsep0 rowsep0" align="char" char=".">2741</td><td class="colsep0 rowsep0" align="char" char=".">5</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>143</b></td><td class="colsep0 rowsep0" align="left">Ph</td><td class="colsep0 rowsep0" align="left">Me</td><td class="colsep0 rowsep0" align="left">Me</td><td class="colsep0 rowsep0" align="left">Me</td><td class="colsep0 rowsep0" align="left">(<i>R</i>)-configuration</td><td class="colsep0 rowsep0" align="char" char=".">72.5</td><td class="colsep0 rowsep0" align="char" char=".">227</td><td class="colsep0 rowsep0" align="char" char=".">0.64</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>144</b></td><td class="colsep0 rowsep0" align="left">Ph</td><td class="colsep0 rowsep0" align="left">Me</td><td class="colsep0 rowsep0" align="left">Me</td><td class="colsep0 rowsep0" align="left">Me</td><td class="colsep0 rowsep0" align="left">(<i>S</i>)-configuration</td><td class="colsep0 rowsep0" align="char" char=".">646</td><td class="colsep0 rowsep0" align="char" char=".">1779</td><td class="colsep0 rowsep0" align="char" char=".">5.08</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>124</b></td><td class="colsep0 rowsep0" align="left">2-F-Ph</td><td class="colsep0 rowsep0" align="left">Me</td><td class="colsep0 rowsep0" align="left">Me</td><td class="colsep0 rowsep0" align="left">Me</td><td class="colsep0 rowsep0" align="left">racemic</td><td class="colsep0 rowsep0" align="char" char=".">579</td><td class="colsep0 rowsep0" align="char" char=".">>10000</td><td class="colsep0 rowsep0" align="char" char=".">7.59</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>145</b></td><td class="colsep0 rowsep0" align="left">2-F-Ph</td><td class="colsep0 rowsep0" align="left">Me</td><td class="colsep0 rowsep0" align="left">Me</td><td class="colsep0 rowsep0" align="left">Me</td><td class="colsep0 rowsep0" align="left">(<i>R</i>)-configuration</td><td class="colsep0 rowsep0" align="char" char=".">270</td><td class="colsep0 rowsep0" align="char" char=".">193</td><td class="colsep0 rowsep0" align="char" char=".">0.75</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>146</b></td><td class="colsep0 rowsep0" align="left">2-F-Ph</td><td class="colsep0 rowsep0" align="left">Me</td><td class="colsep0 rowsep0" align="left">Me</td><td class="colsep0 rowsep0" align="left">Me</td><td class="colsep0 rowsep0" align="left">(<i>S</i>)-configuration</td><td class="colsep0 rowsep0" align="char" char=".">244</td><td class="colsep0 rowsep0" align="char" char=".">1031</td><td class="colsep0 rowsep0" align="char" char=".">10.3</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>131</b></td><td class="colsep0 rowsep0" align="left">4-F-Ph</td><td class="colsep0 rowsep0" align="left">Ph</td><td class="colsep0 rowsep0" align="left">Me</td><td class="colsep0 rowsep0" align="left">Cl</td><td class="colsep0 rowsep0" align="left">racemic</td><td class="colsep0 rowsep0" align="char" char=".">26.7</td><td class="colsep0 rowsep0" align="char" char=".">>10000</td><td class="colsep0 rowsep0" align="char" char=".">478.4</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>147</b></td><td class="colsep0 rowsep0" align="left">4-F-Ph</td><td class="colsep0 rowsep0" align="left">Ph</td><td class="colsep0 rowsep0" align="left">Me</td><td class="colsep0 rowsep0" align="left">Cl</td><td class="colsep0 rowsep0" align="left">(<i>R</i>)-configuration</td><td class="colsep0 rowsep0" align="char" char=".">95</td><td class="colsep0 rowsep0" align="char" char=".">479</td><td class="colsep0 rowsep0" align="char" char=".">257</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>148</b></td><td class="colsep0 rowsep0" align="left">4-F-Ph</td><td class="colsep0 rowsep0" align="left">Ph</td><td class="colsep0 rowsep0" align="left">Me</td><td class="colsep0 rowsep0" align="left">Cl</td><td class="colsep0 rowsep0" align="left">(<i>S</i>)-configuration</td><td class="colsep0 rowsep0" align="char" char=".">20.1</td><td class="colsep0 rowsep0" align="char" char=".">534</td><td class="colsep0 rowsep0" align="char" char=".">232</td></tr></tbody></table></div></div><figure id="fig4" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-18/jm200682b/production/images/medium/jm-2011-00682b_0019.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-18/jm200682b/production/images/large/jm-2011-00682b_0019.jpeg" id="_i10" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Antidepressants Activity immobility in forced swimming test on mice (FST, %). Effects of drugs on immobility in forced swimming test on mice. Drugs (50, 25, and 10 mg/kg) were injected orally (po) 60 min before the testing, and total duration of immobility was recorded during the last 5 min of the 6-min testing period. (Values are means Â± SEM).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-18/jm200682b/production/images/large/jm-2011-00682b_0019.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm200682b&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">To further evaluate this series of compounds, some of the representative compounds have been tested for <i>h</i>ERG inhibition, cytotoxicity at HT22, genotoxicity (Ames test), and inhibition against a panel of cytochrome P450 isoforms, respectively. For instance, compound <b>68</b> showed relatively strong inhibition against <i>h</i>ERG (IC<sub>50</sub> = 1.3 Î¼M). Also <b>68</b> demonstrated moderate inhibitory activity against CYP 2C9 (IC<sub>50</sub> = 2.9 Î¼M) and 2D6 (IC<sub>50</sub> = 5.4 Î¼M), while <b>68</b> lacks inhibitory activity against 1A2 or 3A4. <b>68</b> appeared to show neither cytotoxicity nor mutagenicity as shown in Table <a class="ref showTableEvent internalNav" data-ID="tbl8" href="#tbl8">6</a>. The profile has been improved in dihydrobenzodioxin <b>100</b>. For example, <b>100</b> improved <i>h</i>ERG inhibition in approximately 7-fold, showing IC<sub>50</sub> = 8.7 Î¼M. Inhibition against CYP 2D6 was reduced in greater than 3-fold. However, all of three compounds showed moderate liability against the CYP 2C9 isoform, displaying IC<sub>50</sub> = 2.9â4.4 Î¼M.</div><div class="NLM_table-wrap" id="tbl8"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 6. In Vitro Toxicity of Compound <b>68</b>, <b>70</b>, and <b>100</b></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-18/jm200682b/production/images/medium/jm-2011-00682b_0020.gif" alt="" id="fx11" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-18/jm200682b/production/images/medium/jm-2011-00682b_0021.gif" alt="" id="fx12" /></img><div></div></div><div class="NLM_p">Subsequently, the pharmacokinetic properties of <b>57</b> were measured in male SD rats. After oral administration of 5 mg/kg of <b>57</b> to rats, a <i>C</i><sub>max</sub> of 0.208 Î¼g/mL was obtained at 15 min. The elimination half-life of <b>57</b> following oral administration was 0.37 h in rats. Compound <b>57</b> showed only moderate oral bioavailability (<i>F</i> = 14.92%) in rats. This profile became even worse in 2-methoxyphenylimidazole <b>71</b> as shown in Table <a class="ref showTableEvent internalNav" data-ID="tbl9" href="#tbl9">7</a>, suggesting its solubility-limited absorption.</div><div class="NLM_table-wrap" id="tbl9"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 7. Pharmacokinetic Parameters and Brain/Plasma Ratio of Compounds <b>57</b> and <b>71</b> after Oral (5 mg/kg) and iv (1 mg/kg) Administration to Rat</div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="char" char="Â±" /></col><col align="char" char="Â±" /></col><col align="char" char="Â±" /></col><col align="char" char="Â±" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">Â </th><th class="rowsep1 colsep0" colspan="4" align="center" char="Â±">compd </th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">Â </th><th class="rowsep1 colsep0" colspan="2" align="center" char="Â±"><b>57</b></th><th class="rowsep1 colsep0" colspan="2" align="center" char="Â±"><b>71</b></th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">PK parameters</th><th class="colsep0 rowsep0" align="center" char="Â±">iv (1 mg/kg, <i>n</i> = 3)</th><th class="colsep0 rowsep0" align="center" char="Â±">oral (5 mg/kg, <i>n</i> = 3)</th><th class="colsep0 rowsep0" align="center" char="Â±">iv (1 mg/kg, <i>n</i> = 3)</th><th class="colsep0 rowsep0" align="center" char="Â±">oral (5 mg/kg, <i>n</i> = 3)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><i>C</i><sub>max</sub> (Î¼g/mL)</td><td class="colsep0 rowsep0" align="char" char="Â±">0.245âÂ±â0.032</td><td class="colsep0 rowsep0" align="char" char="Â±">0.208âÂ±â0.117</td><td class="colsep0 rowsep0" align="char" char="Â±">0.408âÂ±â0.056</td><td class="colsep0 rowsep0" align="char" char="Â±">0.065âÂ±â0.046</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">C<sub>last</sub> (Î¼g/mL)</td><td class="colsep0 rowsep0" align="char" char="Â±">0.001âÂ±â0.000</td><td class="colsep0 rowsep0" align="char" char="Â±">0.000âÂ±â0.000</td><td class="colsep0 rowsep0" align="char" char="Â±">0.004âÂ±â0.001</td><td class="colsep0 rowsep0" align="char" char="Â±">0.000âÂ±â0.000</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><i>T</i><sub>max</sub>(h)</td><td class="colsep0 rowsep0" align="char" char="Â±">Â </td><td class="colsep0 rowsep0" align="char" char="Â±">0.250âÂ±â0.000</td><td class="colsep0 rowsep0" align="char" char="Â±">Â </td><td class="colsep0 rowsep0" align="char" char="Â±">0.250âÂ±â0.000</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><i>t</i><sub>1/2</sub> (h)</td><td class="colsep0 rowsep0" align="char" char="Â±">0.438âÂ±â0.064</td><td class="colsep0 rowsep0" align="char" char="Â±">0.372âÂ±â0.012</td><td class="colsep0 rowsep0" align="char" char="Â±">0.226âÂ±â0.019</td><td class="colsep0 rowsep0" align="char" char="Â±">0.121âÂ±â0.038</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">AUC<sub>inf</sub> (minÂ·Î¼g/mL)</td><td class="colsep0 rowsep0" align="char" char="Â±">10.931âÂ±â2.019</td><td class="colsep0 rowsep0" align="char" char="Â±">10.811âÂ±â2.986</td><td class="colsep0 rowsep0" align="char" char="Â±">7.611âÂ±â0.488</td><td class="colsep0 rowsep0" align="char" char="Â±">1.312âÂ±â0.839</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">AUC<sub>inf/dose</sub></td><td class="colsep0 rowsep0" align="char" char="Â±">10.931âÂ±â2.019</td><td class="colsep0 rowsep0" align="char" char="Â±">1.631âÂ±â1.246</td><td class="colsep0 rowsep0" align="char" char="Â±">7.611âÂ±â0.488</td><td class="colsep0 rowsep0" align="char" char="Â±">0.262âÂ±â0.168</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">BA (%)</td><td class="colsep0 rowsep0" colspan="2" align="center" char="Â±">14.92</td><td class="colsep0 rowsep0" colspan="2" align="center" char="Â±">3.45</td></tr></tbody></table></div></div></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i13">Conclusion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_46350" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_46350" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p last">In summary, serotonin antagonist reuptake inhibitor (SARI) drugs that block both 5-HT<sub>2</sub> receptors and the serotonin transporters have been developed. We investigated a series of arylpiperazine containing imidazole 4-carboxamide derivatives for the treatment of depressive disorders. The human 5-HT<sub>2A/2C</sub> receptor has been implicated in several neurological conditions, and potent selective 5-HT<sub>2A/2C</sub> ligands may have therapeutic potential for treatment of CNS diseases such as depression. The imidazole series of compounds was evaluated against 5-HT<sub>2A/2C</sub> and serotonin reuptake inhibition. A few of the compounds in the series showed promising in vitro IC<sub>50</sub> values and in vivo antidepressant-like effect in the forced swimming test (FST). On the basis of these results, current imidazole series of compounds is being used as tool compound to identify a development candidate for promising antidepressant.</div></div><div id="sec5" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i14">Experimental Section</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_70183" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_70183" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec5_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i15" class="anchor-spacer"></div><h3 class="article-section__title" id="_i15"> Chemistry</h3><div class="NLM_p">Unless otherwise noted, all starting materials were obtained from commercial suppliers and used without further purification. All references to ether are to diethyl ether; brine refers to a saturated aqueous solution of NaCl. Unless otherwise indicated, all temperatures are expressed in Â°C. All reactions are conducted under an inert atmosphere at room temperature unless otherwise noted, and all solvents are of the highest available purity unless otherwise indicated. Microwave reaction was conducted with a Biotage Initiator microwave synthesizer. <sup>1</sup>H NMR and <sup>13</sup>C NMR spectra were recorded on Bruker 400 MHz AVANCE III. Chemical shifts were expressed in parts per million (ppm, Î´ units). Coupling constants are in units of hertz (Hz). Splitting patterns describe apparent multiplicities and are designated as s (singlet), d (doublet), t (triplet), q (quartet), m (multiplet), br (broad). Mass spectra were obtained with either a Micromass, Quattro LC triple quadruple tandem mass spectometer, ESI or Agilent, 1200LC/MSD, ESI. For preparative HPLC, ca. 100 mg of a product was injected in 1 mL of DMSO onto a SunFire Prep C18 OBD 5 Î¼m 19 mm Ã 100 mm column with a 10 min gradient from 10% CH<sub>3</sub>CN to 90% CH<sub>3</sub>CN in H<sub>2</sub>O (purification systems from Gilson, Inc. or Waters, Inc.). The tested compounds were determined to be >95% pure by HPLC. Flash chromatography was carried using Merck Silica Gel 60 (230â400 mesh). A Biotage SP1 FLASH purification system or Biotage Isolera FLASH purification system was used for normal phase column chromatography with ethyl acetate/hexane or tetrahydrofuran/hexane. Most of the reactions were monitored by thin-layer chromatography on 0.25 mm E. Merck silica gel plates (60F-254), visualized with UV light using a 5% ethanolic phosphomolybdic acid or <i>p</i>-anisaldehyde solution. Except where otherwise noted, all reactions were run under an inert atmosphere of nitrogen gas using anhydrous solvents.</div><div id="sec5_1_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i16" class="anchor-spacer"></div><h4 class="article-section__title" id="_i16"> Ethyl 2-(Hydroxyimino)-3-oxobutanoate (<b>6</b>)</h4><div class="NLM_p last">To a solution of ethyl acetoacetate (<b>5</b>, 30 g, 0.23 mol) in acetic acid (35 mL) was added slowly sodium nitrite (18.0 g, 0.25 mol) in cold water (40 mL) at â10 Â°C. The reaction mixture was stirred for 1 h, then cold water (120 mL) was added and then stirred for 3 h. The mixture was extracted with diethyl ether (300 mL). The organic layer was washed with saturated NaHCO<sub>3</sub> (400 mL Ã 2), then dried over anhydrous MgSO<sub>4</sub>, filtered, and concentrated in vacuo. The obtained product (21.46 g, white solid) was used for the next step without purification. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) Î´ 13.20 (s, 1H), 4.21 (q, <i>J</i> = 7.2 Hz, 2H), 2.32 (s, 3H), 1.92 (t, <i>J</i> = 6.8 Hz, 3H).</div></div><div id="sec5_1_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i17" class="anchor-spacer"></div><h4 class="article-section__title" id="_i17"> Ethyl 2-Acetamido-3-oxobutanoate (<b>8</b>)</h4><div class="NLM_p last">To a mixture of ethyl 2-(hydroxyimino)-3-oxobutanoate (<b>6</b>, 9.32 g, 58.5 mmol) and Pd/C (400 mg, palladium on carbon, 10 wt %, support activated carbon, wet, Degussa type E101 NE/W) in EtOH was added acetic anhydride (<b>7</b>, 11.0 mL, 117.0 mmol) at room temperature. The reaction mixture was stirred at room temperature under H<sub>2</sub> for 15 h. The palladium was filtered off (Filter aid, Celite 521 AW), and then the filtrate was concentrated in vacuo. The crude product was purified by flash column chromatography (Biotage SP1 FLASH purification system) to provide the title compound (9.48 g, 86%) as a white solid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) Î´ 6.62 (br s, 1H), 5.25 (d, <i>J</i> = 6.4 Hz, 1H), 4.28 (q, <i>J</i> = 7.2 Hz, 2H), 2.39 (s, 3H), 2.07 (s, 3H), 1.32 (t, <i>J</i> = 7.2 Hz, 3H).</div></div><div id="sec5_1_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i18" class="anchor-spacer"></div><h4 class="article-section__title" id="_i18"> Ethyl 2,5-Dimethyl-1-phenyl-1<i>H</i>-imidazole-4-carboxylate (<b>10</b>)</h4><div class="NLM_p last">To a solution of ethyl 2-acetamido-3-oxobutanoate (<b>8</b>) (5.0 g, 26.7 mmol) and aniline (<b>9</b>, 7.3 mL, 80.1 mmol) in butyronitrile (10 mL) was added trifluoroacetic acid (6.2 mL, 80.1 mmol) at room temperature. The reaction mixture was irradiated in a microwave reactor (Biotage Initiator) for 40 min at 140 Â°C. The mixture was concentrated under reduced pressure. The residue was diluted with CH<sub>2</sub>Cl<sub>2</sub> and washed with aqueous K<sub>2</sub>CO<sub>3</sub>. The organic layer was dried over anhydrous MgSO<sub>4</sub>, filtered, and concentrated in vacuo. The crude product was purified by flash column chromatography (Biotage SP1 FLASH purification system) to provide the title compound (4.97 g, 76%) as a yellow solid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) Î´ 7.57â7.51 (m, 3H), 7.20â7.18 (m, 2H), 4.41 (q, <i>J</i> = 6.8 Hz, 2H), 2.31 (s, 3H), 2.22 (s, 3H), 1.42 (t, <i>J</i> = 7.2 Hz, 3H); MH<sup>+</sup> 245.</div></div><div id="sec5_1_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i19" class="anchor-spacer"></div><h4 class="article-section__title" id="_i19"> Lithium 2,5-Dimethyl-1-phenyl-1<i>H</i>-imidazole-4-carboxylate (<b>11</b>)</h4><div class="NLM_p last">To a solution of ethyl 2,5-dimethyl-1-phenyl-1<i>H</i>-imidazole-4-carboxylate (<b>10,</b> 4.97 g, 20.3 mmol) in THF/water (15/15 mL) was added lithium hydroxide monohydrate at room temperature. The reaction mixture was stirred at 55 Â°C for 12 h, and then the mixture was concentrated in vacuo. The crude solid was washed with diethyl ether to provide the title compound (4.06 g, 90%) as a white solid. The obtained product was used for the next step without purification. <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) Î´ 7.59â7.54 (m, 3H), 7.31â7.28 (m, 2H), 2.26 (s, 3H), 2.14 (s, 3H). MS <i>m</i>/<i>z</i>: 217 (MH<sup>+</sup> â Li<sup>+</sup>).</div></div><div id="sec5_1_5" class="NLM_sec NLM_sec_level_3"><div id="ac_i20" class="anchor-spacer"></div><h4 class="article-section__title" id="_i20"> <i>N</i>-Phenylbenzimidamide (<b>13</b>)</h4><div class="NLM_p last">To NaHMDS (49 mL, 48.5 mmol, 1.0 M solution in THF) was added dropwise a solution of aniline (<b>9</b>, 4.5 mL, 48.5 mmol) in anhydrous THF (10 mL) under N<sub>2</sub>. After 20 min, a solution of benzonitrile (<b>12</b>, 5.0 mL, 48.5 mmol) in anhydrous THF (10 mL) was slowly added. The reaction mixture was stirred for 12 h, poured into cold water, and extracted with EtOAc. The organic layer was dried over anhydrous MgSO<sub>4</sub>, filtered, and concentrated in vacuo. The crude product was used for the next step without purification.</div></div><div id="sec5_1_6" class="NLM_sec NLM_sec_level_3"><div id="ac_i21" class="anchor-spacer"></div><h4 class="article-section__title" id="_i21"> Ethyl 5-Methyl-1,2-diphenyl-1<i>H</i>-imidazole-4-carboxylate (<b>15</b>)</h4><div class="NLM_p last">A mixture of <i>N</i>-phenylbenzimidamide (<b>13</b>, 1.0 g, 5.10 mmol), 3-bromo-2-oxovalerate (<b>14</b>, 1.3 g, 6.12 mmol), and NaHCO<sub>3</sub> in <i>i</i>-PrOH was stirred at 90 Â°C for 12 h. The reaction mixture was concentrated under reduced pressure, and then the residue was diluted with EtOAc and washed with H<sub>2</sub>O. The organic layer was dried over anhydrous MgSO<sub>4</sub>, filtered, and concentrated in vacuo. The crude product was purified by flash column chromatography (Biotage Isolera FLASH purification system) to provide the title compound (0.86 g, 55%) as a yellow solid.</div></div><div id="sec5_1_7" class="NLM_sec NLM_sec_level_3"><div id="ac_i22" class="anchor-spacer"></div><h4 class="article-section__title" id="_i22"> Lithium 5-Methyl-1,2-diphenyl-1<i>H</i>-imidazole-4-carboxylate (<b>16</b>)</h4><div class="NLM_p last">Following the procedure for compound <b>11</b>, the desired compound was obtained as a white solid. <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) Î´ 7.52â7.48 (m, 3H), 7.34â7.31 (m, 2H), 7.26â7.17 (m, 5H), 2.36 (s, 3H). MS <i>m</i>/<i>z</i>: 279 (MH<sup>+</sup> â Li<sup>+</sup>).</div></div><div id="sec5_1_8" class="NLM_sec NLM_sec_level_3"><div id="ac_i23" class="anchor-spacer"></div><h4 class="article-section__title" id="_i23"> <i>N</i>-(4-Chlorophenyl)butyrimidamide (<b>19</b>)</h4><div class="NLM_p last">To a solution of butyronitrile (<b>18</b>, 7.5 mL, 86.2 mmol) and AlCl<sub>3</sub> in toluene was added 4-chloroaniline (<b>17</b>, 10.0 g, 78.4 mmol). The reaction mixture was stirred at 115 Â°C for 5 h. The mixture was diluted with water (200 mL) and extracted with EtOAc (200 mL). The aqueous layer was neutralized with saturated NaHCO<sub>3</sub> (500 mL) and extracted with EtOAc (300 mL Ã 2). The organic layer was dried over anhydrous MgSO<sub>4</sub>, filtered, and concentrated in vacuo. The obtained product (9.2 g, pale-brown solid) was used for the next step without purification.</div></div><div id="sec5_1_9" class="NLM_sec NLM_sec_level_3"><div id="ac_i24" class="anchor-spacer"></div><h4 class="article-section__title" id="_i24"> Ethyl 1-(4-Chlorophenyl)-2-propyl-1<i>H</i>-imidazole-4-carboxylate (<b>21</b>)</h4><div class="NLM_p last">To a solution of <i>N</i>-(4-chlorophenyl)butyrimidamide (<b>19</b>, 3.5 g, 17.80 mmol) and NaHCO<sub>3</sub> (3.14 g, 37.38 mmol) in <i>i</i>-PrOH was added ethyl bromopyruvate (<b>20</b>, 4.7 mL, 37.38 mmol) under N<sub>2</sub>. The reaction mixture was stirred at 85 Â°C for 72 h, and then AcOH (15 mL)was added. After 4 h, the mixture was concentrated under reduced pressure. The residue was diluted with H<sub>2</sub>O and extracted with CH<sub>2</sub>Cl<sub>2</sub>. The organic layer was washed with saturated NaHCO<sub>3</sub> and 1N HCl solution and then dried over anhydrous MgSO<sub>4</sub>, filtered, and concentrated in vacuo. The crude product was purified by flash column chromatography (Biotage Isolera FLASH purification system) to provide the title compound (1.28 g, 25%) as a brown oil. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) Î´ 7.62 (s, 1H), 7.51â7.47 (m, 2H), 7.26â7.23 (m, 2H), 4.39 (q, <i>J</i> = 7.2 Hz, 2H), 2.62 (t, <i>J</i> = 7.6 Hz, 2H), 1.71â1.61 (m, 2H), 1.39 (t, <i>J</i> = 6.8 Hz, 3H), 0.86 (t, <i>J</i> = 7.2 Hz, 3H). MH<sup>+</sup> 293.</div></div><div id="sec5_1_10" class="NLM_sec NLM_sec_level_3"><div id="ac_i25" class="anchor-spacer"></div><h4 class="article-section__title" id="_i25"> Lithium 1-(4-Chlorophenyl)-2-propyl-1<i>H</i>-imidazole-4-carboxylate (<b>22</b>)</h4><div class="NLM_p last">Following the procedure for compound <b>11</b>, the desired compound was obtained as a pale-brown solid (3.00 g, 86%). <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) Î´ 7.58â7.56 (m, 2H), 7.49 (s, 1H), 7.43â7.40 (m, 2H), 2.63â2.59 (m, 2H), 1.70â1.61 (m, 2H), 0.86 (t, <i>J</i> = 7.6 Hz, 3H). MS <i>m</i>/<i>z</i>: 265 (MH<sup>+</sup> â Li<sup>+</sup>).</div></div><div id="sec5_1_11" class="NLM_sec NLM_sec_level_3"><div id="ac_i26" class="anchor-spacer"></div><h4 class="article-section__title" id="_i26"> 4-[1-Dimethylamino-eth-(<i>Z</i>)-ylidene]-2-methyl-4<i>H</i>-oxazole-5-one (<b>24</b>)</h4><div class="NLM_p last"><i>N</i>-Acetylglycine (<b>23</b>, 10 g, 85.5 mmol) was dissolved in <i>N</i>,<i>N</i>â²-dimethylacetamide (20 mL, 21.4 mmol), and POCl<sub>3</sub> (19.6 mL, 21.4 mmol) was added dropwise slowly at 0 Â°C. The reaction mixture was stirred at 50 Â°C for 3 h and then cooled to room temperature. CH<sub>2</sub>Cl<sub>2</sub> (50 mL) was added and the mixture poured into iceâwater. The resulting solution was basified with ammonium hydroxide to over than pH 8. The organic extracts were washed with 50 mL of water, dried over MgSO<sub>4</sub>, filtered, and evaporated under reduced pressure. The residue was purified by normal phase preparative column, and the desired compound was obtained as an orange solid (6.7 g, 47%). MH<sup>+</sup> 169.</div></div><div id="sec5_1_12" class="NLM_sec NLM_sec_level_3"><div id="ac_i27" class="anchor-spacer"></div><h4 class="article-section__title" id="_i27"> (<i>E</i>)-Ethyl 2-Acetamido-3-(dimethylamino)but-2-enoate (<b>25</b>)</h4><div class="NLM_p last">4-[1-Dimethylamino-eth-(<i>Z</i>)-ylidene]-2-methyl-4<i>H</i>-oxazole-5-one (<b>24</b>, 7.54 g, 44.8 mmol) was dissolved in ethanol (50 mL), and sodium hydride (179 mg, 4.5 mmol, 60% dispersion in mineral oil) wad added at room temperature. The solution was refluxed for 1 h. The solvent was evaporated, and the crude product was used without any further purification for the next step. MH<sup>+</sup> 215.</div></div><div id="sec5_1_13" class="NLM_sec NLM_sec_level_3"><div id="ac_i28" class="anchor-spacer"></div><h4 class="article-section__title" id="_i28"> (<i>E</i>)-Ethyl 2-Acetamido-3-(cyclopentylamino)but-2-enoate (<b>27</b>)</h4><div class="NLM_p last">(<i>E</i>)-Ethyl 2-acetamido-3-(dimethylamino)but-2-enoate (<b>25</b>, 1 g, 4.67 mmol) and cyclopentylamine (<b>26</b>, 0.5 mL) were stirred at room temperature in AcOH (10 mL) for overnight. The reaction mixture was diluted slowly with water (10 mL) and evaporated under reduced pressure to obtain the desired product as a dark-brown oil, which could be used without any further purification for the next step. MH<sup>+</sup> 256.</div></div><div id="sec5_1_14" class="NLM_sec NLM_sec_level_3"><div id="ac_i29" class="anchor-spacer"></div><h4 class="article-section__title" id="_i29"> Ethyl 1-Cyclopentyl-2,5-dimethyl-1<i>H</i>-imidazole-4-carboxylate (<b>28</b>)</h4><div class="NLM_p last">Ammonium sulfate (100 mg) was added to a solution of (<i>E</i>)-ethyl 2-acetamido-3-(cyclopentylamino)but-2-enoate (<b>27</b>, 1.5 g, 5.9 mmol) and hexamethyldisilazane (15 mL) and refluxed overnight at 150 Â°C. The reaction mixture was evaporated and extracted with EtOAc and water. The organic layer was evaporated, and the residue was purified with 20% methanol in CH<sub>2</sub>Cl<sub>2</sub> to produce as a light-brown solid (1.0 g, 71.4%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) Î´ 4.31 (q, <i>J</i> = 6.5 Hz, 2H), 3.77 (m, 1H), 2.59 (s, 3H), 2.33 (s, 3H), 2.15â2.06 (m, 2H), 1.83â1.80 (m, 2H), 1.72â1.54 (m, 2H), 1.32 (t, <i>J</i> = 6.5 Hz, 3H). MH<sup>+</sup> 237.</div></div><div id="sec5_1_15" class="NLM_sec NLM_sec_level_3"><div id="ac_i30" class="anchor-spacer"></div><h4 class="article-section__title" id="_i30"> 2-(3-(4-(2,3-Dichlorophenyl)piperazin-1-yl)propyl)isoindoline-1,3-dione (<b>32</b>)</h4><div class="NLM_p last">The mixture of 1-(2,3-dichlorophenyl)piperazine hydrochloride (<b>31</b>, 10.0 g, 37.4 mmol), <i>N</i>-(3-bromopropyl)phthalimide (<b>30</b>, 9.09 g, 33.9 mmol), and potassium carbonate (11.7 g, 84.8 mmol) in DMF was stirred at room temperature. The mixture was concentrated under reduced pressure. The residue was diluted with CH<sub>2</sub>Cl<sub>2</sub> and washed with water. The organic layer was dried over anhydrous MgSO<sub>4</sub>, filtered, and concentrated in vacuo. The obtained product was washed with EtOH to provide the title compound (11.2 g, 80%) as a white solid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) Î´ 7.88â7.83 (m, 2H), 7.74â7.69 (m, 2H), 7.15â7.09 (m, 2H), 6.82 (dd, <i>J</i> = 7.6, 2.4 Hz, 1H), 3.80 (t, <i>J</i> = 7.2 Hz, 2H), 2.93â2.87 (m, 4H), 2.62â2.56 (m, 4H), 2.51 (t, <i>J</i> = 5.6 Hz, 2H), 1.94â1.87 (m, 2H). MH<sup>+</sup> 418; mp 119.2 Â°C.</div></div><div id="sec5_1_16" class="NLM_sec NLM_sec_level_3"><div id="ac_i31" class="anchor-spacer"></div><h4 class="article-section__title" id="_i31"> 3-(4-(2,3-Dichlorophenyl)piperazin-1-yl)propan-1-amine Dihydrochloride (<b>33</b>)</h4><div class="NLM_p last">To a suspension of 2-(3-(4-(2,3-dichlorophenyl)piperazin-1-yl)propyl)isoindoline-1,3-dione (<b>32</b>, 11.1 g, 26.5 mmol) in EtOH was added hydrazine monohydrate. The reaction mixture was stirred at room temperature for 6 h and then the white solid filtered off. The filtrate was concentrated under reduced pressure. The residue was diluted with CH<sub>2</sub>Cl<sub>2</sub> and washed with saturated NaHCO<sub>3</sub>. The organic layer was dried over anhydrous MgSO<sub>4</sub>, filtered, and concentrated in vacuo. To the crude product in diethyl ether was added 2 M HCl solution in diethyl ether (10 mL). The obtained product was washed with diethyl ether to provide the title compound (6.98 g, 73%) as a white solid. <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) Î´ 7.22â7.18 (m, 2H), 7.08 (dd, <i>J</i> = 7.2, 2.4 Hz, 1H), 3.06â3.02 (m, 6H), 2.72â2.64 (m, 4H), 2.60 (t, <i>J</i> = 6.8 Hz, 2H), 1.90â1.84 (m, 2H). MS <i>m</i>/<i>z</i>: 288 (MH<sup>+</sup> â 2HCl).</div></div><div id="sec5_1_17" class="NLM_sec NLM_sec_level_3"><div id="ac_i32" class="anchor-spacer"></div><h4 class="article-section__title" id="_i32"> 1-Amino-3-(4-(2,3-dichlorophenyl)piperazin-1-yl)propan-2-ol Dihydrochloride (<b>36</b>)</h4><div class="NLM_p last">To a stirred solution of <i>N</i>-(2,3-epoxypropyl)phthalimide (<b>34</b>, 10 g, 0.049 mol) in THF (100 mL) was added 1-(2,3-dichlorophenyl)piperazine hydrochloride (<b>31</b>, 8.7 g, 0.033 mol) and triethylamine (4.6 mL, 0.033 mol) at room temperature, and then the resultant solution was heated at 80 Â°C overnight. The reaction was quenched with H<sub>2</sub>O and extracted with CH<sub>2</sub>Cl<sub>2</sub>. The organic layer was washed with brine, dried over MgSO<sub>4</sub>, filtered, and evaporated. The solid residue was solidified with CH<sub>2</sub>Cl<sub>2</sub> (20 mL)/diethyl ether (200 mL), filtered, and dried in vacuo, which was used for the following synthesis without further purification. To the prepared white solid piperazine (<b>35</b>, 13 g, 0.030 mol) in EtOH was added hydrazine monohydrate (20 mL), and the reaction solution was refluxed at 80 Â°C for 2 h. The reaction solution was cooled to room temperature and evaporated. The oily crude compound was extracted with EtOAc/H<sub>2</sub>O, and organic the layer was combined and evaporated. The pale-yellow solid was tritulated with ether to afford pure targeted amine (<b>36</b>, 8.7 g, 95%) as white solid. <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) Î´ 7.31â7.27 (m, 2H), 7.19â7.15 (m, 1H), 4.40â4.36 (m, 1H), 3.42â3.39 (m, 4H), 3.37â3.32 (m, 4H), 3.24â2.93 (m, 4H). MS <i>m</i>/<i>z</i>: 304 (MH<sup>+</sup> â 2HCl).</div></div></div><div id="sec5_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i33" class="anchor-spacer"></div><h3 class="article-section__title" id="_i33"> General Procedure (Synthesis of A)</h3><div id="sec5_2_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i34" class="anchor-spacer"></div><h4 class="article-section__title" id="_i34"> <i>N</i>-(3-(4-(2,3-Dichlorophenyl)piperazin-1-yl)propyl)-5-methyl-1,2-diphenyl-1<i>H</i>-imidazole-4-carboxamide Dihydrochloride (<b>43</b>)</h4><div class="NLM_p last">To a mixture of lithium 5-methyl-1,2-diphenyl-1<i>H</i>-imidazole-4-carboxylate (<b>16</b>, 300 mg, 1.06 mmol), 1-amino-3-(4-(2,3-dichlorophenyl)piperazin-1-yl)propan-2-ol dihydrochloride (459 mg, 1.27 mmol), EDCI (305 mg, 1.59 mmol), and HOBt (286 mg, 2.12 mmol) in anhydrous DMF (5 mL) was added NMM (580 Î¼L, 5.30 mmol). The reaction mixture was stirred at room temperature for 15 h. The mixture was concentrated under reduced pressure. The residue was diluted with EtOAc and washed with saturated NaHCO<sub>3</sub>. The organic layer was dried over anhydrous MgSO<sub>4</sub>, filtered, and concentrated in vacuo. The crude product was purified by preparative HPLC (purification system, Gilson Inc.) and followed by treatment of 2 M HCl solution in diethyl ether generated to provide the title compound (267 mg, 46%) as a white solid. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) Î´ 10.52 (s, 1H), 8.45 (s, 1H), 7.59â7.20 (m, 13H), 6.97 (dd, <i>J</i> = 7.2, 2.4 Hz, 1H), 3.81â3.68 (m, 2H), 3.65â3.51 (m, 2H), 3.50â3.31 (m, 4H), 2.77â2.60 (m, 4H), 2.45 (s, 3H), 2.09â1.95 (m, 2H). <sup>13</sup>C NMR (100 MHz, DMSO-<i>d</i><sub>6</sub>) Î´ 161,4, 149.5, 144.3, 134.9, 134.8, 132.7, 130.1, 129.9, 129.8, 128.8, 128.6, 128.3, 128.0, 127.4, 127.0, 126.0, 125.2, 119.8, 53.6, 51.1, 47.6, 35.9, 23.7, 10.2. MS <i>m</i>/<i>z</i>: 548 (MH<sup>+</sup> â 2HCl); positive HR-FAB-MS <i>m</i>/<i>z</i> 548.1990 (MH<sup>+</sup> â 2HCl) (calcd for C<sub>30</sub>H<sub>31</sub>Cl<sub>2</sub>N<sub>5</sub>O: 548.1984).</div></div></div><div id="sec5_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i35" class="anchor-spacer"></div><h3 class="article-section__title" id="_i35"> Biological Methods</h3><div id="sec5_3_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i36" class="anchor-spacer"></div><h4 class="article-section__title" id="_i36"> Measurement of Binding Affinity for Serotonin 5-HT<sub>2A</sub> and 5-HT<sub>2C</sub> Receptors</h4><div class="NLM_p">Receptor binding affinities of the compounds for serotonin receptors were measured by the method described in the literature.<a onclick="showRef(event, 'ref25'); return false;" href="javascript:void(0);" class="ref ref25">(25)</a></div><div class="NLM_p">For serotonin 5-HT<sub>2A</sub> binding, an aliquot of human recombinant serotonin 5-HT<sub>2A</sub> receptor (PerkinElmer Life and Analytical Sciences, USA) expressed in CHO-K1 cells (5 Î¼g/well) and 1 nM [<sup>3</sup>H]Ketanserin (Perkin-Elmer) were used in the presence of mianserin (20 Î¼M) as nonspecific. The reaction mixture was incubated for 60 min at 27 Â°C using 50 mM Tris-HCl (pH 7.4) buffer containing 4 mM CaCl<sub>2</sub> and 0.1% ascorbic acid and harvested through filtermate A glass fiber filter (Wallac, Finland) presoaked in 0.5% polyethyleneimine (PEI) by MicroBeta Filtermate-96 harvester (PerkinElmer) to terminate the reaction and then washed with ice-cold 50 mM Tris-HCl buffer solution (pH 7.4). The filter was then covered with MeltiLex, sealed in a sample bag, and dried in an oven. The radioactivity retained in the filter was finally counted using MicroBeta Plus (Wallac).</div><div class="NLM_p">The binding affinity (IC<sub>50</sub>) of a compound for the receptor was calculated by computerized nonlinear regression analysis (GraphPad Prism Program, San Diego, USA) using 7â8 varied concentrations of the compound run in duplicate tubes.</div><div class="NLM_p last">For serotonin 5-HT<sub>2C</sub> binding, frozen membranes from stable CHO-K1 cell line expressing the human recombinant 5-HT<sub>2C</sub> receptor (PerkinElmer, 4 Î¼g/well), [<sup>3</sup>H]Mesulergine (Amersham, 1.3 nM), and test compounds were added into 50 mM Tris-HCl (pH 7.4) buffer containing 0.1% ascorbic acid and 4 mM CaCl<sub>2</sub>. Nonspecific binding was determined using 100 Î¼M mianserin. The incubations were performed for 60 min at 27 Â°C, and these were terminated by rapid filtration through Filtermate A glass fiber filter presoaked in 0.5% PEI.</div></div><div id="sec5_3_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i37" class="anchor-spacer"></div><h4 class="article-section__title" id="_i37"> Measurement of Binding Affinity for Serotonin Transporter</h4><div class="NLM_p last">For serotonin transporter binding assays, a reaction mixture with a final volume of 0.25 mL was prepared by mixing a test compound, human serotonin transporter membrane expressed in HEK-293 cells (Perkin-Elmer, 5 Î¼g/well), [<sup>3</sup>H]Imipramine (Perkin-Elmer, 2 nM), and 50 mM Tris-HCl (pH 7.4) buffer containing 120 mM NaCl and 5 mM KCl. The reaction mixture was incubated for 30 min at 27 Â°C and harvested through Filtermate A glass fiber filter presoaked in 0.5% PEI with ice-cold 50 mM Tris-HCl buffer (pH 7.4) containing 0.9% NaCl.</div></div><div id="sec5_3_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i38" class="anchor-spacer"></div><h4 class="article-section__title" id="_i38"> Measurement of Antidepressants Activity in Forced Swimming Test</h4><div class="NLM_p">To evaluate the antidepressants activity of the compounds, the inhibitory effects on immobility in forced swimming test in mice were measured according to the methods described by Porsolt et al.<a onclick="showRef(event, 'ref29'); return false;" href="javascript:void(0);" class="ref ref29">(29)</a></div><div class="NLM_p last">Each mouse was placed in a 25 cm glass cylinder (10 cm diameter) containing 15 cm of water maintained at 22 Â± 1 Â°C and was forced to swim for 10 min. Twenty-four hours later, the mouse was replaced into the cylinder and the total duration of immobility was recorded during the last 5 min of the 6 min testing period. Mice are judged immobile when they float in an upright position and make only small movements to keep their head above water. Test drugs were suspended in 3% Tween 80 solution and administered orally (po) 60 min before the testing.</div></div><div id="sec5_3_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i39" class="anchor-spacer"></div><h4 class="article-section__title" id="_i39"> Measurement of Spontaneous Locomotion Activity</h4><div class="NLM_p last">Locomotor activity was assessed with an animal activity monitoring apparatus (EthoVision, Nolduls, Netherlands.). Fifty minutes after the administration, mice were placed individually in 32 cm Ã 45 cm Ã 32 cm plastic cages, to which they had not been previously exposed, under dim light and sound-attenuated conditions. After an initial 10 min of familiarization period, locomotor activity was monitored for 30 min. The results of the locomotor activity tests were expressed as mean Â± SEM.</div></div><div id="sec5_3_5" class="NLM_sec NLM_sec_level_3"><div id="ac_i40" class="anchor-spacer"></div><h4 class="article-section__title" id="_i40"> Pharmacokinetic Study</h4><div class="NLM_p last">Male SpragueâDawley rats (260â280 g) were purchased from Orient Bio Inc. (Gyeonggi-Do, Korea). Two days before dosing, the femoral artery and vein (intravenous (iv) only) were cannulated using polyethylene tube SP28 (Natsume, Tokyo, Japan). For intravenous administration, prepared dosing solution was injected via the femoral vein. The rats were fasted overnight before drug administration and until 6 h after dosing. For the po experiment, rats (three in each group) were given a single dose of 5 mg/kg, and heparinized samples of blood (0.3 mL) were collected at 5, 15, 30, 60, 90, 120, 240, 360, 480, 600 min, and 24 h postdose. For the iv experiment, rats (three in each group) were given a single 1 mg/kg dose, and blood samples were collected at 5, 10, 20, 40, 60, 90, 120, 240, 360, and 480 min postdose. Plasma was harvested after centrifugation and stored frozen at â20 Â°C until analyzed. The concentrations of compounds in plasma were determined by LC/MS/MS (API3200). The results are shown as the maximum plasma concentration (<i>C</i><sub>max</sub>), the time to reach peak plasma concentration (<i>T</i><sub>max</sub>), terminal half-life (<i>t</i><sub>1/2</sub>), and the area under the plasma concentrationâtime curve from zero to time infinity (AUC<sub>0ââ</sub>).</div></div><div id="sec5_3_6" class="NLM_sec NLM_sec_level_3"><div id="ac_i41" class="anchor-spacer"></div><h4 class="article-section__title" id="_i41"> Measurement of <i>h</i>ERG Inhibition</h4><div class="NLM_p last">HEK293 cells stably expressing the <i>h</i>ERG potassium channel are a <i>Homo sapien</i> embryonic kidney epithelial cell line transformed with the adenovirus 5 DNA. The parental HEK293 cell line was devoid of the IKr currents before transfection of the <i>h</i>ERG cDNAs. The HEK293 cells were cotransfected with the <i>h</i>ERG cDNA and G418-resistant gene incorporated into a modified pcDNA3 plasmid. The stable transfectants were maintained under constant selection pressure incorporated into the culture media. The culture media was Minimum Essential Medium (MEM, including Earleâs Salts and <span class="smallcaps smallerCapital">l</span>-glutamine) supplemented with approximately 10% fetal bovine serum, 100 U/mL of penicillin-g, 100 Î¼g/mL streptomycin, 0.1 mM nonessential amino acids (NEAA) solution, 1 mM sodium pyruvate, and 400 Î¼g/mL G418.</div></div><div id="sec5_3_7" class="NLM_sec NLM_sec_level_3"><div id="ac_i42" class="anchor-spacer"></div><h4 class="article-section__title" id="_i42"> Measurement of CYP</h4><div class="NLM_p last">To evaluate the CYP of the compounds, we used P450-Glo screening system. The systems include a membrane preparation containing recombinant human cytochrome P450 (CYP) enzyme, negative control membranes, a luminogenic substrate appropriate for the CYP enzyme, NADPH regeneration system, reaction buffer, Luciferin detection reagent, and Luciferin-Free water. The membranes are prepared from baculovirus-infected insect cells and contain human CYP enzyme and P450 reductase (and cytochrome b5 for CYP2C9, 2C19, and 3A4). The negative control membranes are devoid of CYP activity. The assays are ideal for testing the effects of drugs and new chemical entities on CYP enzyme activities.</div></div><div id="sec5_3_8" class="NLM_sec NLM_sec_level_3"><div id="ac_i43" class="anchor-spacer"></div><h4 class="article-section__title" id="_i43"> Measurement of Cytotoxicity</h4><div class="NLM_p last">HT22 cells (mouse hippocampal neuron, Salk Institute and KRIBB) were plated in a 96-well plates 3 Ã 10<sup>3</sup> cells/well for 18 h before treatment. 3-HMÂ·HBr were treated and incubated for 48 h in growth media (DMEM with 10% FBS and 1% penicillin streptomycin). MTT (3-(4,5-dimethylthazol-2-yl)-2,5-diphenyltetrazolium bromide, Sigma) was treated for 4 h and detected with a plate reader at a wavelength = 450 nm.</div></div><div id="sec5_3_9" class="NLM_sec NLM_sec_level_3"><div id="ac_i44" class="anchor-spacer"></div><h4 class="article-section__title" id="_i44"> Measurement of AMES</h4><div class="NLM_p">This test performed essentially as described by Ames et al. (1973, 1975). Media and positive control chemicals were obtained from commercial sources and were the purest grades available. Strain TA 100 was chosen as the representative tester strain because of its high spontaneous reversion rate. Spontaneous revertant numbers were counted and plotted against the dose of the test chemical to produce a survival curve for the <i>his</i><sup><i>+</i></sup> genotype.</div><div class="NLM_p last">The mutagenicity assay was performed by mixing one of the tester strains which was cultured overnight with the test substance in the presence and in the absence of S9 mixture condition, sodium phosphate buffer added instead of S9 mixture both in negative and positive control in a test tube. Then, incubating the mixture in water bath for 30 min at 37 Â°C and after incubation, the mixture was mixed with top agar containing a minimal amount of histidine and then poured onto the surface of a Î³-ray sterile Petri dish (Falcon, USA) containing 25 mL of solidified bottom agar. The finished plates were incubated for 48 h at 37 Â°C, and revertant colonies were counted later. Negative control plates containing no added test chemical, but positive control plates containing appropriate amounts of chemicals known to be active were included with each tester strain. Sodium azide (SA) and 2-aminoanthracene (2-AA) were used as positive control substances. Compounds were tested at seven concentration points in duplicate at a range of concentrations up to 2500 Î¼g/plate. A response was considered to be positive in our criteria if there was a dose-dependent increase in revertants per plate, resulting in at least a doubling of the background reversion rate for strains TA 100.</div></div></div></div><div class="NLM_back"><div class="article_supporting-info" id="notes-1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i45"><a href="/doi/suppl/10.1021/jm200682b">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_52657" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_52657" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">Experimental procedures for molecules not described in main paper text and <sup>1</sup>H NMR, <sup>13</sup>C NMR, and HPLC spectrum data for compounds <b>57</b>, <b>68</b>, <b>70</b>, <b>71</b>, <b>100</b>, <b>131</b>, <b>143</b>, and <b>145</b>. This material is available free of charge via the Internet at <a href="http://pubs.acs.org" class="extLink">http://pubs.acs.org</a>.</p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/jm200682b/suppl_file/jm200682b_si_001.pdf">jm200682b_si_001.pdf (7.74 MB)</a></li></ul></div></div></div><div class="testing" data-doi="10.1021/jm200682b" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="TermsAndConditionsDropzone3" data-pb-dropzone="TermsAndConditionsDropzone3"><div data-widget-def="UX3HTMLWidget" data-widget-id="85b54935-30e9-4058-a6d2-0b40fb754a85" class="mb-4">
        



        
            <h2 class="">
                Terms & Conditions
            </h2>
        
        <p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system: <a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_01443" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_01443" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Author</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jinhwa Lee</span> - <span class="hlFld-Affiliation affiliation">Research Center, Green Cross Corporation, 303 Bojeong-dong, Giheung-gu, Yongin 446-770, Korea</span>;Â 
    <span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#fd979493958a9c919898bd9a8f9898939e8f928e8ed39e9290"><span class="__cf_email__" data-cfemail="13797a7d7b64727f767653746176767d70617c60603d707c7e">[emailÂ protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Hee Jeong Seo</span> - <span class="hlFld-Affiliation affiliation">Research Center, Green Cross Corporation, 303 Bojeong-dong, Giheung-gu, Yongin 446-770, Korea</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Eun-Jung Park</span> - <span class="hlFld-Affiliation affiliation">Research Center, Green Cross Corporation, 303 Bojeong-dong, Giheung-gu, Yongin 446-770, Korea</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Min Ju Kim</span> - <span class="hlFld-Affiliation affiliation">Research Center, Green Cross Corporation, 303 Bojeong-dong, Giheung-gu, Yongin 446-770, Korea</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Suk Youn Kang</span> - <span class="hlFld-Affiliation affiliation">Research Center, Green Cross Corporation, 303 Bojeong-dong, Giheung-gu, Yongin 446-770, Korea</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Suk Ho Lee</span> - <span class="hlFld-Affiliation affiliation">Research Center, Green Cross Corporation, 303 Bojeong-dong, Giheung-gu, Yongin 446-770, Korea</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Hyun Jung Kim</span> - <span class="hlFld-Affiliation affiliation">Research Center, Green Cross Corporation, 303 Bojeong-dong, Giheung-gu, Yongin 446-770, Korea</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Ki Nam Lee</span> - <span class="hlFld-Affiliation affiliation">Research Center, Green Cross Corporation, 303 Bojeong-dong, Giheung-gu, Yongin 446-770, Korea</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Myung Eun Jung</span> - <span class="hlFld-Affiliation affiliation">Research Center, Green Cross Corporation, 303 Bojeong-dong, Giheung-gu, Yongin 446-770, Korea</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">MinWoo Lee</span> - <span class="hlFld-Affiliation affiliation">Research Center, Green Cross Corporation, 303 Bojeong-dong, Giheung-gu, Yongin 446-770, Korea</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Mi-Soon Kim</span> - <span class="hlFld-Affiliation affiliation">Research Center, Green Cross Corporation, 303 Bojeong-dong, Giheung-gu, Yongin 446-770, Korea</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Eun-Jung Son</span> - <span class="hlFld-Affiliation affiliation">Research Center, Green Cross Corporation, 303 Bojeong-dong, Giheung-gu, Yongin 446-770, Korea</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Woo-Kyu Park</span> - <span class="hlFld-Affiliation affiliation">Pharmacology Research Center, Korea Research Institute of Chemical Technology, 100 Jang-Dong, Yuseong-Gu, Daejeon 305-343, Korea</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jeongmin Kim</span> - <span class="hlFld-Affiliation affiliation">Research Center, Green Cross Corporation, 303 Bojeong-dong, Giheung-gu, Yongin 446-770, Korea</span></div></li></ul></li><li></li><li></li><li></li></ul></div><div class="ack"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i46">Acknowledgment</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_55028" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_55028" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">We are grateful to Dr. Eun Chul Huh for his leadership and supports as head of GCC R&D. This work was in part supported by Korea Ministry of Knowledge Economy.</p></div><div id="" class="NLM_sec NLM_sec_level_1"><div id="ac_i47" class="anchor-spacer"></div><h2 class="article-section__title section__title" id="_i47"> </h2><div class="NLM_p last"><table summary="" class="NLM_def-list" id="dl1"><div id="ac_i48" class="anchor-spacer"></div><h2 class="article-section__title section__title" id="_i48"> Abbreviations Used</h2><tr><td class="NLM_term">SARI</td><td class="NLM_def"><p class="first last">serotonin antagonist and reuptake inhibitor</p></td></tr><tr><td class="NLM_term">5-HT</td><td class="NLM_def"><p class="first last">serotonin or 5-Hydroxytryptamine</p></td></tr><tr><td class="NLM_term">5-HT<sub>2A/2C</sub></td><td class="NLM_def"><p class="first last">serotonin receptor subtype 2A/2C</p></td></tr><tr><td class="NLM_term">CNS</td><td class="NLM_def"><p class="first last">central nervous system</p></td></tr><tr><td class="NLM_term">FST</td><td class="NLM_def"><p class="first last">forced swimming test</p></td></tr><tr><td class="NLM_term">SSRIs</td><td class="NLM_def"><p class="first last">selective serotonin reuptake inhibitors</p></td></tr><tr><td class="NLM_term">SERT</td><td class="NLM_def"><p class="first last">serotonin transporter</p></td></tr><tr><td class="NLM_term">DMF</td><td class="NLM_def"><p class="first last"><i>N</i>,<i>N</i>â²-dimethylformamide</p></td></tr><tr><td class="NLM_term">EDCI</td><td class="NLM_def"><p class="first last"><i>N</i>-(3-dimethylaminopropyl)-<i>N</i>â²-ethylcarbodiimide</p></td></tr><tr><td class="NLM_term">NMM</td><td class="NLM_def"><p class="first last"><i>N</i>-methylmorpholine</p></td></tr><tr><td class="NLM_term">HOBt</td><td class="NLM_def"><p class="first last">1-hydroxybenzotriazole</p></td></tr><tr><td class="NLM_term">CHO-K1 cells</td><td class="NLM_def"><p class="first last">Chinese hamster ovary-K1 cells</p></td></tr><tr><td class="NLM_term">DMSO</td><td class="NLM_def"><p class="first last">dimethyl sulfoxide</p></td></tr><tr><td class="NLM_term">SLA</td><td class="NLM_def"><p class="first last">spontaneous locomotor activity</p></td></tr><tr><td class="NLM_term">SD rat</td><td class="NLM_def"><p class="first last">SpragueâDawley rat</p></td></tr><tr><td class="NLM_term">PK</td><td class="NLM_def"><p class="first last">pharmacokinetics</p></td></tr><tr><td class="NLM_term">AUC</td><td class="NLM_def"><p class="first last">area under the plasma concentration time curve</p></td></tr><tr><td class="NLM_term">IC<sub>50</sub></td><td class="NLM_def"><p class="first last">half-maximal inhibitory concentration</p></td></tr><tr><td class="NLM_term">BA</td><td class="NLM_def"><p class="first last">bioavailability</p></td></tr></table></div></div><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i49">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_76105" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_76105" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 29 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><span class="NLM_contrib-group">Murray, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lopez, A. D.</span><span> </span><span class="NLM_article-title">Global mortality, disability, and the contribution of risk factors: Global Burden of Disease Study</span> <span class="citation_source-journal">Lancet</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1997</span><span class="NLM_x">, </span> <span class="NLM_volume">349</span><span class="NLM_x">, </span> <span class="NLM_fpage">1436</span><span class="NLM_x">â</span> <span class="NLM_lpage">1442</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=349&publication_year=1997&pages=1436-1442&author=C.+J.+Murrayauthor=A.+D.+Lopez&title=Global+mortality%2C+disability%2C+and+the+contribution+of+risk+factors%3A+Global+Burden+of+Disease+Study"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMurray%26aufirst%3DC.%2BJ.%26aulast%3DLopez%26aufirst%3DA.%2BD.%26atitle%3DGlobal%2520mortality%252C%2520disability%252C%2520and%2520the%2520contribution%2520of%2520risk%2520factors%253A%2520Global%2520Burden%2520of%2520Disease%2520Study%26jtitle%3DLancet%26date%3D1997%26volume%3D349%26spage%3D1436%26epage%3D1442" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group">Olesen, J.; Saxena, P.</span>, Eds.  <span class="citation_source-book">5-Hydroxyltryptamine Mechanisms in Primary Headaches</span>, <span class="NLM_edition">1st</span> ed.; <span class="NLM_publisher-name">Raven Press</span>: <span class="NLM_publisher-loc">New York</span>,<span class="NLM_x"> </span><span class="NLM_year">1992</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=1992&author=J.+Olesen&author=P.+Saxena&title=5-Hydroxyltryptamine+Mechanisms+in+Primary+Headaches"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26aulast%3DOlesen%26aufirst%3DJ.%26btitle%3D5-Hydroxyltryptamine%2520Mechanisms%2520in%2520Primary%2520Headaches%26pub%3DRaven%2520Press%26date%3D1992" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group">Murray, C. J. L.; Lopez, A. D.</span>, Eds.  <span class="citation_source-book">The Global Burden of Disease; A Comprehensive Assessment of Mortality and Disability from Disease, Injuries and Risk Factors in 1990 and Projected to 2020</span>. Vol.  <span class="NLM_volume">1</span> of <span class="NLM_series">Global Burden of Disease and Injury Series</span>; <span class="NLM_publisher-name">Harvard University Press</span>: <span class="NLM_publisher-loc">Cambridge, MA</span>,<span class="NLM_x"> </span><span class="NLM_year">1996</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=1996&author=C.+J.+L.+Murray&author=A.+D.+Lopez&title=The+Global+Burden+of+Disease%3B+A+Comprehensive+Assessment+of+Mortality+and+Disability+from+Disease%2C+Injuries+and+Risk+Factors+in+1990+and+Projected+to+2020"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26aulast%3DMurray%26aufirst%3DC.%2BJ.%2BL.%26btitle%3DThe%2520Global%2520Burden%2520of%2520Disease%253B%2520A%2520Comprehensive%2520Assessment%2520of%2520Mortality%2520and%2520Disability%2520from%2520Disease%252C%2520Injuries%2520and%2520Risk%2520Factors%2520in%25201990%2520and%2520Projected%2520to%25202020%26volume%3D1%26pub%3DHarvard%2520University%2520Press%26date%3D1996" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span> </span><span class="NLM_article-title">Mental Health: New Understanding, New Hope; Fact Sheet No. 265</span>. The World Health Report 2001; <span class="NLM_publisher-name">World Health Organization</span>: <span class="NLM_publisher-loc">Geneva</span>,<span class="NLM_x"> </span><span class="NLM_year">2001</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Mental+Health%3A+New+Understanding%2C+New+Hope%3B+Fact+Sheet+No.+265.+The+World+Health+Report+2001%3B+World+Health+Organization%3A+Geneva%2C+2001."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dgov%26sid%3Dliteratum%253Aachs%26atitle%3DMental%2520Health%253A%2520New%2520Understanding%252C%2520New%2520Hope%253B%2520Fact%2520Sheet%2520No.%2520265%26jtitle%3DThe%2520World%2520Health%2520Report%25202001%26pub%3DWorld%2520Health%2520Organization%26date%3D2001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group">Blier, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bergeron, R.</span><span> </span><span class="NLM_article-title">The use of pindolol to potentiate antidepressant medication</span> <span class="citation_source-journal">J. Clin. Psychiatry</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1998</span><span class="NLM_x">, </span> <span class="NLM_volume">59</span><span class="NLM_x"> (</span><span class="NLM_issue">Suppl. 5</span><span class="NLM_x">) </span> <span class="NLM_fpage">16</span><span class="NLM_x">â</span> <span class="NLM_lpage">25</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Fjm200682b&amp;key=9635544" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Fjm200682b&amp;key=1%3ACAS%3A528%3ADyaK1cXjslGksLs%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=1998&pages=16-25&issue=Suppl.+5&author=P.+Blierauthor=R.+Bergeron&title=The+use+of+pindolol+to+potentiate+antidepressant+medication"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">The use of pindolol to potentiate antidepressant medication</span></div><div class="casAuthors">Blier, Pierre; Bergeron, Richard</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Psychiatry</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">Suppl..5</span>),
    <span class="NLM_cas:pages">16-25</span>CODEN:
                <span class="NLM_cas:coden">JCLPDE</span>;
        ISSN:<span class="NLM_cas:issn">0160-6689</span>.
    
            (<span class="NLM_cas:orgname">Physicians Postgraduate Press</span>)
        </div><div class="casAbstract">A review with 32 refs. followed by a discussion.  Serotonin (5-HT) selective reuptake inhibitors (SSRIs) and monoamine oxidase inhibitors are thought to have a delayed onset of antidepressant action attributable in part to the decrease in firing activity of 5-HT neurons they produce upon treatment initiation.  As cell body 5-HT1A autoreceptors desensitize, 5-HT neuronal firing is restored.  The agent pindolol, through its 5-HT1A receptor blocking property, has been shown to prevent the initial decrease in firing of rat 5-HT neurons assocd. with SSRI treatment.  Four open-label studies put into evidence a significant acceleration of the antidepressant effect of SSRIs when combined with pindolol.  Four of five placebo-controlled studies have confirmed this observation.  Controlled trials indicate that a greater rate of response may be obtained by combining pindolol from the beginning of the SSRI treatment.  The strategy of adding pindolol to the regimen of SSRI-resistant patients also appears to produce a therapeutic effect in a significant proportion of patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrz0q4Q6ACnhrVg90H21EOLACvtfcHk0lh8bYBTQVH1BA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXjslGksLs%253D&md5=a2d5fa78635c0e4427bd9c6fd6039271</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBlier%26aufirst%3DP.%26aulast%3DBergeron%26aufirst%3DR.%26atitle%3DThe%2520use%2520of%2520pindolol%2520to%2520potentiate%2520antidepressant%2520medication%26jtitle%3DJ.%2520Clin.%2520Psychiatry%26date%3D1998%26volume%3D59%26issue%3DSuppl.%25205%26spage%3D16%26epage%3D25" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group">Katz, M. M.; Tekell, J. L.; Bowden, C. L.; Brannan, S.; Houston, J. P.; Berman, N.; Frazer, A.</span><span> </span><span class="NLM_article-title">Onset and early behavioral effects of pharmacologically different antidepressants and placebo in depression</span>.  <span class="citation_source-journal">Neuropsychophamacology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">29</span><span class="NLM_x">, </span> <span class="NLM_fpage">566</span><span class="NLM_x">â</span> <span class="NLM_lpage">579</span> and references therein.</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Fjm200682b&amp;key=10.1038%2Fsj.npp.1300341" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Fjm200682b&amp;key=14627997" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Fjm200682b&amp;key=1%3ACAS%3A528%3ADC%252BD2cXhtlWksbg%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2004&pages=566-579&author=M.+M.+Katz&author=J.+L.+Tekell&author=C.+L.+Bowden&author=S.+Brannan&author=J.+P.+Houston&author=N.+Berman&author=A.+Frazer&title=Onset+and+early+behavioral+effects+of+pharmacologically+different+antidepressants+and+placebo+in+depression"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Onset and Early Behavioral Effects of Pharmacologically Different Antidepressants and Placebo in Depression</span></div><div class="casAuthors">Katz, Martin M.; Tekell, Janet L.; Bowden, Charles L.; Brannan, Steve; Houston, John P.; Berman, Nancy; Frazer, Alan</div><div class="citationInfo"><span class="NLM_cas:title">Neuropsychopharmacology</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">29</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">566-579</span>CODEN:
                <span class="NLM_cas:coden">NEROEW</span>;
        ISSN:<span class="NLM_cas:issn">0893-133X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">This study was aimed at resolving the time course of clin. action of antidepressants (ADs) and the type of early behavioral changes that precede recovery in treatment-responsive depressed patients.  The first goal was to identify, during the first 2 wk of treatment, the onset of clin. actions of the selective serotonin reuptake inhibitor (SSRI), paroxetine, and the selective noradrenergic reuptake inhibitor, desipramine (DMI).  The second aim was to test the hypothesis that the two pharmacol. subtypes would induce different early behavioral changes in treatment-responsive patients.  The design was a randomized, parallel group, placebo-controlled, double-blind study for 6 wk of treatment following a 1-wk washout period.  The study utilized measures of the major behavioral components of the depressive disorder as well as overall severity.  The results indicated that the onset of clin. actions of DMI ranged from 3 to 13 days, averaged 13 days for paroxetine, and was 16-42 days for placebo.  Furthermore, as hypothesized, the different types of ADs initially impacted different behavioral aspects of the disorder.  After 1 wk of treatment, DMI produced greater redns. in motor retardation and depressed mood than did paroxetine and placebo, and this difference persisted at the second week of treatment.  Early improvement in depressed mood-motor retardation differentiated patients who responded to DMI after 6 wk of treatment from those that did not.  Paroxetine initially reduced anxiety more in responders than in nonresponders, and by the second week, significantly improved depressed mood and distressed expression in responders to a greater extent.  Depressed patients who responded to placebo showed no consistent early pattern of behavior improvement.  Early drug-specific behavioral changes were highly predictive of ultimate clin. response to the different ADs, results that could eventually be applied directly to clin. practice.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoTBYhGBqQ1ArVg90H21EOLACvtfcHk0lhYKrE-bsrLBA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXhtlWksbg%253D&md5=9d4bb8ceaeecd3e172442a56c23719b6</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1038%2Fsj.npp.1300341&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.npp.1300341%26sid%3Dliteratum%253Aachs%26aulast%3DKatz%26aufirst%3DM.%2BM.%26atitle%3DOnset%2520and%2520early%2520behavioral%2520effects%2520of%2520pharmacologically%2520different%2520antidepressants%2520and%2520placebo%2520in%2520depression%26jtitle%3DNeuropsychophamacology%26date%3D2004%26volume%3D29%26spage%3D566%26epage%3D579" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7a"><span><span class="NLM_contrib-group">Morphy, R.; Kay, C.; Rankovic, Z.</span><span> </span><span class="NLM_article-title">From magic bullets to designed multiple ligands</span>.  <span class="citation_source-journal">Drug Discovery Today</span>,<span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">641</span><span class="NLM_x">â</span> <span class="NLM_lpage">651</span> and reference therein.</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7a&amp;dbid=16&amp;doi=10.1021%2Fjm200682b&amp;key=10.1016%2FS1359-6446%2804%2903163-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7a&amp;dbid=8&amp;doi=10.1021%2Fjm200682b&amp;key=15279847" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7a&amp;dbid=32&amp;doi=10.1021%2Fjm200682b&amp;key=1%3ACAS%3A528%3ADC%252BD2cXmtVSktb8%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2004&pages=641-651&author=R.+Morphy&author=C.+Kay&author=Z.+Rankovic&title=From+magic+bullets+to+designed+multiple+ligands"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7aR"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">From magic bullets to designed multiple ligands</span></div><div class="casAuthors">Morphy, Richard; Kay, Corinne; Rankovic, Zoran</div><div class="citationInfo"><span class="NLM_cas:title">Drug Discovery Today</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">641-651</span>CODEN:
                <span class="NLM_cas:coden">DDTOFS</span>;
        ISSN:<span class="NLM_cas:issn">1359-6446</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">A review.  A major trend in medicinal chem. in the coming years will be the rational design of ligands that are capable of modulating multiple disease-relevant targets in a specific manner.  Increasingly, it is being recognized that a balanced modulation of several targets can provide a superior therapeutic effect and side effect profile compared to the action of a selective ligand.  Rational approaches in which structural features from selective ligands are combined have produced designed multiple ligands that span a wide variety of targets and target classes.  A key challenge in the design of multiple ligands is attaining a balanced activity at each target of interest while simultaneously achieving a wider selectivity and a suitable pharmacokinetic profile.  An anal. of literature examples reveals trends and insights that might help medicinal chemists discover the next generation of these types of compds.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpcsGpfzZok5rVg90H21EOLACvtfcHk0lhYKrE-bsrLBA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXmtVSktb8%253D&md5=cd2491baad707043dbee4f59ccad9e1d</span></div><a href="/servlet/linkout?suffix=cit7a&amp;dbid=16384&amp;doi=10.1016%2FS1359-6446%2804%2903163-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1359-6446%252804%252903163-0%26sid%3Dliteratum%253Aachs%26aulast%3DMorphy%26aufirst%3DR.%26atitle%3DFrom%2520magic%2520bullets%2520to%2520designed%2520multiple%2520ligands%26jtitle%3DDrug%2520Discovery%2520Today%26date%3D2004%26volume%3D9%26spage%3D641%26epage%3D651" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit7b"><span><span class="NLM_contrib-group">Pacher, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kecskemeti, V.</span><span> </span><span class="NLM_article-title">Trends in the development of new antidepressants. Is there a light at the end of the tunnel?</span> <span class="citation_source-journal">Curr. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">925</span><span class="NLM_x">â</span> <span class="NLM_lpage">943</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7b&amp;dbid=16&amp;doi=10.1021%2Fjm200682b&amp;key=10.2174%2F0929867043455594" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7b&amp;dbid=8&amp;doi=10.1021%2Fjm200682b&amp;key=15078174" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7b&amp;dbid=32&amp;doi=10.1021%2Fjm200682b&amp;key=1%3ACAS%3A528%3ADC%252BD2cXivF2mtrk%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2004&pages=925-943&author=P.+Pacherauthor=V.+Kecskemeti&title=Trends+in+the+development+of+new+antidepressants.+Is+there+a+light+at+the+end+of+the+tunnel%3F"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7bR"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Trends in the development of new antidepressants. Is there a light at the end of the tunnel?</span></div><div class="casAuthors">Pacher, Pal; Kecskemeti, Valeria</div><div class="citationInfo"><span class="NLM_cas:title">Current Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">925-943</span>CODEN:
                <span class="NLM_cas:coden">CMCHE7</span>;
        ISSN:<span class="NLM_cas:issn">0929-8673</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Since the introduction of tricyclic antidepressants (TCAs) and monoamine oxidase inhibitors (MAOIs) in mid-1950's, treatment of depression was dominated by monoamine hypotheses.  The well-established clin. efficacy of TCAs and MAOIs is due, at least in part, to the enhancement of noradrenergic or serotonergic mechanisms, or to both.  Unfortunately, their very broad mechanisms of action also include many unwanted effects related to their potent activity on cholinergic, adrenergic, and histaminergic receptors.  The introduction of selective serotonin reuptake inhibitors (SSRIs) over twenty years ago had been the next major step in the evolution of antidepressants to develop drugs as effective as the TCAs but of higher safety and tolerability profile.  During the past 2 decades SSRIs (fluoxetine, fluvoxamine, paroxetine, sertraline, citalopram) gained incredible popularity and have become the most widely prescribed medication in the psychiatric practice.  The evolution of antidepressants continued resulting in introduction of selective and reversible monoamine oxidase inhibitors (eg. moclobemid), selective noradrenaline (eg. reboxetine), dual noradrenaline and serotonin reuptake inhibitors (milnacipram, venlafaxin, duloxetin) and drugs with distinct neurochem. profiles such as mirtazapine, nefazadone, and tianeptine.  Different novel serotonin receptor ligands were also intensively investigated.  In spite of the remarkable structural diversity, most currently introduced antidepressants are "monoamine based".  Furthermore, these newer agents are neither more efficacious nor rapid acting than their predecessors and approx. 30% of the population do not respond to current therapies.  By the turn of the new millennium, the authors are all witnessing a result of innovative developmental strategies based on the better understanding of pathophysiol. of depressive disorder.  Several truly novel concepts have emerged suggesting that the modulation of neuropeptide (substance P, corticotrophin-releasing factor, neuropeptide Y, vasopressin V1b, melanin-concg. hormone-1), N-methyl-D-aspartate, nicotinic acetylcholine, dopaminergic, glucocorticoid, Î´-opioid, cannabinoid and cytokine receptors, gamma-amino butyric acid (GABA) and intracellular messenger systems, transcription, neuroprotective and neurogenic factors, may provide an entirely new set of potential therapeutic targets, giving hope that further major advances might be anticipated in the treatment of depressive disorder soon.  The goal of this review is to give a brief overview of the major advances from monoamine-based treatment strategies, and particularly focus on the new emerging approaches in the treatment of depression.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrhQMckx9QwdLVg90H21EOLACvtfcHk0lhYKrE-bsrLBA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXivF2mtrk%253D&md5=a94d012a3d79d723800333c10f346543</span></div><a href="/servlet/linkout?suffix=cit7b&amp;dbid=16384&amp;doi=10.2174%2F0929867043455594&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F0929867043455594%26sid%3Dliteratum%253Aachs%26aulast%3DPacher%26aufirst%3DP.%26aulast%3DKecskemeti%26aufirst%3DV.%26atitle%3DTrends%2520in%2520the%2520development%2520of%2520new%2520antidepressants.%2520Is%2520there%2520a%2520light%2520at%2520the%2520end%2520of%2520the%2520tunnel%253F%26jtitle%3DCurr.%2520Med.%2520Chem.%26date%3D2004%26volume%3D11%26spage%3D925%26epage%3D943" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group">Roberts, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Price, G. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Middlemiss, D. N.</span><span> </span><span class="NLM_article-title">Ligands for the investigation of 5-HT autoreceptor function</span> <span class="citation_source-journal">Brain Res. Bull.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">56</span><span class="NLM_x">, </span> <span class="NLM_fpage">463</span><span class="NLM_x">â</span> <span class="NLM_lpage">469</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Fjm200682b&amp;key=10.1016%2FS0361-9230%2801%2900628-1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Fjm200682b&amp;key=11750791" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Fjm200682b&amp;key=1%3ACAS%3A528%3ADC%252BD3MXptFylt7s%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2001&pages=463-469&author=C.+Robertsauthor=G.+W.+Priceauthor=D.+N.+Middlemiss&title=Ligands+for+the+investigation+of+5-HT+autoreceptor+function"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Ligands for the investigation of 5-HT autoreceptor function</span></div><div class="casAuthors">Roberts, Claire; Price, Gary W.; Middlemiss, Derek N.</div><div class="citationInfo"><span class="NLM_cas:title">Brain Research Bulletin</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">463-469</span>CODEN:
                <span class="NLM_cas:coden">BRBUDU</span>;
        ISSN:<span class="NLM_cas:issn">0361-9230</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Inc.</span>)
        </div><div class="casAbstract">A review.  The existence of multiple 5-HT autoreceptors in the central nervous system is now firmly established and they have been pharmacol. identified as belonging to the 5-HT1A, 5-HT1B, and 5-HT1D receptor subtypes.  In addn., 5-HT1F, 5-HT5A, and 5-HT7 receptors remain as potential candidates for addnl. autoreceptors.  The emergence of selective ligands, such as SB-224289 (5-HT1B receptor antagonist), BRL 15572 (5-HT1D receptor antagonist), GR 127935 (a mixed 5-HT1B/1D receptor antagonist), LY 334370 (5-HT1F receptor agonist), and SB-269970 (5-HT7 receptor antagonist), has aided the characterization of 5-HT autoreceptors and has highlighted the complexity of mechanisms which modulate the release of 5-HT.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoh3Lk0_xEYELVg90H21EOLACvtfcHk0liY_jQ8VaUxBw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXptFylt7s%253D&md5=1b38f404662c50829d0f1d20bd313d84</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1016%2FS0361-9230%2801%2900628-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0361-9230%252801%252900628-1%26sid%3Dliteratum%253Aachs%26aulast%3DRoberts%26aufirst%3DC.%26aulast%3DPrice%26aufirst%3DG.%2BW.%26aulast%3DMiddlemiss%26aufirst%3DD.%2BN.%26atitle%3DLigands%2520for%2520the%2520investigation%2520of%25205-HT%2520autoreceptor%2520function%26jtitle%3DBrain%2520Res.%2520Bull.%26date%3D2001%26volume%3D56%26spage%3D463%26epage%3D469" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9a"><span><span class="NLM_contrib-group">Dawson, L. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bromidge, S. M.</span><span> </span><span class="NLM_article-title">5-H<sub>T1</sub> receptor augmentation strategies as enhanced efficacy therapeutics for psychiatric disorders</span> <span class="citation_source-journal">Curr. Top. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">8</span><span class="NLM_x">, </span> <span class="NLM_fpage">1008</span><span class="NLM_x">â</span> <span class="NLM_lpage">1023</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9a&amp;dbid=16&amp;doi=10.1021%2Fjm200682b&amp;key=10.2174%2F156802608785161439" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9a&amp;dbid=8&amp;doi=10.1021%2Fjm200682b&amp;key=18691129" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9a&amp;dbid=32&amp;doi=10.1021%2Fjm200682b&amp;key=1%3ACAS%3A528%3ADC%252BD1cXps1OhtLc%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2008&pages=1008-1023&author=L.+A.+Dawsonauthor=S.+M.+Bromidge&title=5-HT1+receptor+augmentation+strategies+as+enhanced+efficacy+therapeutics+for+psychiatric+disorders"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit9aR"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">5-HT1 receptor augmentation strategies as enhanced efficacy therapeutics for psychiatric disorders</span></div><div class="casAuthors">Dawson, Lee A.; Bromidge, Steve M.</div><div class="citationInfo"><span class="NLM_cas:title">Current Topics in Medicinal Chemistry (Sharjah, United Arab Emirates)</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1008-1023</span>CODEN:
                <span class="NLM_cas:coden">CTMCCL</span>;
        ISSN:<span class="NLM_cas:issn">1568-0266</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Since the initial observations linking 5-HT to psychiatric illness, evidence for a role of 5-HT and, in particular, a decreased brain serotonergic function in the pathol. of a plethora of related disorders, has grown.  However, it is the role of 5-HT in the pathogenesis of anxiety disorders and depression and the mechanism of action of antidepressants which has received the most attention.  Thus enhanced serotonergic neurotransmission has become one of the unifying mechanisms of action of modern day antidepressants / anxiolytics such as monoamine oxidase inhibitors, tricyclic antidepressants, and serotonin reuptake inhibitors.  Interestingly all of these treatments are assocd. with a delay to therapeutic efficacy and in some cases treatment resistance, despite immediate enhancements in serotonergic neurotransmission.  The postulated reason for this is the need for temporal neuroplastic changes in the control of serotonergic neurotransmission, and more specifically changes in 5-HT1 autoreceptor function.  Thus significant research has gone into pharmacol. targeting these 5-HT1 autoreceptors as a means of augmenting the efficacy of current therapeutic mechanisms.  Here we will review the rationale behind the various augmentation strategies adopted and the progress made in identifying novel therapeutics for conditions such as depression and anxiety disorders.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqMf53pfeDDRbVg90H21EOLACvtfcHk0liY_jQ8VaUxBw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXps1OhtLc%253D&md5=d8262b01f7af300831084bdf423f5da1</span></div><a href="/servlet/linkout?suffix=cit9a&amp;dbid=16384&amp;doi=10.2174%2F156802608785161439&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F156802608785161439%26sid%3Dliteratum%253Aachs%26aulast%3DDawson%26aufirst%3DL.%2BA.%26aulast%3DBromidge%26aufirst%3DS.%2BM.%26atitle%3D5-HT1%2520receptor%2520augmentation%2520strategies%2520as%2520enhanced%2520efficacy%2520therapeutics%2520for%2520psychiatric%2520disorders%26jtitle%3DCurr.%2520Top.%2520Med.%2520Chem.%26date%3D2008%26volume%3D8%26spage%3D1008%26epage%3D1023" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit9b"><span><span class="NLM_contrib-group">Bromidge, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arban, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bertani, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bison, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Borriello, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cavanni, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Forno, G. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Di-Fabio, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Donati, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fontana, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gianotti, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gordon, L. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Granci, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leslie, C. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moccia, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pasquarello, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sartori, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sava, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Watson, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Worby, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zonzini, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zucchelli, V.</span><span> </span><span class="NLM_article-title">Design and synthesis of novel tricyclic benzoxazine as potent 5-H<sub>T1A/B/D</sub> receptor antagonists leading to the discovery of 6-{2-[4-(2-methyl-5-quinolinyl)-1-piperazinyl]ethyl}-<i>4H</i>-imidazo[5,1<i>-c</i>][1,4]benzoxazine-3-carboxamide (GSK088045)</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">53</span><span class="NLM_x">, </span> <span class="NLM_fpage">5827</span><span class="NLM_x">â</span> <span class="NLM_lpage">5843</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm100482n" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2010&pages=5827-5843&author=S.+M.+Bromidgeauthor=R.+Arbanauthor=B.+Bertaniauthor=S.+Bisonauthor=M.+Borrielloauthor=P.+Cavanniauthor=G.+D.+Fornoauthor=R.+Di-Fabioauthor=D.+Donatiauthor=S.+Fontanaauthor=M.+Gianottiauthor=L.+J.+Gordonauthor=E.+Granciauthor=C.+P.+Leslieauthor=L.+Mocciaauthor=A.+Pasquarelloauthor=I.+Sartoriauthor=A.+Savaauthor=J.+M.+Watsonauthor=A.+Worbyauthor=L.+Zonziniauthor=V.+Zucchelli&title=Design+and+synthesis+of+novel+tricyclic+benzoxazine+as+potent+5-HT1A%2FB%2FD+receptor+antagonists+leading+to+the+discovery+of+6-%7B2-%5B4-%282-methyl-5-quinolinyl%29-1-piperazinyl%5Dethyl%7D-4H-imidazo%5B5%2C1-c%5D%5B1%2C4%5Dbenzoxazine-3-carboxamide+%28GSK088045%29"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit9b&amp;dbid=16384&amp;doi=10.1021%2Fjm100482n&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm100482n%26sid%3Dliteratum%253Aachs%26aulast%3DBromidge%26aufirst%3DS.%2BM.%26aulast%3DArban%26aufirst%3DR.%26aulast%3DBertani%26aufirst%3DB.%26aulast%3DBison%26aufirst%3DS.%26aulast%3DBorriello%26aufirst%3DM.%26aulast%3DCavanni%26aufirst%3DP.%26aulast%3DForno%26aufirst%3DG.%2BD.%26aulast%3DDi-Fabio%26aufirst%3DR.%26aulast%3DDonati%26aufirst%3DD.%26aulast%3DFontana%26aufirst%3DS.%26aulast%3DGianotti%26aufirst%3DM.%26aulast%3DGordon%26aufirst%3DL.%2BJ.%26aulast%3DGranci%26aufirst%3DE.%26aulast%3DLeslie%26aufirst%3DC.%2BP.%26aulast%3DMoccia%26aufirst%3DL.%26aulast%3DPasquarello%26aufirst%3DA.%26aulast%3DSartori%26aufirst%3DI.%26aulast%3DSava%26aufirst%3DA.%26aulast%3DWatson%26aufirst%3DJ.%2BM.%26aulast%3DWorby%26aufirst%3DA.%26aulast%3DZonzini%26aufirst%3DL.%26aulast%3DZucchelli%26aufirst%3DV.%26atitle%3DDesign%2520and%2520synthesis%2520of%2520novel%2520tricyclic%2520benzoxazine%2520as%2520potent%25205-HT1A%252FB%252FD%2520receptor%2520antagonists%2520leading%2520to%2520the%2520discovery%2520of%25206-%257B2-%255B4-%25282-methyl-5-quinolinyl%2529-1-piperazinyl%255Dethyl%257D-4H-imidazo%255B5%252C1-c%255D%255B1%252C4%255Dbenzoxazine-3-carboxamide%2520%2528GSK088045%2529%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2010%26volume%3D53%26spage%3D5827%26epage%3D5843" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10a"><span><span class="NLM_contrib-group">Jurczyk, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kolaczkowski, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maryniak, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zajdel, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pawlowski, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tatarczynska, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Klodzinska, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chojnacka-Wojcik, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bojarski, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Charakchieva-Minol, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Duszynska, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nowak, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maciag, D.</span><span> </span><span class="NLM_article-title">New arylpiperazine 5-HT<sub>1A</sub> receptor ligands containing the pyrimido[2,1-<i>f</i>]purine fragment: Synthesis, in vitro, and in vivo pharmacological evaluation</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">47</span><span class="NLM_x">, </span> <span class="NLM_fpage">2659</span><span class="NLM_x">â</span> <span class="NLM_lpage">2666</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm030946u" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=47&publication_year=2004&pages=2659-2666&author=S.+Jurczykauthor=M.+Kolaczkowskiauthor=E.+Maryniakauthor=P.+Zajdelauthor=M.+Pawlowskiauthor=E.+Tatarczynskaauthor=A.+Klodzinskaauthor=E.+Chojnacka-Wojcikauthor=A.+J.+Bojarskiauthor=S.+Charakchieva-Minolauthor=B.+Duszynskaauthor=G.+Nowakauthor=D.+Maciag&title=New+arylpiperazine+5-HT1A+receptor+ligands+containing+the+pyrimido%5B2%2C1-f%5Dpurine+fragment%3A+Synthesis%2C+in+vitro%2C+and+in+vivo+pharmacological+evaluation"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit10a&amp;dbid=16384&amp;doi=10.1021%2Fjm030946u&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm030946u%26sid%3Dliteratum%253Aachs%26aulast%3DJurczyk%26aufirst%3DS.%26aulast%3DKolaczkowski%26aufirst%3DM.%26aulast%3DMaryniak%26aufirst%3DE.%26aulast%3DZajdel%26aufirst%3DP.%26aulast%3DPawlowski%26aufirst%3DM.%26aulast%3DTatarczynska%26aufirst%3DE.%26aulast%3DKlodzinska%26aufirst%3DA.%26aulast%3DChojnacka-Wojcik%26aufirst%3DE.%26aulast%3DBojarski%26aufirst%3DA.%2BJ.%26aulast%3DCharakchieva-Minol%26aufirst%3DS.%26aulast%3DDuszynska%26aufirst%3DB.%26aulast%3DNowak%26aufirst%3DG.%26aulast%3DMaciag%26aufirst%3DD.%26atitle%3DNew%2520arylpiperazine%25205-HT1A%2520receptor%2520ligands%2520containing%2520the%2520pyrimido%255B2%252C1-f%255Dpurine%2520fragment%253A%2520Synthesis%252C%2520in%2520vitro%252C%2520and%2520in%2520vivo%2520pharmacological%2520evaluation%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2004%26volume%3D47%26spage%3D2659%26epage%3D2666" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit10b"><span><span class="NLM_contrib-group">Abou-Gharbia, M. A.; Yardley, J. P.; Childers, E.</span><div class="note"><p class="first last">(American Home Products Co., USA)</p></div><span> </span><span class="NLM_article-title">Aryl- and heteroaryl piperazinyl carboxamides having central nervous system activity</span>. U.S. Patent 5,380,725, <span class="NLM_month">January</span><span class="NLM_day">10</span>,<span class="NLM_x"> </span><span class="NLM_year">1995</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=1995&author=M.+A.+Abou-Gharbia&author=J.+P.+Yardley&author=E.+Childers&title=Aryl-+and+heteroaryl+piperazinyl+carboxamides+having+central+nervous+system+activity"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit10b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DAbou-Gharbia%26aufirst%3DM.%2BA.%26atitle%3DAryl-%2520and%2520heteroaryl%2520piperazinyl%2520carboxamides%2520having%2520central%2520nervous%2520system%2520activity%26date%3D1995" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group">Ballesteros, J.; Callado, L. F.</span><span> </span><span class="NLM_article-title">Effectiveness of pindolol plus serotonin uptake inhibitors in depression: a meta-analysis of early and late outcomes from randomised controlled trials</span>.  <span class="citation_source-journal">J. Affective Disord.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">79</span><span class="NLM_x">, </span> <span class="NLM_fpage">137</span><span class="NLM_x">â</span> <span class="NLM_lpage">147</span> and reference therein.</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Fjm200682b&amp;key=10.1016%2FS0165-0327%2802%2900404-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Fjm200682b&amp;key=15023488" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Fjm200682b&amp;key=1%3ACAS%3A528%3ADC%252BD2cXitFWkt7k%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=79&publication_year=2004&pages=137-147&author=J.+Ballesteros&author=L.+F.+Callado&title=Effectiveness+of+pindolol+plus+serotonin+uptake+inhibitors+in+depression%3A+a+meta-analysis+of+early+and+late+outcomes+from+randomised+controlled+trials"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Effectiveness of pindolol plus serotonin uptake inhibitors in depression: a meta-analysis of early and late outcomes from randomised controlled trials</span></div><div class="casAuthors">Ballesteros, Javier; Callado, Luis F.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Affective Disorders</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">79</span>
        (<span class="NLM_cas:issue">1-3</span>),
    <span class="NLM_cas:pages">137-147</span>CODEN:
                <span class="NLM_cas:coden">JADID7</span>;
        ISSN:<span class="NLM_cas:issn">0165-0327</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Background: Contradictory results on the efficacy of pindolol assocd. with selective serotonin reuptake inhibitors (SSRIs) in depressive illness have been published and no former review has produced an overall figure of its efficacy.This study aims to review the efficacy and tolerability of pindolol plus SSRIs in depressive illness.  Methods: A meta-anal. of randomised controlled trials (RCTs) comparing pindolol plus SSRIs with placebo plus SSRIs.  Results: Nine RCTs met inclusion criteria.  Outcome favored pindolol at 2 wk time (N=5; OR=2.8; 95% CI 1.4-5.7), but not at four to 6 wk (N=7; OR=1.4; 95% CI 0.8-2.7).  Results for early outcome studies were robust to sensitivity anal.  Nineteen more studies, averaging null results, would be needed to change the overall probability (P=0.0001) to a non-significant figure.  Conclusions: Pindolol seems to hasten the response to SSRIs in depression with a timing window circumscribed to the first weeks of treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq7KQryIvGRabVg90H21EOLACvtfcHk0ljuwQjAN3TVug"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXitFWkt7k%253D&md5=cadc23327131671a25347a38abd3cc24</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1016%2FS0165-0327%2802%2900404-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0165-0327%252802%252900404-4%26sid%3Dliteratum%253Aachs%26aulast%3DBallesteros%26aufirst%3DJ.%26atitle%3DEffectiveness%2520of%2520pindolol%2520plus%2520serotonin%2520uptake%2520inhibitors%2520in%2520depression%253A%2520a%2520meta-analysis%2520of%2520early%2520and%2520late%2520outcomes%2520from%2520randomised%2520controlled%2520trials%26jtitle%3DJ.%2520Affective%2520Disord.%26date%3D2004%26volume%3D79%26spage%3D137%26epage%3D147" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group">Romeo, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arigas, F.</span><span> </span><span class="NLM_article-title">Preferential potentiation of the effects of serotonin uptake inhibitors by 5-HT<sub>1A</sub> receptor antagonists in the dorsal raphe pathway: Role of somatodendritic autoreceptors</span> <span class="citation_source-journal">J. Neurochem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1997</span><span class="NLM_x">, </span> <span class="NLM_volume">68</span><span class="NLM_x">, </span> <span class="NLM_fpage">2593</span><span class="NLM_x">â</span> <span class="NLM_lpage">2603</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Fjm200682b&amp;key=10.1046%2Fj.1471-4159.1997.68062593.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Fjm200682b&amp;key=9166757" title="">PubMed</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=68&publication_year=1997&pages=2593-2603&author=L.+Romeoauthor=F.+Arigas&title=Preferential+potentiation+of+the+effects+of+serotonin+uptake+inhibitors+by+5-HT1A+receptor+antagonists+in+the+dorsal+raphe+pathway%3A+Role+of+somatodendritic+autoreceptors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1046%2Fj.1471-4159.1997.68062593.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1046%252Fj.1471-4159.1997.68062593.x%26sid%3Dliteratum%253Aachs%26aulast%3DRomeo%26aufirst%3DL.%26aulast%3DArigas%26aufirst%3DF.%26atitle%3DPreferential%2520potentiation%2520of%2520the%2520effects%2520of%2520serotonin%2520uptake%2520inhibitors%2520by%25205-HT1A%2520receptor%2520antagonists%2520in%2520the%2520dorsal%2520raphe%2520pathway%253A%2520Role%2520of%2520somatodendritic%2520autoreceptors%26jtitle%3DJ.%2520Neurochem.%26date%3D1997%26volume%3D68%26spage%3D2593%26epage%3D2603" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group">Berman, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Anand, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cappiello, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miller, H. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, X. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oren, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Charney., D. S.</span><span> </span><span class="NLM_article-title">The use of pindolol with fluoxetine in the treatment of major depression: Final results from a double-blind, placebo-controlled trial</span> <span class="citation_source-journal">Biol. Psychiatry</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1999</span><span class="NLM_x">, </span> <span class="NLM_volume">45</span><span class="NLM_x">, </span> <span class="NLM_fpage">1170</span><span class="NLM_x">â</span> <span class="NLM_lpage">1177</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Fjm200682b&amp;key=10.1016%2FS0006-3223%2898%2900383-7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Fjm200682b&amp;key=10331109" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Fjm200682b&amp;key=1%3ACAS%3A528%3ADyaK1MXjsFeju78%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=45&publication_year=1999&pages=1170-1177&author=R.+M.+Bermanauthor=A.+Anandauthor=A.+Cappielloauthor=H.+L.+Millerauthor=X.+S.+Xuauthor=D.+A.+Orenauthor=D.+S.+Charney.&title=The+use+of+pindolol+with+fluoxetine+in+the+treatment+of+major+depression%3A+Final+results+from+a+double-blind%2C+placebo-controlled+trial"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">The use of pindolol with fluoxetine in the treatment of major depression: final results from a double-blind, placebo-controlled trial</span></div><div class="casAuthors">Berman, Robert M.; Anand, Amit; Cappiello, Angela; Miller, Helen L.; Hu, X. Sylvia; Oren, Dan A.; Charney, Dennis S.</div><div class="citationInfo"><span class="NLM_cas:title">Biological Psychiatry</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">45</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1170-1177</span>CODEN:
                <span class="NLM_cas:coden">BIPCBF</span>;
        ISSN:<span class="NLM_cas:issn">0006-3223</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Inc.</span>)
        </div><div class="casAbstract">Preliminary reports have suggested that concomitant institution of pindolol and serotonin reuptake inhibitors robustly hastens clin. response; however, contradictory evidence from a randomized double-blind, controlled trial was recently reported by this group in a population of depressed patients who were prescribed fluoxetine and pindolol.  Herein, we report final results from an extended sample size.  Drug-free outpatients with a major depressive episode were randomized in a double-blind manner to one of two treatment conditions: fluoxetine (20 mg daily) with pindolol (7.5 to 10 mg daily) or fluoxetine (20 mg daily) with placebo.  After 6 wk, patients were followed for 3 more weeks in a single-blind manner, on fluoxetine and placebo pindolol.  Eighty-six patients completed at least 1 or more weeks on protocol, with 45 and 41 patients randomized to the pindolol and placebo groups resp.  After 2 wk on protocol, partial remission (i.e., at least 50% decrease in depression rating scores from baseline) rates for pindolol (16%) and placebo (19%) groups were comparable.  By the study's end, a partial remission was achieved, at least transiently, for 67% of the pindolol group and 80% of the placebo group.  Pindolol treatment was assocd. with statistically significant redn. in blood pressure and pulse as compared to the control group.  The two groups did not have overall differences in rates of attrition, time to response, and side effects.  In accord with our previously published findings, these extended results do not support the efficacy of pindolol in hastening clin. response to fluoxetine in a patient population with predominantly chronic and recurrent depression.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq96N7R9EFBs7Vg90H21EOLACvtfcHk0ljuwQjAN3TVug"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXjsFeju78%253D&md5=a38fd0eaa0ccda8a3c753ce88cbf0116</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1016%2FS0006-3223%2898%2900383-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0006-3223%252898%252900383-7%26sid%3Dliteratum%253Aachs%26aulast%3DBerman%26aufirst%3DR.%2BM.%26aulast%3DAnand%26aufirst%3DA.%26aulast%3DCappiello%26aufirst%3DA.%26aulast%3DMiller%26aufirst%3DH.%2BL.%26aulast%3DXu%26aufirst%3DX.%2BS.%26aulast%3DOren%26aufirst%3DD.%2BA.%26aulast%3DCharney.%26aufirst%3DD.%2BS.%26atitle%3DThe%2520use%2520of%2520pindolol%2520with%2520fluoxetine%2520in%2520the%2520treatment%2520of%2520major%2520depression%253A%2520Final%2520results%2520from%2520a%2520double-blind%252C%2520placebo-controlled%2520trial%26jtitle%3DBiol.%2520Psychiatry%26date%3D1999%26volume%3D45%26spage%3D1170%26epage%3D1177" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group">Pullar, I. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carney, S. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Colvin, E. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lucaites, V. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nelson, D. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wedley, S.</span><span> </span><span class="NLM_article-title">LY367265, an inhibitor of the 5-hydroxytryptamine transporter and 5-hydroxytryptamine<sub>2A</sub> receptor antagonist: A comparison with the antidepressant, nefazodone</span> <span class="citation_source-journal">Eur. J. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">407</span><span class="NLM_x">, </span> <span class="NLM_fpage">39</span><span class="NLM_x">â</span> <span class="NLM_lpage">46</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Fjm200682b&amp;key=10.1016%2FS0014-2999%2800%2900728-7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Fjm200682b&amp;key=11050288" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Fjm200682b&amp;key=1%3ACAS%3A528%3ADC%252BD3cXnsFWqt7o%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=407&publication_year=2000&pages=39-46&author=I.+A.+Pullarauthor=S.+L.+Carneyauthor=E.+M.+Colvinauthor=V.+L.+Lucaitesauthor=D.+L.+Nelsonauthor=S.+Wedley&title=LY367265%2C+an+inhibitor+of+the+5-hydroxytryptamine+transporter+and+5-hydroxytryptamine2A+receptor+antagonist%3A+A+comparison+with+the+antidepressant%2C+nefazodone"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">LY367265, an inhibitor of the 5-hydroxytryptamine transporter and 5-hydroxytryptamine2A receptor antagonist: a comparison with the antidepressant, nefazodone</span></div><div class="casAuthors">Pullar, I. A.; Carney, S. L.; Colvin, E. M.; Lucaites, V. L.; Nelson, D. L.; Wedley, S.</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">407</span>
        (<span class="NLM_cas:issue">1/2</span>),
    <span class="NLM_cas:pages">39-46</span>CODEN:
                <span class="NLM_cas:coden">EJPHAZ</span>;
        ISSN:<span class="NLM_cas:issn">0014-2999</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science B.V.</span>)
        </div><div class="casAbstract">The potential antidepressant, LY367265 (1-[2-[4-(6-fluoro-1H-indol-3-yl)-3,6-dihydro-1(2H)-pyridinyl]ethyl]-5,6-dihydro-1H,4H-[1,2,5]thiadiazolo[4.3.2-ij]quinoline-2,2,-dioxide) has been shown to have a higher affinity for the 5-hydroxytryptamine (5-HT) transporter (Ki=2.3 nM) and 5-HT2A (Ki=0.81 nM) receptor than the clin. effective antidepressant, nefazodone.  It is a potent inhibitor of [3H]5-HT uptake into rat cortical synaptosomes (IC50=3.1 nM) and shows selectivity over that for [3H]noradrenaline (IC50Â°1000 nM).  It potentiates potassium-induced [3H]5-HT outflow from prelabeled guinea pig cortical slices both in the presence (EC50=950 nM) and absence (EC50=250 nM) of a satg. concn. of the 5-HT transport inhibitor, paroxetine, indicating a low level of activity at the 5-HT1B/1D autoreceptor.  These studies indicate that LY367265 is a putative antidepressant which, because of its 5-HT2A receptor antagonist activity, has the potential to produce less sleep disturbance and sexual dysfunction than selective serotonin uptake inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrCax7sIb7CuLVg90H21EOLACvtfcHk0lgzTCNIg2uICw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXnsFWqt7o%253D&md5=f20cbf13b5c9d04cba0a86aeeed0eca2</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1016%2FS0014-2999%2800%2900728-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0014-2999%252800%252900728-7%26sid%3Dliteratum%253Aachs%26aulast%3DPullar%26aufirst%3DI.%2BA.%26aulast%3DCarney%26aufirst%3DS.%2BL.%26aulast%3DColvin%26aufirst%3DE.%2BM.%26aulast%3DLucaites%26aufirst%3DV.%2BL.%26aulast%3DNelson%26aufirst%3DD.%2BL.%26aulast%3DWedley%26aufirst%3DS.%26atitle%3DLY367265%252C%2520an%2520inhibitor%2520of%2520the%25205-hydroxytryptamine%2520transporter%2520and%25205-hydroxytryptamine2A%2520receptor%2520antagonist%253A%2520A%2520comparison%2520with%2520the%2520antidepressant%252C%2520nefazodone%26jtitle%3DEur.%2520J.%2520Pharmacol.%26date%3D2000%26volume%3D407%26spage%3D39%26epage%3D46" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group">Hatanaka, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nomura, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hidaka, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Takeuchi, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yatsugi, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fujii, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yamaguchi, T.</span><span> </span><span class="NLM_article-title">Biochemical profile of YM992, a novel selective serotonin reuptake inhibitor with 5-HT<sub>2A</sub> receptor antagonistic activity</span> <span class="citation_source-journal">Neuropharmacology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1997</span><span class="NLM_x">, </span> <span class="NLM_volume">35</span><span class="NLM_x">, </span> <span class="NLM_fpage">1621</span><span class="NLM_x">â</span> <span class="NLM_lpage">1626</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=35&publication_year=1997&pages=1621-1626&author=K.+Hatanakaauthor=T.+Nomuraauthor=K.+Hidakaauthor=H.+Takeuchiauthor=S.+Yatsugiauthor=M.+Fujiiauthor=T.+Yamaguchi&title=Biochemical+profile+of+YM992%2C+a+novel+selective+serotonin+reuptake+inhibitor+with+5-HT2A+receptor+antagonistic+activity"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DHatanaka%26aufirst%3DK.%26aulast%3DNomura%26aufirst%3DT.%26aulast%3DHidaka%26aufirst%3DK.%26aulast%3DTakeuchi%26aufirst%3DH.%26aulast%3DYatsugi%26aufirst%3DS.%26aulast%3DFujii%26aufirst%3DM.%26aulast%3DYamaguchi%26aufirst%3DT.%26atitle%3DBiochemical%2520profile%2520of%2520YM992%252C%2520a%2520novel%2520selective%2520serotonin%2520reuptake%2520inhibitor%2520with%25205-HT2A%2520receptor%2520antagonistic%2520activity%26jtitle%3DNeuropharmacology%26date%3D1997%26volume%3D35%26spage%3D1621%26epage%3D1626" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16a"><span><span class="NLM_contrib-group">Rush, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Armitage, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gillin, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yonkers, K. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Winokur, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moldofsky, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vogel, G. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kaplita, S. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fleming, J. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Montplaisir, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Erman, M. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Albala, B. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McQuade, R. D.</span><span> </span><span class="NLM_article-title">Comparative effects of nefazodone and fluoxetine on sleep in outpatients with major depressive disorder</span> <span class="citation_source-journal">Biol. Psychiatry</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1998</span><span class="NLM_x">, </span> <span class="NLM_volume">44</span><span class="NLM_x">, </span> <span class="NLM_fpage">3</span><span class="NLM_x">â</span> <span class="NLM_lpage">14</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16a&amp;dbid=16&amp;doi=10.1021%2Fjm200682b&amp;key=10.1016%2FS0006-3223%2898%2900092-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16a&amp;dbid=8&amp;doi=10.1021%2Fjm200682b&amp;key=9646878" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16a&amp;dbid=32&amp;doi=10.1021%2Fjm200682b&amp;key=1%3ACAS%3A528%3ADyaK1cXkt1Kjurg%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=44&publication_year=1998&pages=3-14&author=A.+J.+Rushauthor=R.+Armitageauthor=J.+C.+Gillinauthor=K.+A.+Yonkersauthor=A.+Winokurauthor=H.+Moldofskyauthor=G.+W.+Vogelauthor=S.+B.+Kaplitaauthor=J.+B.+Flemingauthor=J.+Montplaisirauthor=M.+K.+Ermanauthor=B.+J.+Albalaauthor=R.+D.+McQuade&title=Comparative+effects+of+nefazodone+and+fluoxetine+on+sleep+in+outpatients+with+major+depressive+disorder"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit16aR"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Comparative effects of nefazodone and fluoxetine on sleep in outpatients with major depressive disorder</span></div><div class="casAuthors">Rush, A. John; Armitage, Roseanne; Gillin, J. Christian; Yonkers, Kimberly A.; Winokur, Andrew; Moldofsky, Harvey; Vogel, Gerald W.; Kaplita, Stephen B.; Fleming, Jonathan B.; Montplaisir, Jacques; Erman, Milton K.; Albala, Bruce J.; Mcquade, Robert D.</div><div class="citationInfo"><span class="NLM_cas:title">Biological Psychiatry</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">44</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">3-14</span>CODEN:
                <span class="NLM_cas:coden">BIPCBF</span>;
        ISSN:<span class="NLM_cas:issn">0006-3223</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Inc.</span>)
        </div><div class="casAbstract">Sleep disturbances are common in major depressive disorder.  In previous open-label trials, nefazodone improved sleep continuity and increased rapid eye movement (REM) sleep, while not affecting stage 3/4 sleep or REM latency; in contrast, fluoxetine suppressed REM sleep.  This study compared the objective and subjective effects of nefazodone and fluoxetine on sleep.  This paper reports combined results of three identical, multisite, randomized, double-blind, 8-wk, acute-phase trials comparing nefazodone (n = 64) with fluoxetine (n = 61) in outpatients with nonpsychotic major depressive disorder and insomnia.  Sleep electroencephalog. (EEG) recordings were gathered at baseline and weeks 2, 4, and 8.  Clin. ratings were obtained at weeks 1-4, 6, and 8.  Nefazodone and fluoxetine were equally effective in reducing depressive symptoms; however, nefazodone differentially and progressively increased (while fluoxetine reduced) sleep efficiency and reduced (while fluoxetine increased) the no. of awakenings in a linear fashion over the 8-wk trial.  Fluoxetine, but not nefazodone, prolonged REM latency and suppressed REM sleep.  Nefazodone significantly increased total REM sleep time.  Clin. evaluations of sleep quality were significantly improved with nefazodone compared with fluoxetine.  Nefazodone and fluoxetine were equally effective antidepressants.  Nefazodone was assocd. with normal objective, and clinician- and patient-rated assessments of sleep when compared with fluoxetine.  These differential sleep EEG effects are consistent with the notion that nefazodone and fluoxetine may have somewhat different modes and spectra of action.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo-zPEkzYrEZrVg90H21EOLACvtfcHk0lgzTCNIg2uICw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXkt1Kjurg%253D&md5=c42a24385f0ade283a86f078467744aa</span></div><a href="/servlet/linkout?suffix=cit16a&amp;dbid=16384&amp;doi=10.1016%2FS0006-3223%2898%2900092-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0006-3223%252898%252900092-4%26sid%3Dliteratum%253Aachs%26aulast%3DRush%26aufirst%3DA.%2BJ.%26aulast%3DArmitage%26aufirst%3DR.%26aulast%3DGillin%26aufirst%3DJ.%2BC.%26aulast%3DYonkers%26aufirst%3DK.%2BA.%26aulast%3DWinokur%26aufirst%3DA.%26aulast%3DMoldofsky%26aufirst%3DH.%26aulast%3DVogel%26aufirst%3DG.%2BW.%26aulast%3DKaplita%26aufirst%3DS.%2BB.%26aulast%3DFleming%26aufirst%3DJ.%2BB.%26aulast%3DMontplaisir%26aufirst%3DJ.%26aulast%3DErman%26aufirst%3DM.%2BK.%26aulast%3DAlbala%26aufirst%3DB.%2BJ.%26aulast%3DMcQuade%26aufirst%3DR.%2BD.%26atitle%3DComparative%2520effects%2520of%2520nefazodone%2520and%2520fluoxetine%2520on%2520sleep%2520in%2520outpatients%2520with%2520major%2520depressive%2520disorder%26jtitle%3DBiol.%2520Psychiatry%26date%3D1998%26volume%3D44%26spage%3D3%26epage%3D14" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit16b"><span><span class="NLM_contrib-group">Avila, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vardona, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martin-Baranera, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maho, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sastre, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bello, J.</span><span> </span><span class="NLM_article-title">Does nefazodone improve both depression and Parkinson disease? A pilot randomized trial</span> <span class="citation_source-journal">J. Clin. Psychopharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">23</span><span class="NLM_x">, </span> <span class="NLM_fpage">509</span><span class="NLM_x">â</span> <span class="NLM_lpage">513</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16b&amp;dbid=16&amp;doi=10.1021%2Fjm200682b&amp;key=10.1097%2F01.jcp.0000088908.24613.db" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16b&amp;dbid=8&amp;doi=10.1021%2Fjm200682b&amp;key=14520130" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16b&amp;dbid=32&amp;doi=10.1021%2Fjm200682b&amp;key=1%3ACAS%3A528%3ADC%252BD3sXns12qu7w%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2003&pages=509-513&author=A.+Avilaauthor=X.+Vardonaauthor=M.+Martin-Baraneraauthor=P.+Mahoauthor=F.+Sastreauthor=J.+Bello&title=Does+nefazodone+improve+both+depression+and+Parkinson+disease%3F+A+pilot+randomized+trial"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit16bR"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Does Nefazodone Improves Both Depression and Parkinson Disease? A Pilot Randomized Trial</span></div><div class="casAuthors">Avila, Asuncion; Cardona, Xavier; Martin-Baranera, Montserrat; Maho, Placida; Sastre, Francesc; Bello, Juan</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Psychopharmacology</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">509-513</span>CODEN:
                <span class="NLM_cas:coden">JCPYDR</span>;
        ISSN:<span class="NLM_cas:issn">0271-0749</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">Some of the selective serotonin reuptake inhibitors (SSRI)-induced motor side effects are mediated by stimulating 5-HT2 receptors in the basal ganglia, probably because serotonin inhibits the subsequent neuronal dopamine release.  We hypothesized that nefazodone, a serotonin 2 antagonist/reuptake inhibitor (SARI) that selectively blocks 5-HT2 receptors, could disrupt the aforementioned inhibitory pathway.  Therefore, increased dopamine levels in the postsynaptic milieu and an improvement in the motor symptoms in depressed patients with Parkinson disease (PD) should be obsd.  This study was designed to det. whether nefazodone has a dual activity as an antidepressant and as an agent capable of reducing the extrapyramidal symptoms in depressed parkinsonian patients.  Depressed patients with PD were randomly assigned to 2 therapeutic groups: nefazodone or fluoxetine.  Patients were evaluated by a psychiatrist and were blindly assessed by a neurologist with an array of scales.  Patients on nefazodone (n = 9) showed a significant improvement over time in the total Unified Parkinson Disease Rating Scale score (UPDRS) (part II + part III) (P = 0.004) and in the UPDRS subscore part III (P = 0.003).  None of these scores changed over time in the fluoxetine group (n = 7).  Both, nefazodone and fluoxetine were equally effective as antidepressants: beck depression Inventory scores significantly improved (P < 0.001), with no significant differences between treatment groups (P = 0.97).If our results can be confirmed in a larger clin. trial, nefazodone ought to be considered over fluoxetine given its secondary beneficial effects regarding the redn. of extrapyramidal symptoms in depressed PD patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpCpklq8wnZtbVg90H21EOLACvtfcHk0liVx8m3dD1qlw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXns12qu7w%253D&md5=27b0e7a917af9fa7864b20b0e839fe1b</span></div><a href="/servlet/linkout?suffix=cit16b&amp;dbid=16384&amp;doi=10.1097%2F01.jcp.0000088908.24613.db&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252F01.jcp.0000088908.24613.db%26sid%3Dliteratum%253Aachs%26aulast%3DAvila%26aufirst%3DA.%26aulast%3DVardona%26aufirst%3DX.%26aulast%3DMartin-Baranera%26aufirst%3DM.%26aulast%3DMaho%26aufirst%3DP.%26aulast%3DSastre%26aufirst%3DF.%26aulast%3DBello%26aufirst%3DJ.%26atitle%3DDoes%2520nefazodone%2520improve%2520both%2520depression%2520and%2520Parkinson%2520disease%253F%2520A%2520pilot%2520randomized%2520trial%26jtitle%3DJ.%2520Clin.%2520Psychopharmacol.%26date%3D2003%26volume%3D23%26spage%3D509%26epage%3D513" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit16c"><span><span class="NLM_contrib-group">Greene, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barbhaiya, R. H.</span><span> </span><span class="NLM_article-title">Clinical pharmacokinetics of nefazodone</span> <span class="citation_source-journal">Clin. Pharmacokinet.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1997</span><span class="NLM_x">, </span> <span class="NLM_volume">33</span><span class="NLM_x">, </span> <span class="NLM_fpage">260</span><span class="NLM_x">â</span> <span class="NLM_lpage">275</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16c&amp;dbid=16&amp;doi=10.1021%2Fjm200682b&amp;key=10.2165%2F00003088-199733040-00002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16c&amp;dbid=8&amp;doi=10.1021%2Fjm200682b&amp;key=9342502" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16c&amp;dbid=32&amp;doi=10.1021%2Fjm200682b&amp;key=1%3ACAS%3A528%3ADyaK2sXntVGgtrk%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=33&publication_year=1997&pages=260-275&author=D.+Greeneauthor=R.+H.+Barbhaiya&title=Clinical+pharmacokinetics+of+nefazodone"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit16cR"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Clinical pharmacokinetics of nefazodone</span></div><div class="casAuthors">Greene, Douglas S.; Barbhaiya, Rashmi H.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Pharmacokinetics</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">33</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">260-275</span>CODEN:
                <span class="NLM_cas:coden">CPKNDH</span>;
        ISSN:<span class="NLM_cas:issn">0312-5963</span>.
    
            (<span class="NLM_cas:orgname">Adis</span>)
        </div><div class="casAbstract">A review with 51 refs.  Nefazodone is a new antidepressant drug, chem. unrelated to the tricyclic, tetracyclic or selective serotonin uptake inhibitors.  Nefazodone blocks the serotonin 5-HT2 receptors and reversibly inhibits serotonin reuptake in vivo.  Nefazodone is completely and rapidly absorbed after oral administration with a peak plasma concn. obsd. within 2 h of administration.  Nefazodone undergoes significant first-pass metab. resulting in an oral bioavailability of approx. 20%.  Although there is an 18% increase in nefazodone bioavailability with food, this increase is not clin. significant and nefazodone can be administered without regard to meals.  Three pharmacol. active nefazodone metabolites have been identified: hydroxy-nefazodone, triazoledione and m-chlorophenylpiperazine (mCPP).  The pharmacokinetics of nefazodone are nonlinear.  The increase in plasma concns. of nefazodone are greater than would be expected if they were proportional to increases in dose.  Steady-state plasma concns. of nefazodone are attained within 4 days of the commencement of administration.  The pharmacokinetics of nefazodone are not appreciably altered in patients with renal or mild-to-moderate hepatic impairment.  However, nefazodone plasma concns. are increased in severe hepatic impairment and in the elderly, esp. in elderly females.  Lower doses of nefazodone may be necessary in these groups.  Nefazodone is a weak inhibitor of cytochrome P 450 (CYP) 2D6 and does not inhibit CYP1A2.  It is not anticipated that nefazodone will interact with drugs cleared by these isoenzymes.  Indeed, nefazodone did not affect the pharmacokinetics of theophylline, a compd. cleared by CYP1A2.  Nefazodone is metabolized by and inhibits CYP3A4.  Clin. significant interactions have been obsd. between nefazodone and the benzodiazepines triazolam and alprazolam, cyclosporin and carbamazepine.  The potential for a clin. significant interaction between nefazodone and other drugs cleared by CYP3A4 (e.g. terfenadine) should be considered before the coadministration of these compds.  There was an increase in haloperidol plasma concns. when coadministered with nefazodone; nefazodone pharmacokinetics were not affected after coadministration.  No clin. significant interaction was obsd. when nefazodone was administered with lorazepam, lithium, alc., cimetidine, warfarin, theophylline or propranolol.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGowyKhx9mQWVrVg90H21EOLACvtfcHk0liVx8m3dD1qlw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXntVGgtrk%253D&md5=a5606549e2a64ad8d479197334bc3b65</span></div><a href="/servlet/linkout?suffix=cit16c&amp;dbid=16384&amp;doi=10.2165%2F00003088-199733040-00002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2165%252F00003088-199733040-00002%26sid%3Dliteratum%253Aachs%26aulast%3DGreene%26aufirst%3DD.%26aulast%3DBarbhaiya%26aufirst%3DR.%2BH.%26atitle%3DClinical%2520pharmacokinetics%2520of%2520nefazodone%26jtitle%3DClin.%2520Pharmacokinet.%26date%3D1997%26volume%3D33%26spage%3D260%26epage%3D275" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit16d"><span><span class="NLM_contrib-group">Kent, J. M.</span><span> </span><span class="NLM_article-title">SNaRIs, NaSSAs, and NaRIs: New agents for the treatment of depression</span> <span class="citation_source-journal">Lancet</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">355</span><span class="NLM_x">, </span> <span class="NLM_fpage">911</span><span class="NLM_x">â</span> <span class="NLM_lpage">918</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=355&publication_year=2000&pages=911-918&author=J.+M.+Kent&title=SNaRIs%2C+NaSSAs%2C+and+NaRIs%3A+New+agents+for+the+treatment+of+depression"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit16d&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DKent%26aufirst%3DJ.%2BM.%26atitle%3DSNaRIs%252C%2520NaSSAs%252C%2520and%2520NaRIs%253A%2520New%2520agents%2520for%2520the%2520treatment%2520of%2520depression%26jtitle%3DLancet%26date%3D2000%26volume%3D355%26spage%3D911%26epage%3D918" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17a"><span><span class="NLM_contrib-group">Lawler, C. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Prioleau, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lewis, M. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mak, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jian, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schetz, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gonzalez, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sibley, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mailman, R. B.</span><span> </span><span class="NLM_article-title">Interactions of the novel antipsychotic aripiprazole (OPC-14597) with dopamine and serotonin receptor subtypes</span> <span class="citation_source-journal">Neuropsychopahrmacology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1999</span><span class="NLM_x">, </span> <span class="NLM_volume">20</span><span class="NLM_x">, </span> <span class="NLM_fpage">612</span><span class="NLM_x">â</span> <span class="NLM_lpage">627</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17a&amp;dbid=16&amp;doi=10.1021%2Fjm200682b&amp;key=10.1016%2FS0893-133X%2898%2900099-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17a&amp;dbid=8&amp;doi=10.1021%2Fjm200682b&amp;key=10327430" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17a&amp;dbid=32&amp;doi=10.1021%2Fjm200682b&amp;key=1%3ACAS%3A528%3ADyaK1MXjsVamu7c%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=1999&pages=612-627&author=C.+P.+Lawlerauthor=C.+Prioleauauthor=M.+M.+Lewisauthor=C.+Makauthor=D.+Jianauthor=J.+A.+Schetzauthor=A.+M.+Gonzalezauthor=D.+R.+Sibleyauthor=R.+B.+Mailman&title=Interactions+of+the+novel+antipsychotic+aripiprazole+%28OPC-14597%29+with+dopamine+and+serotonin+receptor+subtypes"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit17aR"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Interactions of the novel antipsychotic aripiprazole (OPC-14597) with dopamine and serotonin receptor subtypes</span></div><div class="casAuthors">Lawler, Cindy P.; Prioleau, Cassandra; Lewis, Mechelle M.; Mak, Chun; Jiang, Dong; Schetz, John A.; Gonzalez, Antonio M.; Sibley, David R.; Mailman, Richard B.</div><div class="citationInfo"><span class="NLM_cas:title">Neuropsychopharmacology</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">612-627</span>CODEN:
                <span class="NLM_cas:coden">NEROEW</span>;
        ISSN:<span class="NLM_cas:issn">0893-133X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Inc.</span>)
        </div><div class="casAbstract">OPC-14597 {aripiprazole; 7- (4- (4-(2,3-dichlorophenyl) -1-piperazinyl) butyloxy) -3, 4-dihydro-2 (1H) -quinolinone} is a novel candidate antipsychotic that has high affinity for striatal dopamine D2-like receptors, but causes few extrapyramidal effects.  These studies characterized the mol. pharmacol. of OPC-14597, DM-1451 (its major rodent metabolite), and the related quinolinone deriv. OPC-4392 at each of the cloned dopamine receptors, and at serotonin 5HT6 and 5HT7 receptors.  All three compds. exhibited highest affinity for D2L and D2S receptors relative to the other cloned receptors examd.  Both OPC-4392 and OPC-14597 demonstrated dual agonist/antagonist actions at D2L receptors, although the metabolite DM-1451 behaved as a pure antagonist.  These data suggest that clin. atypicality can occur with drugs that exhibit selectivity for D2L/D2S rather than D3 or D4 receptors, and raise the possibility that the unusual profile of OPC-14597 in vivo (presynaptic agonist and postsynaptic antagonist) may reflect different functional consequences of this compd. interacting with a single dopamine receptor subtype (D2) in distinct cellular locales.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpFhC9HkOART7Vg90H21EOLACvtfcHk0liVx8m3dD1qlw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXjsVamu7c%253D&md5=6075301b17f119d4040742751425bb92</span></div><a href="/servlet/linkout?suffix=cit17a&amp;dbid=16384&amp;doi=10.1016%2FS0893-133X%2898%2900099-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0893-133X%252898%252900099-2%26sid%3Dliteratum%253Aachs%26aulast%3DLawler%26aufirst%3DC.%2BP.%26aulast%3DPrioleau%26aufirst%3DC.%26aulast%3DLewis%26aufirst%3DM.%2BM.%26aulast%3DMak%26aufirst%3DC.%26aulast%3DJian%26aufirst%3DD.%26aulast%3DSchetz%26aufirst%3DJ.%2BA.%26aulast%3DGonzalez%26aufirst%3DA.%2BM.%26aulast%3DSibley%26aufirst%3DD.%2BR.%26aulast%3DMailman%26aufirst%3DR.%2BB.%26atitle%3DInteractions%2520of%2520the%2520novel%2520antipsychotic%2520aripiprazole%2520%2528OPC-14597%2529%2520with%2520dopamine%2520and%2520serotonin%2520receptor%2520subtypes%26jtitle%3DNeuropsychopahrmacology%26date%3D1999%26volume%3D20%26spage%3D612%26epage%3D627" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit17b"><span><span class="NLM_contrib-group">Burstein, e. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ma, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wong, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gao, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pahrm., E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Knapp, A. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nash, N. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Olsson, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Davis, R. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hacksell, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weiner, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brann, M. R.</span><span> </span><span class="NLM_article-title">Intrinsic efficacy of antipsychotics at human D<sub>2</sub>, D<sub>3</sub>, and D<sub>4</sub> dopamine receptors: Identification of the clozapine metabolite <i>N</i>-desmethylclozapine as a D<sub>2</sub>/D<sub>3</sub> partial agonist</span> <span class="citation_source-journal">J. Pharmacol. Exp. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">315</span><span class="NLM_x">, </span> <span class="NLM_fpage">1278</span><span class="NLM_x">â</span> <span class="NLM_lpage">1287</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17b&amp;dbid=16&amp;doi=10.1021%2Fjm200682b&amp;key=10.1124%2Fjpet.105.092155" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17b&amp;dbid=8&amp;doi=10.1021%2Fjm200682b&amp;key=16135699" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17b&amp;dbid=32&amp;doi=10.1021%2Fjm200682b&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhtlalurnL" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=315&publication_year=2005&pages=1278-1287&author=e.+S.+Bursteinauthor=J.+Maauthor=S.+Wongauthor=Y.+Gaoauthor=E.+Pahrm.author=A.+E.+Knappauthor=N.+R.+Nashauthor=R.+Olssonauthor=R.+E.+Davisauthor=U.+Hacksellauthor=D.+M.+Weinerauthor=M.+R.+Brann&title=Intrinsic+efficacy+of+antipsychotics+at+human+D2%2C+D3%2C+and+D4+dopamine+receptors%3A+Identification+of+the+clozapine+metabolite+N-desmethylclozapine+as+a+D2%2FD3+partial+agonist"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit17bR"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Intrinsic efficacy of antipsychotics at human D2, D3, and D4 dopamine receptors: Identification of the clozapine metabolite N-desmethylclozapine as a D2/D3 partial agonist</span></div><div class="casAuthors">Burstein, E. S.; Ma, J.; Wong, S.; Gao, Y.; Pham, E.; Knapp, A. E.; Nash, N. R.; Olsson, R.; Davis, R. E.; Hacksell, U.; Weiner, D. M.; Brann, M. R.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">315</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">1278-1287</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Drugs that antagonize D2-like receptors are effective antipsychotics, but the debilitating movement disorder side effects assocd. with these drugs cannot be dissocd. from dopamine receptor blockade.  The "atypical" antipsychotics have a lower propensity to cause extrapyramidal symptoms (EPS), but the mol. basis for this is not fully understood nor is the impact of inverse agonism upon their clin. properties.  Using a cell-based functional assay, we demonstrate that overexpression of GÎ±o induces constitutive activity in the human D2-like receptors (D2, D3, and D4).  A large collection of typical and atypical antipsychotics was profiled for activity at these receptors.  Virtually all were D2 and D3 inverse agonists, whereas none was D4 inverse agonist, although many were potent D4 antagonists.  The inverse agonist activity of haloperidol at D2 and D3 receptors could be reversed by mesoridazine demonstrating that there were significant differences in the degrees of inverse agonism among the compds. tested.  Aripiprazole and the principle active metabolite of clozapine NDMC [8-chloro-11-(1-piperazinyl)-5H-dibenzo [b,e] [1,4] diazepine] were identified as partial agonists at D2 and D3 receptors, although clozapine itself was an inverse agonist at these receptors.  NDMC-induced functional responses could be reversed by clozapine.  It is proposed that the low incidence of EPS assocd. with clozapine and aripiprazole used may be due, in part, to these partial agonist properties of NDMC and aripiprazole and that bypassing clozapine blockade through direct administration of NDMC to patients may provide superior antipsychotic efficacy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpJpq7vgFnG8rVg90H21EOLACvtfcHk0lj4YUXk0Bo9kQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhtlalurnL&md5=327fe47435bf8fa5215af0d2af4b3b40</span></div><a href="/servlet/linkout?suffix=cit17b&amp;dbid=16384&amp;doi=10.1124%2Fjpet.105.092155&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.105.092155%26sid%3Dliteratum%253Aachs%26aulast%3DBurstein%26aufirst%3De.%2BS.%26aulast%3DMa%26aufirst%3DJ.%26aulast%3DWong%26aufirst%3DS.%26aulast%3DGao%26aufirst%3DY.%26aulast%3DPahrm.%26aufirst%3DE.%26aulast%3DKnapp%26aufirst%3DA.%2BE.%26aulast%3DNash%26aufirst%3DN.%2BR.%26aulast%3DOlsson%26aufirst%3DR.%26aulast%3DDavis%26aufirst%3DR.%2BE.%26aulast%3DHacksell%26aufirst%3DU.%26aulast%3DWeiner%26aufirst%3DD.%2BM.%26aulast%3DBrann%26aufirst%3DM.%2BR.%26atitle%3DIntrinsic%2520efficacy%2520of%2520antipsychotics%2520at%2520human%2520D2%252C%2520D3%252C%2520and%2520D4%2520dopamine%2520receptors%253A%2520Identification%2520of%2520the%2520clozapine%2520metabolite%2520N-desmethylclozapine%2520as%2520a%2520D2%252FD3%2520partial%2520agonist%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2005%26volume%3D315%26spage%3D1278%26epage%3D1287" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group">Oshiro, Y.; Sato, S.; Kurahashi, N.</span> (<div class="note"><p class="first last">Otsuka Pharmaceutical Co., Japan</p></div>) <span> </span><span class="NLM_article-title">Carbostyril derivatives</span>. U.S. Patent 5,006,528, <span class="NLM_month">April</span><span class="NLM_day">9</span>,<span class="NLM_x"> </span><span class="NLM_year">1991</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=1991&author=Y.+Oshiro&author=S.+Sato&author=N.+Kurahashi&title=Carbostyril+derivatives"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DOshiro%26aufirst%3DY.%26atitle%3DCarbostyril%2520derivatives%26date%3D1991" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19a"><span><span class="NLM_contrib-group">Kang, S. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Park, E.-J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Park, W.-K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, H. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jeong, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jung, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Song, K.-S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, S. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Seo, H. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Han, H.-K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Son, E.-J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pae, A. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, J.</span><span> </span><span class="NLM_article-title">Arylpiperazine-containing pyrrole 3-carboxamide derivatives targeting serotonin 5-HT<sub>2A,</sub> 5-HT<sub>2c,</sub> and the serotonin transporter as a potential antidepressant</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">20</span><span class="NLM_x">, </span> <span class="NLM_fpage">1705</span><span class="NLM_x">â</span> <span class="NLM_lpage">1711</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2010&pages=1705-1711&author=S.+Y.+Kangauthor=E.-J.+Parkauthor=W.-K.+Parkauthor=H.+J.+Kimauthor=D.+Jeongauthor=M.+E.+Jungauthor=K.-S.+Songauthor=S.+H.+Leeauthor=H.+J.+Seoauthor=M.+J.+Kimauthor=M.+Leeauthor=H.-K.+Hanauthor=E.-J.+Sonauthor=A.+N.+Paeauthor=J.+Kimauthor=J.+Lee&title=Arylpiperazine-containing+pyrrole+3-carboxamide+derivatives+targeting+serotonin+5-HT2A%2C+5-HT2c%2C+and+the+serotonin+transporter+as+a+potential+antidepressant"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit19a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DKang%26aufirst%3DS.%2BY.%26aulast%3DPark%26aufirst%3DE.-J.%26aulast%3DPark%26aufirst%3DW.-K.%26aulast%3DKim%26aufirst%3DH.%2BJ.%26aulast%3DJeong%26aufirst%3DD.%26aulast%3DJung%26aufirst%3DM.%2BE.%26aulast%3DSong%26aufirst%3DK.-S.%26aulast%3DLee%26aufirst%3DS.%2BH.%26aulast%3DSeo%26aufirst%3DH.%2BJ.%26aulast%3DKim%26aufirst%3DM.%2BJ.%26aulast%3DLee%26aufirst%3DM.%26aulast%3DHan%26aufirst%3DH.-K.%26aulast%3DSon%26aufirst%3DE.-J.%26aulast%3DPae%26aufirst%3DA.%2BN.%26aulast%3DKim%26aufirst%3DJ.%26aulast%3DLee%26aufirst%3DJ.%26atitle%3DArylpiperazine-containing%2520pyrrole%25203-carboxamide%2520derivatives%2520targeting%2520serotonin%25205-HT2A%252C%25205-HT2c%252C%2520and%2520the%2520serotonin%2520transporter%2520as%2520a%2520potential%2520antidepressant%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2010%26volume%3D20%26spage%3D1705%26epage%3D1711" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit19b"><span><span class="NLM_contrib-group">Kang, S. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Park, E.-J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Park, W.-K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, H. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Choi, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jung, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Seo, H. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pae, A. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, J.</span><span> </span><span class="NLM_article-title">Further optimization of novel pyrrole 3-carboxamides for targeting serotonin 5-HT<sub>2A</sub>, 5-HT<sub>2c</sub>, and the serotonin transporter as a potential antidepressant</span> <span class="citation_source-journal">Bioorg. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">18</span><span class="NLM_x">, </span> <span class="NLM_fpage">6156</span><span class="NLM_x">â</span> <span class="NLM_lpage">6169</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2010&pages=6156-6169&author=S.+Y.+Kangauthor=E.-J.+Parkauthor=W.-K.+Parkauthor=H.+J.+Kimauthor=G.+Choiauthor=M.+E.+Jungauthor=H.+J.+Seoauthor=M.+J.+Kimauthor=A.+N.+Paeauthor=J.+Kimauthor=J.+Lee&title=Further+optimization+of+novel+pyrrole+3-carboxamides+for+targeting+serotonin+5-HT2A%2C+5-HT2c%2C+and+the+serotonin+transporter+as+a+potential+antidepressant"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit19b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DKang%26aufirst%3DS.%2BY.%26aulast%3DPark%26aufirst%3DE.-J.%26aulast%3DPark%26aufirst%3DW.-K.%26aulast%3DKim%26aufirst%3DH.%2BJ.%26aulast%3DChoi%26aufirst%3DG.%26aulast%3DJung%26aufirst%3DM.%2BE.%26aulast%3DSeo%26aufirst%3DH.%2BJ.%26aulast%3DKim%26aufirst%3DM.%2BJ.%26aulast%3DPae%26aufirst%3DA.%2BN.%26aulast%3DKim%26aufirst%3DJ.%26aulast%3DLee%26aufirst%3DJ.%26atitle%3DFurther%2520optimization%2520of%2520novel%2520pyrrole%25203-carboxamides%2520for%2520targeting%2520serotonin%25205-HT2A%252C%25205-HT2c%252C%2520and%2520the%2520serotonin%2520transporter%2520as%2520a%2520potential%2520antidepressant%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2010%26volume%3D18%26spage%3D6156%26epage%3D6169" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit19c"><span><span class="NLM_contrib-group">Kim, J. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kang, S. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Park, W.-K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, H. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jung, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Son, E.-J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pae, A. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, J.</span><span> </span><span class="NLM_article-title">Arylpiperazine-containing pyrimidine 4-carboxamide derivatives targeting serotonin 5-HT<sub>2A</sub>, 5-HT<sub>2c</sub>, and the serotonin transporter as a potential antidepressant</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">20</span><span class="NLM_x">, </span> <span class="NLM_fpage">6439</span><span class="NLM_x">â</span> <span class="NLM_lpage">6442</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2010&pages=6439-6442&author=J.+Y.+Kimauthor=D.+Kimauthor=S.+Y.+Kangauthor=W.-K.+Parkauthor=H.+J.+Kimauthor=M.+E.+Jungauthor=E.-J.+Sonauthor=A.+N.+Paeauthor=J.+Kimauthor=J.+Lee&title=Arylpiperazine-containing+pyrimidine+4-carboxamide+derivatives+targeting+serotonin+5-HT2A%2C+5-HT2c%2C+and+the+serotonin+transporter+as+a+potential+antidepressant"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit19c&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DKim%26aufirst%3DJ.%2BY.%26aulast%3DKim%26aufirst%3DD.%26aulast%3DKang%26aufirst%3DS.%2BY.%26aulast%3DPark%26aufirst%3DW.-K.%26aulast%3DKim%26aufirst%3DH.%2BJ.%26aulast%3DJung%26aufirst%3DM.%2BE.%26aulast%3DSon%26aufirst%3DE.-J.%26aulast%3DPae%26aufirst%3DA.%2BN.%26aulast%3DKim%26aufirst%3DJ.%26aulast%3DLee%26aufirst%3DJ.%26atitle%3DArylpiperazine-containing%2520pyrimidine%25204-carboxamide%2520derivatives%2520targeting%2520serotonin%25205-HT2A%252C%25205-HT2c%252C%2520and%2520the%2520serotonin%2520transporter%2520as%2520a%2520potential%2520antidepressant%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2010%26volume%3D20%26spage%3D6439%26epage%3D6442" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group">Lange, J. H. M.; Stuivenberg, H. H. V.; Vliet, B. J. V.</span> (<div class="note"><p class="first last">Solvay Pharmaceuticals</p></div>) <span> </span><span class="NLM_article-title">1<i>H</i>-imidazole derivatives as cannabinoid CB2 receptor modulators</span>. U.S. Patent Application 2006/0194779, <span class="NLM_month">August</span><span class="NLM_day">31</span>,<span class="NLM_x"> </span><span class="NLM_year">2006</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2006&author=J.+H.+M.+Lange&author=H.+H.+V.+Stuivenberg&author=B.+J.+V.+Vliet&title=1H-imidazole+derivatives+as+cannabinoid+CB2+receptor+modulators"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DLange%26aufirst%3DJ.%2BH.%2BM.%26atitle%3D1H-imidazole%2520derivatives%2520as%2520cannabinoid%2520CB2%2520receptor%2520modulators%26date%3D2006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21a"><span><span class="NLM_contrib-group">Lange, J. H. M.</span><span class="NLM_etal"></span><span> </span><span class="NLM_article-title">Bioisosteric replacements of the pyrazole moiety of rimonabant: Synthesis, biological properties, and molecular modeling investigations of thiazoles, triazoles, and imidazoles as potent and selective CB1 cannabinoid receptor antagonists</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">48</span><span class="NLM_x">, </span> <span class="NLM_fpage">1823</span><span class="NLM_x">â</span> <span class="NLM_lpage">1838</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm040843r" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref21/cit21a&amp;dbid=32&amp;doi=10.1021%2Fjm200682b&amp;key=1%3ACAS%3A528%3ADC%252BD2cXnvFSrsLg%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=2005&pages=1823-1838&author=J.+H.+M.+Lange&title=Bioisosteric+replacements+of+the+pyrazole+moiety+of+rimonabant%3A+Synthesis%2C+biological+properties%2C+and+molecular+modeling+investigations+of+thiazoles%2C+triazoles%2C+and+imidazoles+as+potent+and+selective+CB1+cannabinoid+receptor+antagonists"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit21aR"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Bioisosteric Replacements of the Pyrazole Moiety of Rimonabant: Synthesis, Biological Properties, and Molecular Modeling Investigations of Thiazoles, Triazoles, and Imidazoles as Potent and Selective CB1 Cannabinoid Receptor Antagonists</span></div><div class="casAuthors">Lange, Jos H. M.; van Stuivenberg, Herman H.; Coolen, Hein K. A. C.; Adolfs, Tiny J. P.; McCreary, Andrew C.; Keizer, Hiskias G.; Wals, Henri C.; Veerman, Willem; Borst, Alice J. M.; de Looff, Wouter; Verveer, Peter C.; Kruse, Chris G.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">48</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1823-1838</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Series of thiazoles, triazoles, and imidazoles were designed as bioisosteres, based on the 1,5-diarylpyrazole motif that is present in the potent CB1 receptor antagonist rimonabant.  A no. of target compds. were synthesized and evaluated in cannabinoid (hCB1 and hCB2) receptor assays.  The thiazoles, triazoles, and imidazoles elicited in vitro CB1 antagonistic activities and in general exhibited considerable CB1 vs CB2 receptor subtype selectivities, thereby demonstrating to be cannabinoid bioisosteres of the original diarylpyrazole class.  Some key representatives in the imidazole series showed potent pharmacol. in vivo activities after oral administration in both a CB agonist-induced hypotension model and a CB agonist-induced hypothermia model.  Mol. modeling studies showed a close three-dimensional structural overlap between the imidazole I and rimonabant.  A structure-activity relationship (SAR) study revealed a close correlation between the biol. results in the imidazole and pyrazole series.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp16SsR1EEEVbVg90H21EOLACvtfcHk0lhjDmr7Km5Kuw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXnvFSrsLg%253D&md5=c3b80380a273d7f69a33c812a45e0154</span></div><a href="/servlet/linkout?suffix=cit21a&amp;dbid=16384&amp;doi=10.1021%2Fjm040843r&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm040843r%26sid%3Dliteratum%253Aachs%26aulast%3DLange%26aufirst%3DJ.%2BH.%2BM.%26atitle%3DBioisosteric%2520replacements%2520of%2520the%2520pyrazole%2520moiety%2520of%2520rimonabant%253A%2520Synthesis%252C%2520biological%2520properties%252C%2520and%2520molecular%2520modeling%2520investigations%2520of%2520thiazoles%252C%2520triazoles%252C%2520and%2520imidazoles%2520as%2520potent%2520and%2520selective%2520CB1%2520cannabinoid%2520receptor%2520antagonists%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2005%26volume%3D48%26spage%3D1823%26epage%3D1838" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit21b"><span><span class="NLM_contrib-group">Kim, J. Y.</span><span class="NLM_etal"></span><span> </span><span class="NLM_article-title">Diarylimidazolyl oxadiazole and thiadiazole derivatives as cannabinoid CB1 receptor antagonists</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x">, </span> <span class="NLM_fpage">142</span><span class="NLM_x">â</span> <span class="NLM_lpage">145</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2009&pages=142-145&author=J.+Y.+Kim&title=Diarylimidazolyl+oxadiazole+and+thiadiazole+derivatives+as+cannabinoid+CB1+receptor+antagonists"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit21b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DKim%26aufirst%3DJ.%2BY.%26atitle%3DDiarylimidazolyl%2520oxadiazole%2520and%2520thiadiazole%2520derivatives%2520as%2520cannabinoid%2520CB1%2520receptor%2520antagonists%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2009%26volume%3D19%26spage%3D142%26epage%3D145" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group">Smith, R. A.; OâConnor, S. J.; Wirtz, S.-N.; Wong, W. C.; Choi, S.; Kluender, H. C. E.; Su, N.; Wang, G.; Achebe, F.; Ying, S.</span> (<div class="note"><p class="first last">Bayer Pharmaceuticals Co.</p></div>) <span> </span><span class="NLM_article-title">Imidazole-4-carboxamide derivatives, preparation and use thereof for treatment of obesity</span>. WO 03/040107, <span class="NLM_month">May</span><span class="NLM_day">15</span>,<span class="NLM_x"> </span><span class="NLM_year">2003</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2003&author=R.+A.+Smith&author=S.+J.+O%E2%80%99Connor&author=S.-N.+Wirtz&author=W.+C.+Wong&author=S.+Choi&author=H.+C.+E.+Kluender&author=N.+Su&author=G.+Wang&author=F.+Achebe&author=S.+Ying&title=Imidazole-4-carboxamide+derivatives%2C+preparation+and+use+thereof+for+treatment+of+obesity"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DSmith%26aufirst%3DR.%2BA.%26atitle%3DImidazole-4-carboxamide%2520derivatives%252C%2520preparation%2520and%2520use%2520thereof%2520for%2520treatment%2520of%2520obesity%26date%3D2003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span><span class="NLM_contrib-group">Buettelmann, B.; Ceccarelli, S. M.; Jaeschke, G.; Kolczewski, S.; Porter, R. H. P.; Vieira, E.</span> (<div class="note"><p class="first last">F. Hoffmann-La Roche AG</p></div>) <span> </span><span class="NLM_article-title">Imidazole derivatives III</span>. WO 2005/003117, <span class="NLM_month">January</span><span class="NLM_day">13</span>,<span class="NLM_x"> </span><span class="NLM_year">2005</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2005&author=B.+Buettelmann&author=S.+M.+Ceccarelli&author=G.+Jaeschke&author=S.+Kolczewski&author=R.+H.+P.+Porter&author=E.+Vieira&title=Imidazole+derivatives+III"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DBuettelmann%26aufirst%3DB.%26atitle%3DImidazole%2520derivatives%2520III%26date%3D2005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span><span class="NLM_contrib-group">Robarge, M. J.</span><span class="NLM_etal"></span><span> </span><span class="NLM_article-title">Design and synthesis of [(2,3-dichlorophenyl)piperazin-1-yl]alkylfluorenylcarboxamides as novel ligands selective for the dopamine D<sub>3</sub> receptor subtype</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">44</span><span class="NLM_x">, </span> <span class="NLM_fpage">3175</span><span class="NLM_x">â</span> <span class="NLM_lpage">3186</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm010146o" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=44&publication_year=2001&pages=3175-3186&author=M.+J.+Robarge&title=Design+and+synthesis+of+%5B%282%2C3-dichlorophenyl%29piperazin-1-yl%5Dalkylfluorenylcarboxamides+as+novel+ligands+selective+for+the+dopamine+D3+receptor+subtype"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1021%2Fjm010146o&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm010146o%26sid%3Dliteratum%253Aachs%26aulast%3DRobarge%26aufirst%3DM.%2BJ.%26atitle%3DDesign%2520and%2520synthesis%2520of%2520%255B%25282%252C3-dichlorophenyl%2529piperazin-1-yl%255Dalkylfluorenylcarboxamides%2520as%2520novel%2520ligands%2520selective%2520for%2520the%2520dopamine%2520D3%2520receptor%2520subtype%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2001%26volume%3D44%26spage%3D3175%26epage%3D3186" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25"><span><span class="NLM_contrib-group">Park, W.-K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jeong, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cho, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cha, M. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pae, A. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Choi, K. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koh, H. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kong, J. Y.</span><span> </span><span class="NLM_article-title">KKHA-761, a potent D<sub>3</sub> receptor antagonist with high 5-HT<sub>1A</sub> receptor affinity, exhibits antipsychotic properties in animal models of schizophrenia</span> <span class="citation_source-journal">Pharmacol., Biochem. Behav.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">82</span><span class="NLM_x">, </span> <span class="NLM_fpage">361</span><span class="NLM_x">â</span> <span class="NLM_lpage">372</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=82&publication_year=2005&pages=361-372&author=W.-K.+Parkauthor=D.+Jeongauthor=H.+Choauthor=S.+J.+Leeauthor=M.+Y.+Chaauthor=A.+N.+Paeauthor=K.+I.+Choiauthor=H.+Y.+Kohauthor=J.+Y.+Kong&title=KKHA-761%2C+a+potent+D3+receptor+antagonist+with+high+5-HT1A+receptor+affinity%2C+exhibits+antipsychotic+properties+in+animal+models+of+schizophrenia"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DPark%26aufirst%3DW.-K.%26aulast%3DJeong%26aufirst%3DD.%26aulast%3DCho%26aufirst%3DH.%26aulast%3DLee%26aufirst%3DS.%2BJ.%26aulast%3DCha%26aufirst%3DM.%2BY.%26aulast%3DPae%26aufirst%3DA.%2BN.%26aulast%3DChoi%26aufirst%3DK.%2BI.%26aulast%3DKoh%26aufirst%3DH.%2BY.%26aulast%3DKong%26aufirst%3DJ.%2BY.%26atitle%3DKKHA-761%252C%2520a%2520potent%2520D3%2520receptor%2520antagonist%2520with%2520high%25205-HT1A%2520receptor%2520affinity%252C%2520exhibits%2520antipsychotic%2520properties%2520in%2520animal%2520models%2520of%2520schizophrenia%26jtitle%3DPharmacol.%252C%2520Biochem.%2520Behav.%26date%3D2005%26volume%3D82%26spage%3D361%26epage%3D372" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit26"><span><span class="NLM_contrib-group">Chiu, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marcoe, K. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bounds, S. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, C. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Feng, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cheng, F. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Crumb, W. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mitchell, R.</span><span> </span><span class="NLM_article-title">Validation of a [<sup>3</sup>H]Astemizole binding assay in HEK293 cells expressing HERG K<sup>+</sup> channels</span> <span class="citation_source-journal">J. Pharmacol. Sci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">95</span><span class="NLM_x">, </span> <span class="NLM_fpage">311</span><span class="NLM_x">â</span> <span class="NLM_lpage">319</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Fjm200682b&amp;key=10.1254%2Fjphs.FPE0040101" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Fjm200682b&amp;key=15272206" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Fjm200682b&amp;key=1%3ACAS%3A528%3ADC%252BD2cXmtFeksbs%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=95&publication_year=2004&pages=311-319&author=P.+J.+Chiuauthor=K.+F.+Marcoeauthor=S.+E.+Boundsauthor=C.+H.+Linauthor=J.+J.+Fengauthor=A.+Linauthor=F.+C.+Chengauthor=W.+J.+Crumbauthor=R.+Mitchell&title=Validation+of+a+%5B3H%5DAstemizole+binding+assay+in+HEK293+cells+expressing+HERG+K%2B+channels"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Validation of a [3H]astemizole binding assay in HEK293 cells expressing HERG K+ channels</span></div><div class="casAuthors">Chiu, Peter J. S.; Marcoe, Karen F.; Bounds, Sidney E.; Lin, Chun-Hsiung; Feng, Jin-Jye; Lin, Atsui; Cheng, Fong-Chi; Crumb, William J.; Mitchell, Richard</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacological Sciences (Tokyo, Japan)</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">95</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">311-319</span>CODEN:
                <span class="NLM_cas:coden">JPSTGJ</span>;
        ISSN:<span class="NLM_cas:issn">1347-8613</span>.
    
            (<span class="NLM_cas:orgname">Japanese Pharmacological Society</span>)
        </div><div class="casAbstract">A radioligand binding assay for the HERG (human ether-a-go-go-related gene) K+ channel was developed to identify compds. which may have inhibitory activity and potential cardiotoxicity.  Pharmacol. characterization of the [3H]astemizole binding assay for HERG K+ channels was performed using HERG-expressing HEK293 cells.  The assay conditions employed yielded 90% specific binding using 10 Î¼g/well of membrane protein with 1.5 nM of [3H]astemizole at 25Â°.  The Kd and Bmax values were 5.91Â±0.81 nM and 6.36Â±0.26 pmol/mg, resp.  The intraassay and interassay variations were 11.4% and 14.9%, resp.  Binding affinities for 32 ref. compds. (including dofetilide, cisapride, and terfenadine) with diverse structures demonstrated a similar potency rank order for HERG inhibition to that reported in the literature.  Moreover, the [3H]astemizole binding data demonstrated a rank order of affinity that was highly correlated to that of inhibitory potency in the electrophysiol. studies for HERG in HEK293 (rSP=0.91, P<0.05).  In conclusion, the [3H]astemizole binding assay is rapid and capable of detecting HERG inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrGxk529fo22rVg90H21EOLACvtfcHk0liKb7cpCOXlNQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXmtFeksbs%253D&md5=2e75917b530755e7c039c22deff36908</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1254%2Fjphs.FPE0040101&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1254%252Fjphs.FPE0040101%26sid%3Dliteratum%253Aachs%26aulast%3DChiu%26aufirst%3DP.%2BJ.%26aulast%3DMarcoe%26aufirst%3DK.%2BF.%26aulast%3DBounds%26aufirst%3DS.%2BE.%26aulast%3DLin%26aufirst%3DC.%2BH.%26aulast%3DFeng%26aufirst%3DJ.%2BJ.%26aulast%3DLin%26aufirst%3DA.%26aulast%3DCheng%26aufirst%3DF.%2BC.%26aulast%3DCrumb%26aufirst%3DW.%2BJ.%26aulast%3DMitchell%26aufirst%3DR.%26atitle%3DValidation%2520of%2520a%2520%255B3H%255DAstemizole%2520binding%2520assay%2520in%2520HEK293%2520cells%2520expressing%2520HERG%2520K%252B%2520channels%26jtitle%3DJ.%2520Pharmacol.%2520Sci.%26date%3D2004%26volume%3D95%26spage%3D311%26epage%3D319" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit27a"><span><span class="NLM_contrib-group">Ostroff, R. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nelson, J. C.</span><span> </span><span class="NLM_article-title">Risperidone augmentation of selective serotonin reuptake inhibitors in major depression</span> <span class="citation_source-journal">J. Clin. Psychiatry</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1999</span><span class="NLM_x">, </span> <span class="NLM_volume">60</span><span class="NLM_x">, </span> <span class="NLM_fpage">256</span><span class="NLM_x">â</span> <span class="NLM_lpage">259</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27a&amp;dbid=16&amp;doi=10.1021%2Fjm200682b&amp;key=10.4088%2FJCP.v60n0410" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27a&amp;dbid=8&amp;doi=10.1021%2Fjm200682b&amp;key=10221288" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27a&amp;dbid=32&amp;doi=10.1021%2Fjm200682b&amp;key=1%3ACAS%3A528%3ADyaK1MXivFekuro%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=1999&pages=256-259&author=R.+B.+Ostroffauthor=J.+C.+Nelson&title=Risperidone+augmentation+of+selective+serotonin+reuptake+inhibitors+in+major+depression"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit27aR"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Risperidone augmentation of selective serotonin reuptake inhibitors in major depression</span></div><div class="casAuthors">Ostroff, Robert B.; Nelson, J. Craig</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Psychiatry</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">256-259</span>CODEN:
                <span class="NLM_cas:coden">JCLPDE</span>;
        ISSN:<span class="NLM_cas:issn">0160-6689</span>.
    
            (<span class="NLM_cas:orgname">Physicians Postgraduate Press, Inc.</span>)
        </div><div class="casAbstract">Background: At low doses, risperidone acts as a 5-HT2 antagonist.  Preclin. data suggest 5-HT2 antagonists may enhance the action of serotonin.  This report examines the clin. use of risperidone to augment selective serotonin reuptake inhibitor (SSRI) antidepressants in patients who have not responded to SSRI therapy.  Method: In 8 patients with major depressive disorder without psychotic features (DSM-IV) who had not responded to an SSRI, risperidone was added to the ongoing SSRI treatment.  Hamilton Rating Scale for Depression scores were obtained before and after the addn. of risperidone.  Results: These 8 patients remitted within 1 wk of the addn. of risperidone.  Risperidone also appeared to have beneficial effects on sleep disturbance and sexual dysfunction.  Conclusion: Risperidone may be a useful adjunct to SSRIs in the treatment of depression.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoESVKe73GdRLVg90H21EOLACvtfcHk0liKb7cpCOXlNQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXivFekuro%253D&md5=a438999ad3a5c6cf6d8a432f533d7d6d</span></div><a href="/servlet/linkout?suffix=cit27a&amp;dbid=16384&amp;doi=10.4088%2FJCP.v60n0410&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4088%252FJCP.v60n0410%26sid%3Dliteratum%253Aachs%26aulast%3DOstroff%26aufirst%3DR.%2BB.%26aulast%3DNelson%26aufirst%3DJ.%2BC.%26atitle%3DRisperidone%2520augmentation%2520of%2520selective%2520serotonin%2520reuptake%2520inhibitors%2520in%2520major%2520depression%26jtitle%3DJ.%2520Clin.%2520Psychiatry%26date%3D1999%26volume%3D60%26spage%3D256%26epage%3D259" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit27b"><span><span class="NLM_contrib-group">Shelton, R. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tollefson, G. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tohen, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stahl, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gannon, K. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jacobs, T. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buras, W. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bymaster, F. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Spencer, K. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Feldman, P. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meltzer, H. Y.</span><span> </span><span class="NLM_article-title">A novel augmentation strategy for treating resistant major depression</span> <span class="citation_source-journal">Am. J. Psychiatry.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">158</span><span class="NLM_x">, </span> <span class="NLM_fpage">131</span><span class="NLM_x">â</span> <span class="NLM_lpage">134</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27b&amp;dbid=16&amp;doi=10.1021%2Fjm200682b&amp;key=10.1176%2Fappi.ajp.158.1.131" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27b&amp;dbid=8&amp;doi=10.1021%2Fjm200682b&amp;key=11136647" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27b&amp;dbid=32&amp;doi=10.1021%2Fjm200682b&amp;key=1%3ACAS%3A280%3ADC%252BD3M7isVCgsw%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=158&publication_year=2001&pages=131-134&author=R.+C.+Sheltonauthor=G.+D.+Tollefsonauthor=M.+Tohenauthor=S.+Stahlauthor=K.+S.+Gannonauthor=T.+G.+Jacobsauthor=W.+R.+Burasauthor=F.+P.+Bymasterauthor=W.+Zhangauthor=K.+A.+Spencerauthor=P.+D.+Feldmanauthor=H.+Y.+Meltzer&title=A+novel+augmentation+strategy+for+treating+resistant+major+depression"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit27bR"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">A novel augmentation strategy for treating resistant major depression</span></div><div class="casAuthors">Shelton R C; Tollefson G D; Tohen M; Stahl S; Gannon K S; Jacobs T G; Buras W R; Bymaster F P; Zhang W; Spencer K A; Feldman P D; Meltzer H Y</div><div class="citationInfo"><span class="NLM_cas:title">The American journal of psychiatry</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">158</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">131-4</span>
        ISSN:<span class="NLM_cas:issn">0002-953X</span>.
    </div><div class="casAbstract">OBJECTIVE:  Treatment-resistant depression is a significant public health concern; drug switching or augmentation often produce limited results.  The authors hypothesized that fluoxetine could be augmented with olanzapine to successfully treat resistant depression.  METHOD:  An 8-week double-blind study was conducted with 28 patients who were diagnosed with recurrent, nonbipolar, treatment-resistant depression without psychotic features.  Subjects were randomly assigned to one of three groups: olanzapine plus placebo, fluoxetine plus placebo, or olanzapine plus fluoxetine.  RESULTS:  Fluoxetine monotherapy produced minimal improvement on various scales that rate severity of depression.  The benefits of olanzapine monotherapy were modest.  Olanzapine plus fluoxetine produced significantly greater improvement than either monotherapy on one measure and significantly greater improvement than olanzapine monotherapy on the other measures after 1 week.  There were no significant differences between treatment groups on extrapyramidal measures nor significant adverse drug interactions.  CONCLUSIONS:  Olanzapine plus fluoxetine demonstrated superior efficacy for treating resistant depression compared to either agent alone.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTbFiAxqdsjlHp3bfzSLaX5fW6udTcc2eadgZItbcLMgbntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD3M7isVCgsw%253D%253D&md5=d6138dcb65d8be1b2dc6d67e34af364e</span></div><a href="/servlet/linkout?suffix=cit27b&amp;dbid=16384&amp;doi=10.1176%2Fappi.ajp.158.1.131&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1176%252Fappi.ajp.158.1.131%26sid%3Dliteratum%253Aachs%26aulast%3DShelton%26aufirst%3DR.%2BC.%26aulast%3DTollefson%26aufirst%3DG.%2BD.%26aulast%3DTohen%26aufirst%3DM.%26aulast%3DStahl%26aufirst%3DS.%26aulast%3DGannon%26aufirst%3DK.%2BS.%26aulast%3DJacobs%26aufirst%3DT.%2BG.%26aulast%3DBuras%26aufirst%3DW.%2BR.%26aulast%3DBymaster%26aufirst%3DF.%2BP.%26aulast%3DZhang%26aufirst%3DW.%26aulast%3DSpencer%26aufirst%3DK.%2BA.%26aulast%3DFeldman%26aufirst%3DP.%2BD.%26aulast%3DMeltzer%26aufirst%3DH.%2BY.%26atitle%3DA%2520novel%2520augmentation%2520strategy%2520for%2520treating%2520resistant%2520major%2520depression%26jtitle%3DAm.%2520J.%2520Psychiatry.%26date%3D2001%26volume%3D158%26spage%3D131%26epage%3D134" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit27c"><span><span class="NLM_contrib-group">Carpenter, L. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yasmin, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Price, L. H.</span><span> </span><span class="NLM_article-title">A double-blind, placebo-controlled study of antidepressant augmentation with mirtazapine</span> <span class="citation_source-journal">Biol. Psychiatry</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">51</span><span class="NLM_x">, </span> <span class="NLM_fpage">183</span><span class="NLM_x">â</span> <span class="NLM_lpage">188</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27c&amp;dbid=16&amp;doi=10.1021%2Fjm200682b&amp;key=10.1016%2FS0006-3223%2801%2901262-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27c&amp;dbid=8&amp;doi=10.1021%2Fjm200682b&amp;key=11822997" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27c&amp;dbid=32&amp;doi=10.1021%2Fjm200682b&amp;key=1%3ACAS%3A528%3ADC%252BD38Xos1CitA%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2002&pages=183-188&author=L.+L.+Carpenterauthor=S.+Yasminauthor=L.+H.+Price&title=A+double-blind%2C+placebo-controlled+study+of+antidepressant+augmentation+with+mirtazapine"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit27cR"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">A double-blind, placebo-controlled study of antidepressant augmentation with Mirtazapine</span></div><div class="casAuthors">Carpenter, Linda L.; Yasmin, Sarah; Price, Lawrence H.</div><div class="citationInfo"><span class="NLM_cas:title">Biological Psychiatry</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">51</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">183-188</span>CODEN:
                <span class="NLM_cas:coden">BIPCBF</span>;
        ISSN:<span class="NLM_cas:issn">0006-3223</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Inc.</span>)
        </div><div class="casAbstract">Background: A previous pilot study of open-label mirtazapine augmentation conducted by the authors in 20 depressed patients yielded a 55% response rate at week 4.  A double-blind controlled trial was undertaken to further elucidate the efficacy of this intervention.  Methods: 26 adult outpatients with persistent major depression despite adequate antidepressant monotherapy were randomized to receive 4 wk of mirtazapine or placebo augmentation.  Mirtazapine was begun at 15 mg at bedtime, with possible titrn. to 30 mg at bedtime per physician's discretion after week 1.  Results: Categorical pos. response rate at end point was 64% for active drug and 20% for placebo.  Remission rates were 45.4% and 13.3% for active drug and placebo groups, resp., Mirtazapine demonstrated statistically significant superiority to placebo on most major outcome measures, and was assocd. with improvement in overall functioning and quality of life.  There were no significant group differences with regard to emergent side effects, wt. change, or serum concns. of primary antidepressants.  Conclusions: Mirtazapine appears safe and effective for short-term antidepressant augmentation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp1FktNE8OvDbVg90H21EOLACvtfcHk0lg_kgXnNO78pA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38Xos1CitA%253D%253D&md5=1a2e576459c244a9d8d39b1f9442ba2e</span></div><a href="/servlet/linkout?suffix=cit27c&amp;dbid=16384&amp;doi=10.1016%2FS0006-3223%2801%2901262-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0006-3223%252801%252901262-8%26sid%3Dliteratum%253Aachs%26aulast%3DCarpenter%26aufirst%3DL.%2BL.%26aulast%3DYasmin%26aufirst%3DS.%26aulast%3DPrice%26aufirst%3DL.%2BH.%26atitle%3DA%2520double-blind%252C%2520placebo-controlled%2520study%2520of%2520antidepressant%2520augmentation%2520with%2520mirtazapine%26jtitle%3DBiol.%2520Psychiatry%26date%3D2002%26volume%3D51%26spage%3D183%26epage%3D188" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref28"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref28'); return false;" data-citation="" class="refNumLink">28</a></strong><div class="NLM_citation" id="cit28"><span><span class="NLM_contrib-group">Marek, G. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carpenter, L. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McDougle, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Price, L. H.</span><span> </span><span class="NLM_article-title">Synergistic action of 5-HT<sub>2A</sub> antagonists and selective serotonin reuptake inhibitors in neuropsychiatric disorders</span> <span class="citation_source-journal">Neuropsychopharmacology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">28</span><span class="NLM_x">, </span> <span class="NLM_fpage">402</span><span class="NLM_x">â</span> <span class="NLM_lpage">412</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2003&pages=402-412&author=G.+J.+Marekauthor=L.+L.+Carpenterauthor=C.+J.+McDougleauthor=L.+H.+Price&title=Synergistic+action+of+5-HT2A+antagonists+and+selective+serotonin+reuptake+inhibitors+in+neuropsychiatric+disorders"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMarek%26aufirst%3DG.%2BJ.%26aulast%3DCarpenter%26aufirst%3DL.%2BL.%26aulast%3DMcDougle%26aufirst%3DC.%2BJ.%26aulast%3DPrice%26aufirst%3DL.%2BH.%26atitle%3DSynergistic%2520action%2520of%25205-HT2A%2520antagonists%2520and%2520selective%2520serotonin%2520reuptake%2520inhibitors%2520in%2520neuropsychiatric%2520disorders%26jtitle%3DNeuropsychopharmacology%26date%3D2003%26volume%3D28%26spage%3D402%26epage%3D412" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref29"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref29'); return false;" data-citation="" class="refNumLink">29</a></strong><div class="NLM_citation" id="cit29"><span><span class="NLM_contrib-group">Porsolt, R. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bertin, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jalfre, M.</span><span> </span><span class="NLM_article-title">âBehavioural despairâ in rats and mice: Strain differences and the effects of imipramine</span> <span class="citation_source-journal">Eur. J. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1978</span><span class="NLM_x">, </span> <span class="NLM_volume">51</span><span class="NLM_x">, </span> <span class="NLM_fpage">291</span><span class="NLM_x">â</span> <span class="NLM_lpage">294</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Fjm200682b&amp;key=10.1016%2F0014-2999%2878%2990414-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Fjm200682b&amp;key=568552" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Fjm200682b&amp;key=1%3ACAS%3A528%3ADyaE1MXkvVCksg%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=1978&pages=291-294&author=R.+D.+Porsoltauthor=A.+Bertinauthor=M.+Jalfre&title=%E2%80%9CBehavioural+despair%E2%80%9D+in+rats+and+mice%3A+Strain+differences+and+the+effects+of+imipramine"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">"Behavioral despair" in rats and mice:  strain differences and the effects of imipramine</span></div><div class="casAuthors">Porsolt, Roger D.; Bertin, Anne; Jalfre, Maurice</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Pharmacology</span>
        (<span class="NLM_cas:date">1978</span>),
    <span class="NLM_cas:volume">51</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">291-4</span>CODEN:
                <span class="NLM_cas:coden">EJPHAZ</span>;
        ISSN:<span class="NLM_cas:issn">0014-2999</span>.
    </div><div class="casAbstract">Imipramine-HCl (I-HCl)  [113-52-0] dose-dependently decreased the immobility of Sprague-Dawley and Wistar/Charles River strains of rats forced to swim in a restricted space; I, however, had no effects on the immobility in Wistar/Iffa Credo rats.  I decreased the immobility in 3 different strain of mice, although a significant base-line strain difference was obsd. with the 3 strains without I pretreatment.  The results are discussed with regard to possible strain differences in the behavioral effects of pharmacol. agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrMNU10A5PpWLVg90H21EOLACvtfcHk0lil_KFWlR7EIg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaE1MXkvVCksg%253D%253D&md5=629df41e4ba1ea421f084411086a7f57</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1016%2F0014-2999%2878%2990414-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0014-2999%252878%252990414-4%26sid%3Dliteratum%253Aachs%26aulast%3DPorsolt%26aufirst%3DR.%2BD.%26aulast%3DBertin%26aufirst%3DA.%26aulast%3DJalfre%26aufirst%3DM.%26atitle%3D%25E2%2580%259CBehavioural%2520despair%25E2%2580%259D%2520in%2520rats%2520and%2520mice%253A%2520Strain%2520differences%2520and%2520the%2520effects%2520of%2520imipramine%26jtitle%3DEur.%2520J.%2520Pharmacol.%26date%3D1978%26volume%3D51%26spage%3D291%26epage%3D294" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7a','cit7b'],'ref8':['cit8'],'ref9':['cit9a','cit9b'],'ref10':['cit10a','cit10b'],'ref11':['cit11'],'ref12':['cit12'],'ref13':['cit13'],'ref14':['cit14'],'ref15':['cit15'],'ref16':['cit16a','cit16b','cit16c','cit16d'],'ref17':['cit17a','cit17b'],'ref18':['cit18'],'ref19':['cit19a','cit19b','cit19c'],'ref20':['cit20'],'ref21':['cit21a','cit21b'],'ref22':['cit22'],'ref23':['cit23'],'ref24':['cit24'],'ref25':['cit25'],'ref26':['cit26'],'ref27':['cit27a','cit27b','cit27c'],'ref28':['cit28'],'ref29':['cit29']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article is cited by 27 publications.</p><ol class="cited-content_cbyCitation"><li><span class="cited-content_cbyCitation_article-contributors">Elena Lenci, Lorenzo Calugi, <span class="NLM_string-name hlFld-ContribAuthor">Andrea Trabocchi</span>. </span><span class="cited-content_cbyCitation_article-title">Occurrence of Morpholine in Central Nervous System Drug Discovery. </span><span class="cited-content_cbyCitation_journal-name">ACS Chemical Neuroscience</span><span> <strong>2021,</strong> <em>12 </em>
                                    (3)
                                     , 378-390. <a href="https://doi.org/10.1021/acschemneuro.0c00729" title="DOI URL">https://doi.org/10.1021/acschemneuro.0c00729</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acschemneuro.0c00729&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facschemneuro.0c00729%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Chemical%2520Neuroscience%26atitle%3DOccurrence%252Bof%252BMorpholine%252Bin%252BCentral%252BNervous%252BSystem%252BDrug%252BDiscovery%26aulast%3DLenci%26aufirst%3DElena%26date%3D2021%26date%3D2021%26date%3D2021%26date%3D2020%26date%3D13112020%26date%3D11012021%26date%3D18012021%26volume%3D12%26issue%3D3%26spage%3D378%26epage%3D390" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">AnikÃ³ Angyal, AndrÃ¡s DemjÃ©n, JÃ¡nos WÃ¶lfling, LÃ¡szlÃ³ G. PuskÃ¡s, <span class="NLM_string-name hlFld-ContribAuthor">IvÃ¡n Kanizsai</span>. </span><span class="cited-content_cbyCitation_article-title">Acid-Catalyzed 1,3-Dipolar Cycloaddition of 2H-Azirines with Nitrones: An Unexpected Access to 1,2,4,5-Tetrasubstituted Imidazoles. </span><span class="cited-content_cbyCitation_journal-name">The Journal of Organic Chemistry</span><span> <strong>2020,</strong> <em>85 </em>
                                    (5)
                                     , 3587-3595. <a href="https://doi.org/10.1021/acs.joc.9b03288" title="DOI URL">https://doi.org/10.1021/acs.joc.9b03288</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.joc.9b03288&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.joc.9b03288%26sid%3Dliteratum%253Aachs%26jtitle%3DThe%2520Journal%2520of%2520Organic%2520Chemistry%26atitle%3DAcid-Catalyzed%252B1%25252C3-Dipolar%252BCycloaddition%252Bof%252B2H-Azirines%252Bwith%252BNitrones%25253A%252BAn%252BUnexpected%252BAccess%252Bto%252B1%25252C2%25252C4%25252C5-Tetrasubstituted%252BImidazoles%26aulast%3DAngyal%26aufirst%3DAnik%25C3%25B3%26date%3D2020%26date%3D2020%26date%3D2019%26date%3D06122019%26date%3D17022020%26date%3D05022020%26volume%3D85%26issue%3D5%26spage%3D3587%26epage%3D3595" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">F. Esra Ãnen
Bayram, Sarah A. A. Alradhwani, Gulcin Tugcu, <span class="NLM_string-name hlFld-ContribAuthor">Hande Sipahi</span>. </span><span class="cited-content_cbyCitation_article-title">Do We Build Similar Molecules for Comorbid Diseases? Tevarud in Drug Design, an Analysis for Depression and Inflammation. </span><span class="cited-content_cbyCitation_journal-name">ACS Medicinal Chemistry Letters</span><span> <strong>2020,</strong> <em>11 </em>
                                    (2)
                                     , 147-153. <a href="https://doi.org/10.1021/acsmedchemlett.9b00519" title="DOI URL">https://doi.org/10.1021/acsmedchemlett.9b00519</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acsmedchemlett.9b00519&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facsmedchemlett.9b00519%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DDo%252BWe%252BBuild%252BSimilar%252BMolecules%252Bfor%252BComorbid%252BDiseases%25253F%252BTevarud%252Bin%252BDrug%252BDesign%25252C%252Ban%252BAnalysis%252Bfor%252BDepression%252Band%252BInflammation%26aulast%3D%25C3%2596nen%2BBayram%26aufirst%3DF.%2BEsra%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D2019%26date%3D11112019%26date%3D16012020%26date%3D22012020%26date%3D16012020%26volume%3D11%26issue%3D2%26spage%3D147%26epage%3D153" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">RenÃ© Lebl, Trevor Murray, Andrea Adamo, David Cantillo, <span class="NLM_string-name hlFld-ContribAuthor">C. Oliver Kappe</span>. </span><span class="cited-content_cbyCitation_article-title">Continuous Flow Synthesis of Methyl Oximino Acetoacetate: Accessing Greener Purification Methods with Inline LiquidâLiquid Extraction and Membrane Separation Technology. </span><span class="cited-content_cbyCitation_journal-name">ACS Sustainable Chemistry & Engineering</span><span> <strong>2019,</strong> <em>7 </em>
                                    (24)
                                     , 20088-20096. <a href="https://doi.org/10.1021/acssuschemeng.9b05954" title="DOI URL">https://doi.org/10.1021/acssuschemeng.9b05954</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acssuschemeng.9b05954&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facssuschemeng.9b05954%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Sustainable%2520Chemistry%2520%2526%2520Engineering%26atitle%3DContinuous%252BFlow%252BSynthesis%252Bof%252BMethyl%252BOximino%252BAcetoacetate%25253A%252BAccessing%252BGreener%252BPurification%252BMethods%252Bwith%252BInline%252BLiquid%2525E2%252580%252593Liquid%252BExtraction%252Band%252BMembrane%252BSeparation%252BTechnology%26aulast%3DLebl%26aufirst%3DRen%25C3%25A9%26date%3D2019%26date%3D2019%26date%3D2019%26date%3D2019%26date%3D06102019%26date%3D13112019%26date%3D02122019%26date%3D15112019%26volume%3D7%26issue%3D24%26spage%3D20088%26epage%3D20096" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Manikandan  Selvaraju</span> and <span class="hlFld-ContribAuthor ">Chung-Ming  Sun</span>  . </span><span class="cited-content_cbyCitation_article-title">Unprecedented One-Pot Chemocontrolled Entry to Thioxoimidazolidinones and Aminoimidazolones: Synthesis of Kinase Inhibitor Leucettamine B. </span><span class="cited-content_cbyCitation_journal-name">ACS Combinatorial Science</span><span> <strong>2015,</strong> <em>17 </em>
                                    (3)
                                     , 182-189. <a href="https://doi.org/10.1021/co500152s" title="DOI URL">https://doi.org/10.1021/co500152s</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/co500152s&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Fco500152s%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Combinatorial%2520Science%26atitle%3DUnprecedented%252BOne-Pot%252BChemocontrolled%252BEntry%252Bto%252BThioxoimidazolidinones%252Band%252BAminoimidazolones%25253A%252BSynthesis%252Bof%252BKinase%252BInhibitor%252BLeucettamine%252BB%26aulast%3DSelvaraju%26aufirst%3DManikandan%26date%3D2015%26date%3D2015%26date%3D2014%26date%3D2015%26date%3D07102014%26date%3D03012015%26date%3D22012015%26date%3D09032015%26date%3D08012015%26volume%3D17%26issue%3D3%26spage%3D182%26epage%3D189" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Peng  Li</span>, <span class="hlFld-ContribAuthor ">Qiang  Zhang</span>, <span class="hlFld-ContribAuthor ">Albert J.  Robichaud</span>, <span class="hlFld-ContribAuthor ">Taekyu  Lee</span>, <span class="hlFld-ContribAuthor ">John  Tomesch</span>, <span class="hlFld-ContribAuthor ">Wei  Yao</span>, <span class="hlFld-ContribAuthor ">J. David  Beard</span>, <span class="hlFld-ContribAuthor ">Gretchen L.  Snyder</span>, <span class="hlFld-ContribAuthor ">Hongwen  Zhu</span>, <span class="hlFld-ContribAuthor ">Youyi  Peng</span>, <span class="hlFld-ContribAuthor ">Joseph P.  Hendrick</span>, <span class="hlFld-ContribAuthor ">Kimberly E.  Vanover</span>, <span class="hlFld-ContribAuthor ">Robert E.  Davis</span>, <span class="hlFld-ContribAuthor ">Sharon  Mates</span>, and <span class="hlFld-ContribAuthor ">Lawrence P.  Wennogle</span>  . </span><span class="cited-content_cbyCitation_article-title">Discovery of a Tetracyclic Quinoxaline Derivative as a Potent and Orally Active Multifunctional Drug Candidate for the Treatment of Neuropsychiatric and Neurological Disorders. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2014,</strong> <em>57 </em>
                                    (6)
                                     , 2670-2682. <a href="https://doi.org/10.1021/jm401958n" title="DOI URL">https://doi.org/10.1021/jm401958n</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/jm401958n&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Fjm401958n%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252Ba%252BTetracyclic%252BQuinoxaline%252BDerivative%252Bas%252Ba%252BPotent%252Band%252BOrally%252BActive%252BMultifunctional%252BDrug%252BCandidate%252Bfor%252Bthe%252BTreatment%252Bof%252BNeuropsychiatric%252Band%252BNeurological%252BDisorders%26aulast%3DLi%26aufirst%3DPeng%26date%3D2014%26date%3D2014%26date%3D2013%26date%3D20122013%26date%3D05032014%26date%3D27032014%26date%3D21022014%26volume%3D57%26issue%3D6%26spage%3D2670%26epage%3D2682" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Karanvir  Singh</span>, <span class="hlFld-ContribAuthor ">Rohit  Pal</span>, <span class="hlFld-ContribAuthor ">Shah Alam  Khan</span>, <span class="hlFld-ContribAuthor ">Bhupinder  Kumar</span>, <span class="hlFld-ContribAuthor ">Md Jawaid  Akhtar</span>. </span><span class="cited-content_cbyCitation_article-title">Insights into the structure activity relationship of nitrogen-containing heterocyclics for the development of antidepressant compounds: An updated review. </span><span class="cited-content_cbyCitation_journal-name">Journal of Molecular Structure</span><span> <strong>2021,</strong> <em>1237 </em>, 130369. <a href="https://doi.org/10.1016/j.molstruc.2021.130369" title="DOI URL">https://doi.org/10.1016/j.molstruc.2021.130369</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.molstruc.2021.130369&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.molstruc.2021.130369%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Molecular%2520Structure%26atitle%3DInsights%252Binto%252Bthe%252Bstructure%252Bactivity%252Brelationship%252Bof%252Bnitrogen-containing%252Bheterocyclics%252Bfor%252Bthe%252Bdevelopment%252Bof%252Bantidepressant%252Bcompounds%25253A%252BAn%252Bupdated%252Breview%26aulast%3DSingh%26aufirst%3DKaranvir%26date%3D2021%26volume%3D1237%26spage%3D130369" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Tam Minh  Le</span>, <span class="hlFld-ContribAuthor ">Thu  Huynh</span>, <span class="hlFld-ContribAuthor ">Fatima Zahra  Bamou</span>, <span class="hlFld-ContribAuthor ">AndrÃ¡s  Szekeres</span>, <span class="hlFld-ContribAuthor ">Ferenc  FÃ¼lÃ¶p</span>, <span class="hlFld-ContribAuthor ">Zsolt  Szakonyi</span>. </span><span class="cited-content_cbyCitation_article-title">Novel (+)-Neoisopulegol-Based O-Benzyl Derivatives as Antimicrobial Agents. </span><span class="cited-content_cbyCitation_journal-name">International Journal of Molecular Sciences</span><span> <strong>2021,</strong> <em>22 </em>
                                    (11)
                                     , 5626. <a href="https://doi.org/10.3390/ijms22115626" title="DOI URL">https://doi.org/10.3390/ijms22115626</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/ijms22115626&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fijms22115626%26sid%3Dliteratum%253Aachs%26jtitle%3DInternational%2520Journal%2520of%2520Molecular%2520Sciences%26atitle%3DNovel%252B%252528%25252B%252529-Neoisopulegol-Based%252BO-Benzyl%252BDerivatives%252Bas%252BAntimicrobial%252BAgents%26aulast%3DLe%26aufirst%3DTam%2BMinh%26date%3D2021%26date%3D2021%26volume%3D22%26issue%3D11%26spage%3D5626" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Sabitu Babatunde  Olasupo</span>, <span class="hlFld-ContribAuthor ">Adamu  Uzairu</span>, <span class="hlFld-ContribAuthor ">Gideon Shallangwa  Adamu</span>, <span class="hlFld-ContribAuthor ">Sani  Uba</span>. </span><span class="cited-content_cbyCitation_article-title">Computational Modeling and Pharmacokinetics/ADMET Study of Some Arylpiperazine Derivatives as Novel Antipsychotic Agents Targeting Depression. </span><span class="cited-content_cbyCitation_journal-name">Chemistry Africa</span><span> <strong>2020,</strong> <em>3 </em>
                                    (4)
                                     , 979-988. <a href="https://doi.org/10.1007/s42250-020-00161-4" title="DOI URL">https://doi.org/10.1007/s42250-020-00161-4</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/s42250-020-00161-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2Fs42250-020-00161-4%26sid%3Dliteratum%253Aachs%26jtitle%3DChemistry%2520Africa%26atitle%3DComputational%252BModeling%252Band%252BPharmacokinetics%25252FADMET%252BStudy%252Bof%252BSome%252BArylpiperazine%252BDerivatives%252Bas%252BNovel%252BAntipsychotic%252BAgents%252BTargeting%252BDepression%26aulast%3DOlasupo%26aufirst%3DSabitu%2BBabatunde%26date%3D2020%26date%3D2020%26volume%3D3%26issue%3D4%26spage%3D979%26epage%3D988" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Aiqing  Feng</span>, <span class="hlFld-ContribAuthor ">Bin  Lv</span>. </span><span class="cited-content_cbyCitation_article-title">Crystal structure of 1-(3-chlorophenyl)-4-(4-(((2,3-dihydro-1H-inden-5-yl)oxy)methyl)phenethyl)piperazine, C28H31ClN2O. </span><span class="cited-content_cbyCitation_journal-name">Zeitschrift fÃ¼r Kristallographie - New Crystal Structures</span><span> <strong>2020,</strong> <em>235 </em>
                                    (4)
                                     , 783-785. <a href="https://doi.org/10.1515/ncrs-2020-0005" title="DOI URL">https://doi.org/10.1515/ncrs-2020-0005</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1515/ncrs-2020-0005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1515%2Fncrs-2020-0005%26sid%3Dliteratum%253Aachs%26jtitle%3DZeitschrift%2520f%25C3%25BCr%2520Kristallographie%2520-%2520New%2520Crystal%2520Structures%26atitle%3DCrystal%252Bstructure%252Bof%252B1-%2525283-chlorophenyl%252529-4-%2525284-%252528%252528%2525282%25252C3-dihydro-1H-inden-5-yl%252529oxy%252529methyl%252529phenethyl%252529piperazine%25252C%252BC28H31ClN2O%26aulast%3DFeng%26aufirst%3DAiqing%26date%3D2020%26volume%3D235%26issue%3D4%26spage%3D783%26epage%3D785" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Indrani  Banerjee</span>, <span class="hlFld-ContribAuthor ">Shweta  Sagar</span>, <span class="hlFld-ContribAuthor ">Tarun K.  Panda</span>. </span><span class="cited-content_cbyCitation_article-title">Calcium mediated efficient synthesis of
              N
              -arylamidines from organic nitriles and amines. </span><span class="cited-content_cbyCitation_journal-name">Organic & Biomolecular Chemistry</span><span> <strong>2020,</strong> <em>18 </em>
                                    (22)
                                     , 4231-4237. <a href="https://doi.org/10.1039/D0OB00805B" title="DOI URL">https://doi.org/10.1039/D0OB00805B</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/D0OB00805B&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FD0OB00805B%26sid%3Dliteratum%253Aachs%26jtitle%3DOrganic%2520%2526%2520Biomolecular%2520Chemistry%26atitle%3DCalcium%252Bmediated%252Befficient%252Bsynthesis%252Bof%252BN%252B-arylamidines%252Bfrom%252Borganic%252Bnitriles%252Band%252Bamines%26aulast%3DBanerjee%26aufirst%3DIndrani%26date%3D2020%26date%3D2020%26volume%3D18%26issue%3D22%26spage%3D4231%26epage%3D4237" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Aiqing  Feng</span>, <span class="hlFld-ContribAuthor ">Bin  Lv</span>. </span><span class="cited-content_cbyCitation_article-title">Crystal structure of 2-(3-(2-(4-phenylpiperazin-1-yl)ethyl)benzyl)isoindoline-1,3-dione, C27H27N3O2. </span><span class="cited-content_cbyCitation_journal-name">Zeitschrift fÃ¼r Kristallographie - New Crystal Structures</span><span> <strong>2019,</strong> <em>235 </em>
                                    (1)
                                     , 49-51. <a href="https://doi.org/10.1515/ncrs-2019-0463" title="DOI URL">https://doi.org/10.1515/ncrs-2019-0463</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1515/ncrs-2019-0463&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1515%2Fncrs-2019-0463%26sid%3Dliteratum%253Aachs%26jtitle%3DZeitschrift%2520f%25C3%25BCr%2520Kristallographie%2520-%2520New%2520Crystal%2520Structures%26atitle%3DCrystal%252Bstructure%252Bof%252B2-%2525283-%2525282-%2525284-phenylpiperazin-1-yl%252529ethyl%252529benzyl%252529isoindoline-1%25252C3-dione%25252C%252BC27H27N3O2%26aulast%3DFeng%26aufirst%3DAiqing%26date%3D2019%26volume%3D235%26issue%3D1%26spage%3D49%26epage%3D51" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Renzo  Rossi</span>, <span class="hlFld-ContribAuthor ">Gaetano  Angelici</span>, <span class="hlFld-ContribAuthor ">Gianluca  Casotti</span>, <span class="hlFld-ContribAuthor ">Chiara  Manzini</span>, <span class="hlFld-ContribAuthor ">Marco  Lessi</span>. </span><span class="cited-content_cbyCitation_article-title">Catalytic Synthesis of 1,2,4,5âTetrasubstituted 1
              H
              âImidazole Derivatives: State of the Art. </span><span class="cited-content_cbyCitation_journal-name">Advanced Synthesis & Catalysis</span><span> <strong>2019,</strong> <em>361 </em>
                                    (12)
                                     , 2737-2803. <a href="https://doi.org/10.1002/adsc.201801381" title="DOI URL">https://doi.org/10.1002/adsc.201801381</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/adsc.201801381&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fadsc.201801381%26sid%3Dliteratum%253Aachs%26jtitle%3DAdvanced%2520Synthesis%2520%2526%2520Catalysis%26atitle%3DCatalytic%252BSynthesis%252Bof%252B1%25252C2%25252C4%25252C5%2525E2%252580%252590Tetrasubstituted%252B1%252BH%252B%2525E2%252580%252590Imidazole%252BDerivatives%25253A%252BState%252Bof%252Bthe%252BArt%26aulast%3DRossi%26aufirst%3DRenzo%26date%3D2019%26date%3D2019%26volume%3D361%26issue%3D12%26spage%3D2737%26epage%3D2803" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Hong  Chen</span>, <span class="hlFld-ContribAuthor ">Yu-Zhong  Yu</span>, <span class="hlFld-ContribAuthor ">Xiu-Mei  Tian</span>, <span class="hlFld-ContribAuthor ">Cai-Lu  Wang</span>, <span class="hlFld-ContribAuthor ">Yu-Na  Qian</span>, <span class="hlFld-ContribAuthor ">Zai-An  Deng</span>, <span class="hlFld-ContribAuthor ">Jing-Xiao  Zhang</span>, <span class="hlFld-ContribAuthor ">Dao-Jun  Lv</span>, <span class="hlFld-ContribAuthor ">Hai-Bo  Zhang</span>, <span class="hlFld-ContribAuthor ">Jian-Liang  Shen</span>, <span class="hlFld-ContribAuthor ">Mu  Yuan</span>, <span class="hlFld-ContribAuthor ">Shan-Chao  Zhao</span>. </span><span class="cited-content_cbyCitation_article-title">Synthesis and biological evaluation of arylpiperazine derivatives as potential anti-prostate cancer agents. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry</span><span> <strong>2019,</strong> <em>27 </em>
                                    (1)
                                     , 133-143. <a href="https://doi.org/10.1016/j.bmc.2018.11.029" title="DOI URL">https://doi.org/10.1016/j.bmc.2018.11.029</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmc.2018.11.029&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmc.2018.11.029%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%26atitle%3DSynthesis%252Band%252Bbiological%252Bevaluation%252Bof%252Barylpiperazine%252Bderivatives%252Bas%252Bpotential%252Banti-prostate%252Bcancer%252Bagents%26aulast%3DChen%26aufirst%3DHong%26date%3D2019%26volume%3D27%26issue%3D1%26spage%3D133%26epage%3D143" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Hong  Chen</span>, <span class="hlFld-ContribAuthor ">Xue  Liang</span>, <span class="hlFld-ContribAuthor ">Tao  Sun</span>, <span class="hlFld-ContribAuthor ">Xiaoguang  Qiao</span>, <span class="hlFld-ContribAuthor ">Zhou  Zhan</span>, <span class="hlFld-ContribAuthor ">Ziyong  Li</span>, <span class="hlFld-ContribAuthor ">Chaojun  He</span>, <span class="hlFld-ContribAuthor ">Huiyuan  Ya</span>, <span class="hlFld-ContribAuthor ">Mu  Yuan</span>. </span><span class="cited-content_cbyCitation_article-title">Synthesis and biological evaluation of estrone 3- O -ether derivatives containing the piperazine moiety. </span><span class="cited-content_cbyCitation_journal-name">Steroids</span><span> <strong>2018,</strong> <em>134 </em>, 101-109. <a href="https://doi.org/10.1016/j.steroids.2018.02.002" title="DOI URL">https://doi.org/10.1016/j.steroids.2018.02.002</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.steroids.2018.02.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.steroids.2018.02.002%26sid%3Dliteratum%253Aachs%26jtitle%3DSteroids%26atitle%3DSynthesis%252Band%252Bbiological%252Bevaluation%252Bof%252Bestrone%252B3-%252BO%252B-ether%252Bderivatives%252Bcontaining%252Bthe%252Bpiperazine%252Bmoiety%26aulast%3DChen%26aufirst%3DHong%26date%3D2018%26volume%3D134%26spage%3D101%26epage%3D109" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Renzo  Rossi</span>, <span class="hlFld-ContribAuthor ">Marco  Lessi</span>, <span class="hlFld-ContribAuthor ">Chiara  Manzini</span>, <span class="hlFld-ContribAuthor ">Fabio  Bellina</span>. </span><span class="cited-content_cbyCitation_article-title">Synthesis and Biological Profiles of 4,5-, 1,5-, and 1,2-Diaryl-1 H -imidazoles. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2018,</strong>,, 83-160. <a href="https://doi.org/10.1016/B978-0-08-102237-5.00004-3" title="DOI URL">https://doi.org/10.1016/B978-0-08-102237-5.00004-3</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/B978-0-08-102237-5.00004-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2FB978-0-08-102237-5.00004-3%26sid%3Dliteratum%253Aachs%26atitle%3DSynthesis%252Band%252BBiological%252BProfiles%252Bof%252B4%25252C5-%25252C%252B1%25252C5-%25252C%252Band%252B1%25252C2-Diaryl-1%252BH%252B-imidazoles%26aulast%3DRossi%26aufirst%3DRenzo%26date%3D2018%26spage%3D83%26epage%3D160%26pub%3DElsevier%26atitle%3DVicinal%252BDiaryl%252BSubstituted%252BHeterocycles%26date%3D2018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Feng  Lin</span>, <span class="hlFld-ContribAuthor ">Feng  Li</span>, <span class="hlFld-ContribAuthor ">Chao  Wang</span>, <span class="hlFld-ContribAuthor ">Jinghui  Wang</span>, <span class="hlFld-ContribAuthor ">Yinfeng  Yang</span>, <span class="hlFld-ContribAuthor ">Ling  Yang</span>, <span class="hlFld-ContribAuthor ">Yan  Li</span>. </span><span class="cited-content_cbyCitation_article-title">Mechanism Exploration of Arylpiperazine Derivatives Targeting the 5-HT2A Receptor by In Silico Methods. </span><span class="cited-content_cbyCitation_journal-name">Molecules</span><span> <strong>2017,</strong> <em>22 </em>
                                    (7)
                                     , 1064. <a href="https://doi.org/10.3390/molecules22071064" title="DOI URL">https://doi.org/10.3390/molecules22071064</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/molecules22071064&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fmolecules22071064%26sid%3Dliteratum%253Aachs%26jtitle%3DMolecules%26atitle%3DMechanism%252BExploration%252Bof%252BArylpiperazine%252BDerivatives%252BTargeting%252Bthe%252B5-HT2A%252BReceptor%252Bby%252BIn%252BSilico%252BMethods%26aulast%3DLin%26aufirst%3DFeng%26date%3D2017%26date%3D2017%26volume%3D22%26issue%3D7%26spage%3D1064" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Imran  Khan</span>, <span class="hlFld-ContribAuthor ">Mushtaq A.  Tantray</span>, <span class="hlFld-ContribAuthor ">Hinna  Hamid</span>, <span class="hlFld-ContribAuthor ">Mohammad Sarwar  Alam</span>, <span class="hlFld-ContribAuthor ">Abul  Kalam</span>, <span class="hlFld-ContribAuthor ">Faraz  Shaikh</span>, <span class="hlFld-ContribAuthor ">Anamik  Shah</span>, <span class="hlFld-ContribAuthor ">Firasat  Hussain</span>. </span><span class="cited-content_cbyCitation_article-title">Synthesis of Novel Pyrimidin-4-One Bearing Piperazine Ring-Based Amides as Glycogen Synthase Kinase-3
              Î²
              Inhibitors with Antidepressant Activity. </span><span class="cited-content_cbyCitation_journal-name">Chemical Biology & Drug Design</span><span> <strong>2016,</strong> <em>87 </em>
                                    (5)
                                     , 764-772. <a href="https://doi.org/10.1111/cbdd.12710" title="DOI URL">https://doi.org/10.1111/cbdd.12710</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1111/cbdd.12710&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1111%2Fcbdd.12710%26sid%3Dliteratum%253Aachs%26jtitle%3DChemical%2520Biology%2520%2526%2520Drug%2520Design%26atitle%3DSynthesis%252Bof%252BNovel%252BPyrimidin-4-One%252BBearing%252BPiperazine%252BRing-Based%252BAmides%252Bas%252BGlycogen%252BSynthase%252BKinase-3%252B%2525CE%2525B2%252BInhibitors%252Bwith%252BAntidepressant%252BActivity%26aulast%3DKhan%26aufirst%3DImran%26date%3D2016%26date%3D2016%26volume%3D87%26issue%3D5%26spage%3D764%26epage%3D772" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Hong  Chen</span>, <span class="hlFld-ContribAuthor ">Fang  Xu</span>, <span class="hlFld-ContribAuthor ">Xue  Liang</span>, <span class="hlFld-ContribAuthor ">Bing-Bing  Xu</span>, <span class="hlFld-ContribAuthor ">Zong-Lin  Yang</span>, <span class="hlFld-ContribAuthor ">Xue-Lan  He</span>, <span class="hlFld-ContribAuthor ">Bi-Yun  Huang</span>, <span class="hlFld-ContribAuthor ">Mu  Yuan</span>. </span><span class="cited-content_cbyCitation_article-title">Design, synthesis and biological evaluation of novel arylpiperazine derivatives on human prostate cancer cell lines. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry Letters</span><span> <strong>2015,</strong> <em>25 </em>
                                    (2)
                                     , 285-287. <a href="https://doi.org/10.1016/j.bmcl.2014.11.049" title="DOI URL">https://doi.org/10.1016/j.bmcl.2014.11.049</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmcl.2014.11.049&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmcl.2014.11.049%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DDesign%25252C%252Bsynthesis%252Band%252Bbiological%252Bevaluation%252Bof%252Bnovel%252Barylpiperazine%252Bderivatives%252Bon%252Bhuman%252Bprostate%252Bcancer%252Bcell%252Blines%26aulast%3DChen%26aufirst%3DHong%26date%3D2015%26volume%3D25%26issue%3D2%26spage%3D285%26epage%3D287" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ferdinando  Fiorino</span>, <span class="hlFld-ContribAuthor ">Elisa  Magli</span>, <span class="hlFld-ContribAuthor ">Beatrice  Severino</span>, <span class="hlFld-ContribAuthor ">Angela  Corvino</span>, <span class="hlFld-ContribAuthor ">Antonio  Ciano</span>, <span class="hlFld-ContribAuthor ">Elisa  Perissutti</span>, <span class="hlFld-ContribAuthor ">Francesco  Frecentese</span>, <span class="hlFld-ContribAuthor ">Paola  Massarelli</span>, <span class="hlFld-ContribAuthor ">Cristina  Nencini</span>, <span class="hlFld-ContribAuthor ">Vincenzo  Santagada</span>, <span class="hlFld-ContribAuthor ">Giuseppe  Caliendo</span>. </span><span class="cited-content_cbyCitation_article-title">Synthesis and
              In Vitro
              Pharmacological Evaluation of Novel 2-Hydroxypropyl-4-arylpiperazine Derivatives as Serotoninergic Ligands. </span><span class="cited-content_cbyCitation_journal-name">Archiv der Pharmazie</span><span> <strong>2014,</strong> <em>347 </em>
                                    (10)
                                     , 698-706. <a href="https://doi.org/10.1002/ardp.201400174" title="DOI URL">https://doi.org/10.1002/ardp.201400174</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/ardp.201400174&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fardp.201400174%26sid%3Dliteratum%253Aachs%26jtitle%3DArchiv%2520der%2520Pharmazie%26atitle%3DSynthesis%252Band%252BIn%252BVitro%252BPharmacological%252BEvaluation%252Bof%252BNovel%252B2-Hydroxypropyl-4-arylpiperazine%252BDerivatives%252Bas%252BSerotoninergic%252BLigands%26aulast%3DFiorino%26aufirst%3DFerdinando%26date%3D2014%26date%3D2014%26volume%3D347%26issue%3D10%26spage%3D698%26epage%3D706" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Hong  Chen</span>, <span class="hlFld-ContribAuthor ">Xue  Liang</span>, <span class="hlFld-ContribAuthor ">Fang  Xu</span>, <span class="hlFld-ContribAuthor ">Bingbing  Xu</span>, <span class="hlFld-ContribAuthor ">Xuelan  He</span>, <span class="hlFld-ContribAuthor ">Biyun  Huang</span>, <span class="hlFld-ContribAuthor ">Mu  Yuan</span>. </span><span class="cited-content_cbyCitation_article-title">Synthesis and Cytotoxic Activity Evaluation of Novel Arylpiperazine Derivatives on Human Prostate Cancer Cell Lines. </span><span class="cited-content_cbyCitation_journal-name">Molecules</span><span> <strong>2014,</strong> <em>19 </em>
                                    (8)
                                     , 12048-12064. <a href="https://doi.org/10.3390/molecules190812048" title="DOI URL">https://doi.org/10.3390/molecules190812048</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/molecules190812048&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fmolecules190812048%26sid%3Dliteratum%253Aachs%26jtitle%3DMolecules%26atitle%3DSynthesis%252Band%252BCytotoxic%252BActivity%252BEvaluation%252Bof%252BNovel%252BArylpiperazine%252BDerivatives%252Bon%252BHuman%252BProstate%252BCancer%252BCell%252BLines%26aulast%3DChen%26aufirst%3DHong%26date%3D2014%26date%3D2014%26volume%3D19%26issue%3D8%26spage%3D12048%26epage%3D12064" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ling  Zhang</span>, <span class="hlFld-ContribAuthor ">Xin-Mei  Peng</span>, <span class="hlFld-ContribAuthor ">Guri L. V.  Damu</span>, <span class="hlFld-ContribAuthor ">Rong-Xia  Geng</span>, <span class="hlFld-ContribAuthor ">Cheng-He  Zhou</span>. </span><span class="cited-content_cbyCitation_article-title">Comprehensive Review in Current Developments of Imidazole-Based Medicinal Chemistry. </span><span class="cited-content_cbyCitation_journal-name">Medicinal Research Reviews</span><span> <strong>2014,</strong> <em>34 </em>
                                    (2)
                                     , 340-437. <a href="https://doi.org/10.1002/med.21290" title="DOI URL">https://doi.org/10.1002/med.21290</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/med.21290&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fmed.21290%26sid%3Dliteratum%253Aachs%26jtitle%3DMedicinal%2520Research%2520Reviews%26atitle%3DComprehensive%252BReview%252Bin%252BCurrent%252BDevelopments%252Bof%252BImidazole-Based%252BMedicinal%252BChemistry%26aulast%3DZhang%26aufirst%3DLing%26date%3D2014%26date%3D2013%26volume%3D34%26issue%3D2%26spage%3D340%26epage%3D437" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Edward  KrzyÅ¼ak</span>, <span class="hlFld-ContribAuthor ">Berenika  SzczÄÅniak-SiÄga</span>, <span class="hlFld-ContribAuthor ">WiesÅaw  Malinka</span>. </span><span class="cited-content_cbyCitation_article-title">Synthesis and thermal behaviour of new benzo-1,2-thiazine long-chain aryl-piperazine derivatives. </span><span class="cited-content_cbyCitation_journal-name">Journal of Thermal Analysis and Calorimetry</span><span> <strong>2014,</strong> <em>115 </em>
                                    (1)
                                     , 793-802. <a href="https://doi.org/10.1007/s10973-013-3185-1" title="DOI URL">https://doi.org/10.1007/s10973-013-3185-1</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/s10973-013-3185-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2Fs10973-013-3185-1%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Thermal%2520Analysis%2520and%2520Calorimetry%26atitle%3DSynthesis%252Band%252Bthermal%252Bbehaviour%252Bof%252Bnew%252Bbenzo-1%25252C2-thiazine%252Blong-chain%252Baryl-piperazine%252Bderivatives%26aulast%3DKrzy%25C5%25BCak%26aufirst%3DEdward%26date%3D2014%26date%3D2013%26volume%3D115%26issue%3D1%26spage%3D793%26epage%3D802" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Elizabeth O'Bryan  McCusker</span>, <span class="hlFld-ContribAuthor ">Karl A.  Scheidt</span>. </span><span class="cited-content_cbyCitation_article-title">Enantioselective N
              -
              Heterocyclic Carbene Catalyzed Annulation Reactions with Imidazolidinones. </span><span class="cited-content_cbyCitation_journal-name">Angewandte Chemie</span><span> <strong>2013,</strong> <em>125 </em>
                                    (51)
                                     , 13861-13865. <a href="https://doi.org/10.1002/ange.201307292" title="DOI URL">https://doi.org/10.1002/ange.201307292</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/ange.201307292&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fange.201307292%26sid%3Dliteratum%253Aachs%26jtitle%3DAngewandte%2520Chemie%26atitle%3DEnantioselective%252BN%252B-%252BHeterocyclic%252BCarbene%252BCatalyzed%252BAnnulation%252BReactions%252Bwith%252BImidazolidinones%26aulast%3DMcCusker%26aufirst%3DElizabeth%2BO%2527Bryan%26date%3D2013%26date%3D2013%26volume%3D125%26issue%3D51%26spage%3D13861%26epage%3D13865" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Elizabeth O'Bryan  McCusker</span>, <span class="hlFld-ContribAuthor ">Karl A.  Scheidt</span>. </span><span class="cited-content_cbyCitation_article-title">Enantioselective N
              -
              Heterocyclic Carbene Catalyzed Annulation Reactions with Imidazolidinones. </span><span class="cited-content_cbyCitation_journal-name">Angewandte Chemie International Edition</span><span> <strong>2013,</strong> <em>52 </em>
                                    (51)
                                     , 13616-13620. <a href="https://doi.org/10.1002/anie.201307292" title="DOI URL">https://doi.org/10.1002/anie.201307292</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/anie.201307292&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fanie.201307292%26sid%3Dliteratum%253Aachs%26jtitle%3DAngewandte%2520Chemie%2520International%2520Edition%26atitle%3DEnantioselective%252BN%252B-%252BHeterocyclic%252BCarbene%252BCatalyzed%252BAnnulation%252BReactions%252Bwith%252BImidazolidinones%26aulast%3DMcCusker%26aufirst%3DElizabeth%2BO%2527Bryan%26date%3D2013%26date%3D2013%26volume%3D52%26issue%3D51%26spage%3D13616%26epage%3D13620" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Maik  Micksch</span>, <span class="hlFld-ContribAuthor ">Mario  Tenne</span>, <span class="hlFld-ContribAuthor ">Thomas  Strassner</span>. </span><span class="cited-content_cbyCitation_article-title">Synthesis of 1,2-Diaryl- and 1-Aryl-2-alkylimidazoles with Sterically Demanding Substituents. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Organic Chemistry</span><span> <strong>2013,</strong> <em>2013 </em>
                                    (27)
                                     , 6137-6145. <a href="https://doi.org/10.1002/ejoc.201300688" title="DOI URL">https://doi.org/10.1002/ejoc.201300688</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/ejoc.201300688&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fejoc.201300688%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Organic%2520Chemistry%26atitle%3DSynthesis%252Bof%252B1%25252C2-Diaryl-%252Band%252B1-Aryl-2-alkylimidazoles%252Bwith%252BSterically%252BDemanding%252BSubstituents%26aulast%3DMicksch%26aufirst%3DMaik%26date%3D2013%26date%3D2013%26volume%3D2013%26issue%3D27%26spage%3D6137%26epage%3D6145" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Harpreet  Kour</span>, <span class="hlFld-ContribAuthor ">Satya  Paul</span>, <span class="hlFld-ContribAuthor ">Parvinder Pal  Singh</span>, <span class="hlFld-ContribAuthor ">Monika  Gupta</span>, <span class="hlFld-ContribAuthor ">Rajive  Gupta</span>. </span><span class="cited-content_cbyCitation_article-title">A simple one-pot method for the mercuric oxide mediated synthesis of piperazines via oxidative diamination of olefins. </span><span class="cited-content_cbyCitation_journal-name">Tetrahedron Letters</span><span> <strong>2013,</strong> <em>54 </em>
                                    (8)
                                     , 761-764. <a href="https://doi.org/10.1016/j.tetlet.2012.11.110" title="DOI URL">https://doi.org/10.1016/j.tetlet.2012.11.110</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.tetlet.2012.11.110&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.tetlet.2012.11.110%26sid%3Dliteratum%253Aachs%26jtitle%3DTetrahedron%2520Letters%26atitle%3DA%252Bsimple%252Bone-pot%252Bmethod%252Bfor%252Bthe%252Bmercuric%252Boxide%252Bmediated%252Bsynthesis%252Bof%252Bpiperazines%252Bvia%252Boxidative%252Bdiamination%252Bof%252Bolefins%26aulast%3DKour%26aufirst%3DHarpreet%26date%3D2013%26volume%3D54%26issue%3D8%26spage%3D761%26epage%3D764" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li></ol></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li><li role="presentation"><a id="pane-m3con" href="#pane-m3" aria-controls="pane-m3" role="tab" data-toggle="tab" title="Support Info" aria-selected="false" class="empty tab__nav-suppInfo"><i class="icon-supporting-info"></i><span>Support Info</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="f_tgr1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-18/jm200682b/production/images/medium/jm-2011-00682b_0022.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-18/jm200682b/production/images/large/jm-2011-00682b_0022.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm200682b&amp;id=f_tgr1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-18/jm200682b/production/images/medium/jm-2011-00682b_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-18/jm200682b/production/images/large/jm-2011-00682b_0002.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Chemical structures of representative antidepressant compounds.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-18/jm200682b/production/images/large/jm-2011-00682b_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm200682b&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-18/jm200682b/production/images/medium/jm-2011-00682b_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-18/jm200682b/production/images/large/jm-2011-00682b_0003.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Preparation of target compounds using peptide bond formation.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-18/jm200682b/production/images/large/jm-2011-00682b_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm200682b&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch1" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-18/jm200682b/production/images/medium/jm-2011-00682b_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-18/jm200682b/production/images/large/jm-2011-00682b_0004.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Scheme 1. <sup>a</sup></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-18/jm200682b/production/images/large/jm-2011-00682b_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm200682b&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents: (a) NaNO<sub>2</sub>, AcOH, â10 Â°C to rt, 2 h, 70%; (b) <b>7</b>, Pd/C, H<sub>2</sub>, EtOH, rt, 12 h, 86%; (c) <b>9</b>, TFA or AcOH, butyronitrile, microwave, 140 Â°C, 40 min, 76%; (d) LiOHÂ·H<sub>2</sub>O, THF/H<sub>2</sub>O(1/1), heat, 12 h, 90%.</p></p></figure><figure data-id="sch2" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-18/jm200682b/production/images/medium/jm-2011-00682b_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-18/jm200682b/production/images/large/jm-2011-00682b_0005.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Scheme 2. <sup>a</sup></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-18/jm200682b/production/images/large/jm-2011-00682b_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm200682b&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents: (a) <b>9</b>, NaHMDS, THF, rt; (b) <b>14</b>, NaHCO<sub>3</sub>, <i>i</i>-PrOH, reflux, 55%; (c) LiOHÂ·H<sub>2</sub>O, THF/H<sub>2</sub>O(1/1), heat, 12 h.</p></p></figure><figure data-id="sch3" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-18/jm200682b/production/images/medium/jm-2011-00682b_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-18/jm200682b/production/images/large/jm-2011-00682b_0006.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Scheme 3. <sup>a</sup></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-18/jm200682b/production/images/large/jm-2011-00682b_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm200682b&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents: (a) <b>18</b>, AlCl<sub>3</sub>, toluene, reflux, 5 h, 60%; (b) <b>20</b>, Na<sub>2</sub>CO<sub>3</sub>, toluene, reflux, 4 h, 37%; (c) LiOHÂ·H<sub>2</sub>O, THF/H<sub>2</sub>O(1/1), heat, 12 h, 86%.</p></p></figure><figure data-id="sch4" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Scheme 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-18/jm200682b/production/images/medium/jm-2011-00682b_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-18/jm200682b/production/images/large/jm-2011-00682b_0007.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Scheme 4. <sup>a</sup></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-18/jm200682b/production/images/large/jm-2011-00682b_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm200682b&amp;id=sch4"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents: (a) POCl<sub>3</sub>, DMA, 45 Â°C, 50%; (b) NaH, EtOH, rt, then reflux, 1 h; (c) <b>26</b>, AcOH, rt, 12 h; (d) (NH<sub>4</sub>)<sub>2</sub>SO<sub>4</sub>, AcOH, HMDS, reflux; (e) NaOH, aq MeOH, reflux.</p></p></figure><figure data-id="sch5" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Scheme 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-18/jm200682b/production/images/medium/jm-2011-00682b_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-18/jm200682b/production/images/large/jm-2011-00682b_0008.jpeg" id="rightTab-gr7" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Scheme 5. <sup>a</sup></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-18/jm200682b/production/images/large/jm-2011-00682b_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm200682b&amp;id=sch5"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents: (a) K<sub>2</sub>CO<sub>3</sub>, DMF, rt, 8 h, 80%; (b) (i) H<sub>2</sub>NNH<sub>2</sub>Â·H<sub>2</sub>O, EtOH, rt, 6 h, (ii) 2 M HCl solution in diethyl ether, 76%.</p></p></figure><figure data-id="sch6" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Scheme 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-18/jm200682b/production/images/medium/jm-2011-00682b_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-18/jm200682b/production/images/large/jm-2011-00682b_0009.jpeg" id="rightTab-gr8" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Scheme 6. <sup>a</sup></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-18/jm200682b/production/images/large/jm-2011-00682b_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm200682b&amp;id=sch6"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents: (a) TEA, THF, 80 Â°C, 92%; (b) (i) H<sub>2</sub>NNH<sub>2</sub>Â·H<sub>2</sub>O, EtOH, rt, 6 h, (ii) 2 M HCl solution in diethyl ether, 95%.</p></p></figure><figure data-id="sch7" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Scheme 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-18/jm200682b/production/images/medium/jm-2011-00682b_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-18/jm200682b/production/images/large/jm-2011-00682b_0010.jpeg" id="rightTab-gr9" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Scheme 7. <sup>a</sup></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-18/jm200682b/production/images/large/jm-2011-00682b_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm200682b&amp;id=sch7"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents: (a) (i) EDCI, HOBt, NMM, DMF, rt, 12 h, (ii) 2 M HCl solution in diethyl ether.</p></p></figure><figure data-id="fig3" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-18/jm200682b/production/images/medium/jm-2011-00682b_0017.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-18/jm200682b/production/images/large/jm-2011-00682b_0017.jpeg" id="rightTab-_i8" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Antidepressants activity immobility in forced swimming test on mice (FST, %) and spontaneous locomotor activity (SLA, cm). Effects of the drugs on immobility in forced swimming test on mice. a) Drugs (50, 25, and 10 mg/kg) were injected orally (po) 60 min before the testing, and total duration of immobility was recorded during the last 5 min of the 6-min testing period. (Values are means Â± SEM). b) Locomotor activities of the mice treated with compounds or vehicle were counted for 30 min by Activity Analyzer. Compound (50 mg/kg) or vehicle was administered orally (po) 60 min before the test. Data were expressed as mean Â± SEM of 6â7 mice.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-18/jm200682b/production/images/large/jm-2011-00682b_0017.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm200682b&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig4" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-18/jm200682b/production/images/medium/jm-2011-00682b_0019.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-18/jm200682b/production/images/large/jm-2011-00682b_0019.jpeg" id="rightTab-_i10" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Antidepressants Activity immobility in forced swimming test on mice (FST, %). Effects of drugs on immobility in forced swimming test on mice. Drugs (50, 25, and 10 mg/kg) were injected orally (po) 60 min before the testing, and total duration of immobility was recorded during the last 5 min of the 6-min testing period. (Values are means Â± SEM).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-18/jm200682b/production/images/large/jm-2011-00682b_0019.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm200682b&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i49">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_51211" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_51211" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 29 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><span class="NLM_contrib-group">Murray, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lopez, A. D.</span><span> </span><span class="NLM_article-title">Global mortality, disability, and the contribution of risk factors: Global Burden of Disease Study</span> <span class="citation_source-journal">Lancet</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1997</span><span class="NLM_x">, </span> <span class="NLM_volume">349</span><span class="NLM_x">, </span> <span class="NLM_fpage">1436</span><span class="NLM_x">â</span> <span class="NLM_lpage">1442</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=349&publication_year=1997&pages=1436-1442&author=C.+J.+Murrayauthor=A.+D.+Lopez&title=Global+mortality%2C+disability%2C+and+the+contribution+of+risk+factors%3A+Global+Burden+of+Disease+Study"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMurray%26aufirst%3DC.%2BJ.%26aulast%3DLopez%26aufirst%3DA.%2BD.%26atitle%3DGlobal%2520mortality%252C%2520disability%252C%2520and%2520the%2520contribution%2520of%2520risk%2520factors%253A%2520Global%2520Burden%2520of%2520Disease%2520Study%26jtitle%3DLancet%26date%3D1997%26volume%3D349%26spage%3D1436%26epage%3D1442" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group">Olesen, J.; Saxena, P.</span>, Eds.  <span class="citation_source-book">5-Hydroxyltryptamine Mechanisms in Primary Headaches</span>, <span class="NLM_edition">1st</span> ed.; <span class="NLM_publisher-name">Raven Press</span>: <span class="NLM_publisher-loc">New York</span>,<span class="NLM_x"> </span><span class="NLM_year">1992</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=1992&author=J.+Olesen&author=P.+Saxena&title=5-Hydroxyltryptamine+Mechanisms+in+Primary+Headaches"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26aulast%3DOlesen%26aufirst%3DJ.%26btitle%3D5-Hydroxyltryptamine%2520Mechanisms%2520in%2520Primary%2520Headaches%26pub%3DRaven%2520Press%26date%3D1992" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group">Murray, C. J. L.; Lopez, A. D.</span>, Eds.  <span class="citation_source-book">The Global Burden of Disease; A Comprehensive Assessment of Mortality and Disability from Disease, Injuries and Risk Factors in 1990 and Projected to 2020</span>. Vol.  <span class="NLM_volume">1</span> of <span class="NLM_series">Global Burden of Disease and Injury Series</span>; <span class="NLM_publisher-name">Harvard University Press</span>: <span class="NLM_publisher-loc">Cambridge, MA</span>,<span class="NLM_x"> </span><span class="NLM_year">1996</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=1996&author=C.+J.+L.+Murray&author=A.+D.+Lopez&title=The+Global+Burden+of+Disease%3B+A+Comprehensive+Assessment+of+Mortality+and+Disability+from+Disease%2C+Injuries+and+Risk+Factors+in+1990+and+Projected+to+2020"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26aulast%3DMurray%26aufirst%3DC.%2BJ.%2BL.%26btitle%3DThe%2520Global%2520Burden%2520of%2520Disease%253B%2520A%2520Comprehensive%2520Assessment%2520of%2520Mortality%2520and%2520Disability%2520from%2520Disease%252C%2520Injuries%2520and%2520Risk%2520Factors%2520in%25201990%2520and%2520Projected%2520to%25202020%26volume%3D1%26pub%3DHarvard%2520University%2520Press%26date%3D1996" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span> </span><span class="NLM_article-title">Mental Health: New Understanding, New Hope; Fact Sheet No. 265</span>. The World Health Report 2001; <span class="NLM_publisher-name">World Health Organization</span>: <span class="NLM_publisher-loc">Geneva</span>,<span class="NLM_x"> </span><span class="NLM_year">2001</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Mental+Health%3A+New+Understanding%2C+New+Hope%3B+Fact+Sheet+No.+265.+The+World+Health+Report+2001%3B+World+Health+Organization%3A+Geneva%2C+2001."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dgov%26sid%3Dliteratum%253Aachs%26atitle%3DMental%2520Health%253A%2520New%2520Understanding%252C%2520New%2520Hope%253B%2520Fact%2520Sheet%2520No.%2520265%26jtitle%3DThe%2520World%2520Health%2520Report%25202001%26pub%3DWorld%2520Health%2520Organization%26date%3D2001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group">Blier, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bergeron, R.</span><span> </span><span class="NLM_article-title">The use of pindolol to potentiate antidepressant medication</span> <span class="citation_source-journal">J. Clin. Psychiatry</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1998</span><span class="NLM_x">, </span> <span class="NLM_volume">59</span><span class="NLM_x"> (</span><span class="NLM_issue">Suppl. 5</span><span class="NLM_x">) </span> <span class="NLM_fpage">16</span><span class="NLM_x">â</span> <span class="NLM_lpage">25</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Fjm200682b&amp;key=9635544" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Fjm200682b&amp;key=1%3ACAS%3A528%3ADyaK1cXjslGksLs%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=1998&pages=16-25&issue=Suppl.+5&author=P.+Blierauthor=R.+Bergeron&title=The+use+of+pindolol+to+potentiate+antidepressant+medication"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">The use of pindolol to potentiate antidepressant medication</span></div><div class="casAuthors">Blier, Pierre; Bergeron, Richard</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Psychiatry</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">Suppl..5</span>),
    <span class="NLM_cas:pages">16-25</span>CODEN:
                <span class="NLM_cas:coden">JCLPDE</span>;
        ISSN:<span class="NLM_cas:issn">0160-6689</span>.
    
            (<span class="NLM_cas:orgname">Physicians Postgraduate Press</span>)
        </div><div class="casAbstract">A review with 32 refs. followed by a discussion.  Serotonin (5-HT) selective reuptake inhibitors (SSRIs) and monoamine oxidase inhibitors are thought to have a delayed onset of antidepressant action attributable in part to the decrease in firing activity of 5-HT neurons they produce upon treatment initiation.  As cell body 5-HT1A autoreceptors desensitize, 5-HT neuronal firing is restored.  The agent pindolol, through its 5-HT1A receptor blocking property, has been shown to prevent the initial decrease in firing of rat 5-HT neurons assocd. with SSRI treatment.  Four open-label studies put into evidence a significant acceleration of the antidepressant effect of SSRIs when combined with pindolol.  Four of five placebo-controlled studies have confirmed this observation.  Controlled trials indicate that a greater rate of response may be obtained by combining pindolol from the beginning of the SSRI treatment.  The strategy of adding pindolol to the regimen of SSRI-resistant patients also appears to produce a therapeutic effect in a significant proportion of patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrz0q4Q6ACnhrVg90H21EOLACvtfcHk0lghij8-EOU54A"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXjslGksLs%253D&md5=a2d5fa78635c0e4427bd9c6fd6039271</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBlier%26aufirst%3DP.%26aulast%3DBergeron%26aufirst%3DR.%26atitle%3DThe%2520use%2520of%2520pindolol%2520to%2520potentiate%2520antidepressant%2520medication%26jtitle%3DJ.%2520Clin.%2520Psychiatry%26date%3D1998%26volume%3D59%26issue%3DSuppl.%25205%26spage%3D16%26epage%3D25" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group">Katz, M. M.; Tekell, J. L.; Bowden, C. L.; Brannan, S.; Houston, J. P.; Berman, N.; Frazer, A.</span><span> </span><span class="NLM_article-title">Onset and early behavioral effects of pharmacologically different antidepressants and placebo in depression</span>.  <span class="citation_source-journal">Neuropsychophamacology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">29</span><span class="NLM_x">, </span> <span class="NLM_fpage">566</span><span class="NLM_x">â</span> <span class="NLM_lpage">579</span> and references therein.</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Fjm200682b&amp;key=10.1038%2Fsj.npp.1300341" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Fjm200682b&amp;key=14627997" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Fjm200682b&amp;key=1%3ACAS%3A528%3ADC%252BD2cXhtlWksbg%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2004&pages=566-579&author=M.+M.+Katz&author=J.+L.+Tekell&author=C.+L.+Bowden&author=S.+Brannan&author=J.+P.+Houston&author=N.+Berman&author=A.+Frazer&title=Onset+and+early+behavioral+effects+of+pharmacologically+different+antidepressants+and+placebo+in+depression"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Onset and Early Behavioral Effects of Pharmacologically Different Antidepressants and Placebo in Depression</span></div><div class="casAuthors">Katz, Martin M.; Tekell, Janet L.; Bowden, Charles L.; Brannan, Steve; Houston, John P.; Berman, Nancy; Frazer, Alan</div><div class="citationInfo"><span class="NLM_cas:title">Neuropsychopharmacology</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">29</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">566-579</span>CODEN:
                <span class="NLM_cas:coden">NEROEW</span>;
        ISSN:<span class="NLM_cas:issn">0893-133X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">This study was aimed at resolving the time course of clin. action of antidepressants (ADs) and the type of early behavioral changes that precede recovery in treatment-responsive depressed patients.  The first goal was to identify, during the first 2 wk of treatment, the onset of clin. actions of the selective serotonin reuptake inhibitor (SSRI), paroxetine, and the selective noradrenergic reuptake inhibitor, desipramine (DMI).  The second aim was to test the hypothesis that the two pharmacol. subtypes would induce different early behavioral changes in treatment-responsive patients.  The design was a randomized, parallel group, placebo-controlled, double-blind study for 6 wk of treatment following a 1-wk washout period.  The study utilized measures of the major behavioral components of the depressive disorder as well as overall severity.  The results indicated that the onset of clin. actions of DMI ranged from 3 to 13 days, averaged 13 days for paroxetine, and was 16-42 days for placebo.  Furthermore, as hypothesized, the different types of ADs initially impacted different behavioral aspects of the disorder.  After 1 wk of treatment, DMI produced greater redns. in motor retardation and depressed mood than did paroxetine and placebo, and this difference persisted at the second week of treatment.  Early improvement in depressed mood-motor retardation differentiated patients who responded to DMI after 6 wk of treatment from those that did not.  Paroxetine initially reduced anxiety more in responders than in nonresponders, and by the second week, significantly improved depressed mood and distressed expression in responders to a greater extent.  Depressed patients who responded to placebo showed no consistent early pattern of behavior improvement.  Early drug-specific behavioral changes were highly predictive of ultimate clin. response to the different ADs, results that could eventually be applied directly to clin. practice.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoTBYhGBqQ1ArVg90H21EOLACvtfcHk0lhTqQREtJyHwg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXhtlWksbg%253D&md5=9d4bb8ceaeecd3e172442a56c23719b6</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1038%2Fsj.npp.1300341&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.npp.1300341%26sid%3Dliteratum%253Aachs%26aulast%3DKatz%26aufirst%3DM.%2BM.%26atitle%3DOnset%2520and%2520early%2520behavioral%2520effects%2520of%2520pharmacologically%2520different%2520antidepressants%2520and%2520placebo%2520in%2520depression%26jtitle%3DNeuropsychophamacology%26date%3D2004%26volume%3D29%26spage%3D566%26epage%3D579" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7a"><span><span class="NLM_contrib-group">Morphy, R.; Kay, C.; Rankovic, Z.</span><span> </span><span class="NLM_article-title">From magic bullets to designed multiple ligands</span>.  <span class="citation_source-journal">Drug Discovery Today</span>,<span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">641</span><span class="NLM_x">â</span> <span class="NLM_lpage">651</span> and reference therein.</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7a&amp;dbid=16&amp;doi=10.1021%2Fjm200682b&amp;key=10.1016%2FS1359-6446%2804%2903163-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7a&amp;dbid=8&amp;doi=10.1021%2Fjm200682b&amp;key=15279847" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7a&amp;dbid=32&amp;doi=10.1021%2Fjm200682b&amp;key=1%3ACAS%3A528%3ADC%252BD2cXmtVSktb8%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2004&pages=641-651&author=R.+Morphy&author=C.+Kay&author=Z.+Rankovic&title=From+magic+bullets+to+designed+multiple+ligands"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7aR"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">From magic bullets to designed multiple ligands</span></div><div class="casAuthors">Morphy, Richard; Kay, Corinne; Rankovic, Zoran</div><div class="citationInfo"><span class="NLM_cas:title">Drug Discovery Today</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">641-651</span>CODEN:
                <span class="NLM_cas:coden">DDTOFS</span>;
        ISSN:<span class="NLM_cas:issn">1359-6446</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">A review.  A major trend in medicinal chem. in the coming years will be the rational design of ligands that are capable of modulating multiple disease-relevant targets in a specific manner.  Increasingly, it is being recognized that a balanced modulation of several targets can provide a superior therapeutic effect and side effect profile compared to the action of a selective ligand.  Rational approaches in which structural features from selective ligands are combined have produced designed multiple ligands that span a wide variety of targets and target classes.  A key challenge in the design of multiple ligands is attaining a balanced activity at each target of interest while simultaneously achieving a wider selectivity and a suitable pharmacokinetic profile.  An anal. of literature examples reveals trends and insights that might help medicinal chemists discover the next generation of these types of compds.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpcsGpfzZok5rVg90H21EOLACvtfcHk0lhTqQREtJyHwg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXmtVSktb8%253D&md5=cd2491baad707043dbee4f59ccad9e1d</span></div><a href="/servlet/linkout?suffix=cit7a&amp;dbid=16384&amp;doi=10.1016%2FS1359-6446%2804%2903163-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1359-6446%252804%252903163-0%26sid%3Dliteratum%253Aachs%26aulast%3DMorphy%26aufirst%3DR.%26atitle%3DFrom%2520magic%2520bullets%2520to%2520designed%2520multiple%2520ligands%26jtitle%3DDrug%2520Discovery%2520Today%26date%3D2004%26volume%3D9%26spage%3D641%26epage%3D651" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit7b"><span><span class="NLM_contrib-group">Pacher, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kecskemeti, V.</span><span> </span><span class="NLM_article-title">Trends in the development of new antidepressants. Is there a light at the end of the tunnel?</span> <span class="citation_source-journal">Curr. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">925</span><span class="NLM_x">â</span> <span class="NLM_lpage">943</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7b&amp;dbid=16&amp;doi=10.1021%2Fjm200682b&amp;key=10.2174%2F0929867043455594" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7b&amp;dbid=8&amp;doi=10.1021%2Fjm200682b&amp;key=15078174" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7b&amp;dbid=32&amp;doi=10.1021%2Fjm200682b&amp;key=1%3ACAS%3A528%3ADC%252BD2cXivF2mtrk%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2004&pages=925-943&author=P.+Pacherauthor=V.+Kecskemeti&title=Trends+in+the+development+of+new+antidepressants.+Is+there+a+light+at+the+end+of+the+tunnel%3F"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7bR"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Trends in the development of new antidepressants. Is there a light at the end of the tunnel?</span></div><div class="casAuthors">Pacher, Pal; Kecskemeti, Valeria</div><div class="citationInfo"><span class="NLM_cas:title">Current Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">925-943</span>CODEN:
                <span class="NLM_cas:coden">CMCHE7</span>;
        ISSN:<span class="NLM_cas:issn">0929-8673</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Since the introduction of tricyclic antidepressants (TCAs) and monoamine oxidase inhibitors (MAOIs) in mid-1950's, treatment of depression was dominated by monoamine hypotheses.  The well-established clin. efficacy of TCAs and MAOIs is due, at least in part, to the enhancement of noradrenergic or serotonergic mechanisms, or to both.  Unfortunately, their very broad mechanisms of action also include many unwanted effects related to their potent activity on cholinergic, adrenergic, and histaminergic receptors.  The introduction of selective serotonin reuptake inhibitors (SSRIs) over twenty years ago had been the next major step in the evolution of antidepressants to develop drugs as effective as the TCAs but of higher safety and tolerability profile.  During the past 2 decades SSRIs (fluoxetine, fluvoxamine, paroxetine, sertraline, citalopram) gained incredible popularity and have become the most widely prescribed medication in the psychiatric practice.  The evolution of antidepressants continued resulting in introduction of selective and reversible monoamine oxidase inhibitors (eg. moclobemid), selective noradrenaline (eg. reboxetine), dual noradrenaline and serotonin reuptake inhibitors (milnacipram, venlafaxin, duloxetin) and drugs with distinct neurochem. profiles such as mirtazapine, nefazadone, and tianeptine.  Different novel serotonin receptor ligands were also intensively investigated.  In spite of the remarkable structural diversity, most currently introduced antidepressants are "monoamine based".  Furthermore, these newer agents are neither more efficacious nor rapid acting than their predecessors and approx. 30% of the population do not respond to current therapies.  By the turn of the new millennium, the authors are all witnessing a result of innovative developmental strategies based on the better understanding of pathophysiol. of depressive disorder.  Several truly novel concepts have emerged suggesting that the modulation of neuropeptide (substance P, corticotrophin-releasing factor, neuropeptide Y, vasopressin V1b, melanin-concg. hormone-1), N-methyl-D-aspartate, nicotinic acetylcholine, dopaminergic, glucocorticoid, Î´-opioid, cannabinoid and cytokine receptors, gamma-amino butyric acid (GABA) and intracellular messenger systems, transcription, neuroprotective and neurogenic factors, may provide an entirely new set of potential therapeutic targets, giving hope that further major advances might be anticipated in the treatment of depressive disorder soon.  The goal of this review is to give a brief overview of the major advances from monoamine-based treatment strategies, and particularly focus on the new emerging approaches in the treatment of depression.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrhQMckx9QwdLVg90H21EOLACvtfcHk0lhTqQREtJyHwg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXivF2mtrk%253D&md5=a94d012a3d79d723800333c10f346543</span></div><a href="/servlet/linkout?suffix=cit7b&amp;dbid=16384&amp;doi=10.2174%2F0929867043455594&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F0929867043455594%26sid%3Dliteratum%253Aachs%26aulast%3DPacher%26aufirst%3DP.%26aulast%3DKecskemeti%26aufirst%3DV.%26atitle%3DTrends%2520in%2520the%2520development%2520of%2520new%2520antidepressants.%2520Is%2520there%2520a%2520light%2520at%2520the%2520end%2520of%2520the%2520tunnel%253F%26jtitle%3DCurr.%2520Med.%2520Chem.%26date%3D2004%26volume%3D11%26spage%3D925%26epage%3D943" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group">Roberts, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Price, G. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Middlemiss, D. N.</span><span> </span><span class="NLM_article-title">Ligands for the investigation of 5-HT autoreceptor function</span> <span class="citation_source-journal">Brain Res. Bull.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">56</span><span class="NLM_x">, </span> <span class="NLM_fpage">463</span><span class="NLM_x">â</span> <span class="NLM_lpage">469</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Fjm200682b&amp;key=10.1016%2FS0361-9230%2801%2900628-1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Fjm200682b&amp;key=11750791" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Fjm200682b&amp;key=1%3ACAS%3A528%3ADC%252BD3MXptFylt7s%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2001&pages=463-469&author=C.+Robertsauthor=G.+W.+Priceauthor=D.+N.+Middlemiss&title=Ligands+for+the+investigation+of+5-HT+autoreceptor+function"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Ligands for the investigation of 5-HT autoreceptor function</span></div><div class="casAuthors">Roberts, Claire; Price, Gary W.; Middlemiss, Derek N.</div><div class="citationInfo"><span class="NLM_cas:title">Brain Research Bulletin</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">463-469</span>CODEN:
                <span class="NLM_cas:coden">BRBUDU</span>;
        ISSN:<span class="NLM_cas:issn">0361-9230</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Inc.</span>)
        </div><div class="casAbstract">A review.  The existence of multiple 5-HT autoreceptors in the central nervous system is now firmly established and they have been pharmacol. identified as belonging to the 5-HT1A, 5-HT1B, and 5-HT1D receptor subtypes.  In addn., 5-HT1F, 5-HT5A, and 5-HT7 receptors remain as potential candidates for addnl. autoreceptors.  The emergence of selective ligands, such as SB-224289 (5-HT1B receptor antagonist), BRL 15572 (5-HT1D receptor antagonist), GR 127935 (a mixed 5-HT1B/1D receptor antagonist), LY 334370 (5-HT1F receptor agonist), and SB-269970 (5-HT7 receptor antagonist), has aided the characterization of 5-HT autoreceptors and has highlighted the complexity of mechanisms which modulate the release of 5-HT.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoh3Lk0_xEYELVg90H21EOLACvtfcHk0ljy7EevGfLGlA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXptFylt7s%253D&md5=1b38f404662c50829d0f1d20bd313d84</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1016%2FS0361-9230%2801%2900628-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0361-9230%252801%252900628-1%26sid%3Dliteratum%253Aachs%26aulast%3DRoberts%26aufirst%3DC.%26aulast%3DPrice%26aufirst%3DG.%2BW.%26aulast%3DMiddlemiss%26aufirst%3DD.%2BN.%26atitle%3DLigands%2520for%2520the%2520investigation%2520of%25205-HT%2520autoreceptor%2520function%26jtitle%3DBrain%2520Res.%2520Bull.%26date%3D2001%26volume%3D56%26spage%3D463%26epage%3D469" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9a"><span><span class="NLM_contrib-group">Dawson, L. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bromidge, S. M.</span><span> </span><span class="NLM_article-title">5-H<sub>T1</sub> receptor augmentation strategies as enhanced efficacy therapeutics for psychiatric disorders</span> <span class="citation_source-journal">Curr. Top. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">8</span><span class="NLM_x">, </span> <span class="NLM_fpage">1008</span><span class="NLM_x">â</span> <span class="NLM_lpage">1023</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9a&amp;dbid=16&amp;doi=10.1021%2Fjm200682b&amp;key=10.2174%2F156802608785161439" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9a&amp;dbid=8&amp;doi=10.1021%2Fjm200682b&amp;key=18691129" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9a&amp;dbid=32&amp;doi=10.1021%2Fjm200682b&amp;key=1%3ACAS%3A528%3ADC%252BD1cXps1OhtLc%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2008&pages=1008-1023&author=L.+A.+Dawsonauthor=S.+M.+Bromidge&title=5-HT1+receptor+augmentation+strategies+as+enhanced+efficacy+therapeutics+for+psychiatric+disorders"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit9aR"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">5-HT1 receptor augmentation strategies as enhanced efficacy therapeutics for psychiatric disorders</span></div><div class="casAuthors">Dawson, Lee A.; Bromidge, Steve M.</div><div class="citationInfo"><span class="NLM_cas:title">Current Topics in Medicinal Chemistry (Sharjah, United Arab Emirates)</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1008-1023</span>CODEN:
                <span class="NLM_cas:coden">CTMCCL</span>;
        ISSN:<span class="NLM_cas:issn">1568-0266</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Since the initial observations linking 5-HT to psychiatric illness, evidence for a role of 5-HT and, in particular, a decreased brain serotonergic function in the pathol. of a plethora of related disorders, has grown.  However, it is the role of 5-HT in the pathogenesis of anxiety disorders and depression and the mechanism of action of antidepressants which has received the most attention.  Thus enhanced serotonergic neurotransmission has become one of the unifying mechanisms of action of modern day antidepressants / anxiolytics such as monoamine oxidase inhibitors, tricyclic antidepressants, and serotonin reuptake inhibitors.  Interestingly all of these treatments are assocd. with a delay to therapeutic efficacy and in some cases treatment resistance, despite immediate enhancements in serotonergic neurotransmission.  The postulated reason for this is the need for temporal neuroplastic changes in the control of serotonergic neurotransmission, and more specifically changes in 5-HT1 autoreceptor function.  Thus significant research has gone into pharmacol. targeting these 5-HT1 autoreceptors as a means of augmenting the efficacy of current therapeutic mechanisms.  Here we will review the rationale behind the various augmentation strategies adopted and the progress made in identifying novel therapeutics for conditions such as depression and anxiety disorders.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqMf53pfeDDRbVg90H21EOLACvtfcHk0ljy7EevGfLGlA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXps1OhtLc%253D&md5=d8262b01f7af300831084bdf423f5da1</span></div><a href="/servlet/linkout?suffix=cit9a&amp;dbid=16384&amp;doi=10.2174%2F156802608785161439&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F156802608785161439%26sid%3Dliteratum%253Aachs%26aulast%3DDawson%26aufirst%3DL.%2BA.%26aulast%3DBromidge%26aufirst%3DS.%2BM.%26atitle%3D5-HT1%2520receptor%2520augmentation%2520strategies%2520as%2520enhanced%2520efficacy%2520therapeutics%2520for%2520psychiatric%2520disorders%26jtitle%3DCurr.%2520Top.%2520Med.%2520Chem.%26date%3D2008%26volume%3D8%26spage%3D1008%26epage%3D1023" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit9b"><span><span class="NLM_contrib-group">Bromidge, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arban, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bertani, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bison, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Borriello, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cavanni, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Forno, G. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Di-Fabio, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Donati, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fontana, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gianotti, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gordon, L. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Granci, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leslie, C. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moccia, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pasquarello, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sartori, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sava, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Watson, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Worby, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zonzini, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zucchelli, V.</span><span> </span><span class="NLM_article-title">Design and synthesis of novel tricyclic benzoxazine as potent 5-H<sub>T1A/B/D</sub> receptor antagonists leading to the discovery of 6-{2-[4-(2-methyl-5-quinolinyl)-1-piperazinyl]ethyl}-<i>4H</i>-imidazo[5,1<i>-c</i>][1,4]benzoxazine-3-carboxamide (GSK088045)</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">53</span><span class="NLM_x">, </span> <span class="NLM_fpage">5827</span><span class="NLM_x">â</span> <span class="NLM_lpage">5843</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm100482n" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2010&pages=5827-5843&author=S.+M.+Bromidgeauthor=R.+Arbanauthor=B.+Bertaniauthor=S.+Bisonauthor=M.+Borrielloauthor=P.+Cavanniauthor=G.+D.+Fornoauthor=R.+Di-Fabioauthor=D.+Donatiauthor=S.+Fontanaauthor=M.+Gianottiauthor=L.+J.+Gordonauthor=E.+Granciauthor=C.+P.+Leslieauthor=L.+Mocciaauthor=A.+Pasquarelloauthor=I.+Sartoriauthor=A.+Savaauthor=J.+M.+Watsonauthor=A.+Worbyauthor=L.+Zonziniauthor=V.+Zucchelli&title=Design+and+synthesis+of+novel+tricyclic+benzoxazine+as+potent+5-HT1A%2FB%2FD+receptor+antagonists+leading+to+the+discovery+of+6-%7B2-%5B4-%282-methyl-5-quinolinyl%29-1-piperazinyl%5Dethyl%7D-4H-imidazo%5B5%2C1-c%5D%5B1%2C4%5Dbenzoxazine-3-carboxamide+%28GSK088045%29"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit9b&amp;dbid=16384&amp;doi=10.1021%2Fjm100482n&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm100482n%26sid%3Dliteratum%253Aachs%26aulast%3DBromidge%26aufirst%3DS.%2BM.%26aulast%3DArban%26aufirst%3DR.%26aulast%3DBertani%26aufirst%3DB.%26aulast%3DBison%26aufirst%3DS.%26aulast%3DBorriello%26aufirst%3DM.%26aulast%3DCavanni%26aufirst%3DP.%26aulast%3DForno%26aufirst%3DG.%2BD.%26aulast%3DDi-Fabio%26aufirst%3DR.%26aulast%3DDonati%26aufirst%3DD.%26aulast%3DFontana%26aufirst%3DS.%26aulast%3DGianotti%26aufirst%3DM.%26aulast%3DGordon%26aufirst%3DL.%2BJ.%26aulast%3DGranci%26aufirst%3DE.%26aulast%3DLeslie%26aufirst%3DC.%2BP.%26aulast%3DMoccia%26aufirst%3DL.%26aulast%3DPasquarello%26aufirst%3DA.%26aulast%3DSartori%26aufirst%3DI.%26aulast%3DSava%26aufirst%3DA.%26aulast%3DWatson%26aufirst%3DJ.%2BM.%26aulast%3DWorby%26aufirst%3DA.%26aulast%3DZonzini%26aufirst%3DL.%26aulast%3DZucchelli%26aufirst%3DV.%26atitle%3DDesign%2520and%2520synthesis%2520of%2520novel%2520tricyclic%2520benzoxazine%2520as%2520potent%25205-HT1A%252FB%252FD%2520receptor%2520antagonists%2520leading%2520to%2520the%2520discovery%2520of%25206-%257B2-%255B4-%25282-methyl-5-quinolinyl%2529-1-piperazinyl%255Dethyl%257D-4H-imidazo%255B5%252C1-c%255D%255B1%252C4%255Dbenzoxazine-3-carboxamide%2520%2528GSK088045%2529%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2010%26volume%3D53%26spage%3D5827%26epage%3D5843" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10a"><span><span class="NLM_contrib-group">Jurczyk, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kolaczkowski, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maryniak, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zajdel, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pawlowski, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tatarczynska, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Klodzinska, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chojnacka-Wojcik, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bojarski, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Charakchieva-Minol, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Duszynska, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nowak, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maciag, D.</span><span> </span><span class="NLM_article-title">New arylpiperazine 5-HT<sub>1A</sub> receptor ligands containing the pyrimido[2,1-<i>f</i>]purine fragment: Synthesis, in vitro, and in vivo pharmacological evaluation</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">47</span><span class="NLM_x">, </span> <span class="NLM_fpage">2659</span><span class="NLM_x">â</span> <span class="NLM_lpage">2666</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm030946u" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=47&publication_year=2004&pages=2659-2666&author=S.+Jurczykauthor=M.+Kolaczkowskiauthor=E.+Maryniakauthor=P.+Zajdelauthor=M.+Pawlowskiauthor=E.+Tatarczynskaauthor=A.+Klodzinskaauthor=E.+Chojnacka-Wojcikauthor=A.+J.+Bojarskiauthor=S.+Charakchieva-Minolauthor=B.+Duszynskaauthor=G.+Nowakauthor=D.+Maciag&title=New+arylpiperazine+5-HT1A+receptor+ligands+containing+the+pyrimido%5B2%2C1-f%5Dpurine+fragment%3A+Synthesis%2C+in+vitro%2C+and+in+vivo+pharmacological+evaluation"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit10a&amp;dbid=16384&amp;doi=10.1021%2Fjm030946u&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm030946u%26sid%3Dliteratum%253Aachs%26aulast%3DJurczyk%26aufirst%3DS.%26aulast%3DKolaczkowski%26aufirst%3DM.%26aulast%3DMaryniak%26aufirst%3DE.%26aulast%3DZajdel%26aufirst%3DP.%26aulast%3DPawlowski%26aufirst%3DM.%26aulast%3DTatarczynska%26aufirst%3DE.%26aulast%3DKlodzinska%26aufirst%3DA.%26aulast%3DChojnacka-Wojcik%26aufirst%3DE.%26aulast%3DBojarski%26aufirst%3DA.%2BJ.%26aulast%3DCharakchieva-Minol%26aufirst%3DS.%26aulast%3DDuszynska%26aufirst%3DB.%26aulast%3DNowak%26aufirst%3DG.%26aulast%3DMaciag%26aufirst%3DD.%26atitle%3DNew%2520arylpiperazine%25205-HT1A%2520receptor%2520ligands%2520containing%2520the%2520pyrimido%255B2%252C1-f%255Dpurine%2520fragment%253A%2520Synthesis%252C%2520in%2520vitro%252C%2520and%2520in%2520vivo%2520pharmacological%2520evaluation%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2004%26volume%3D47%26spage%3D2659%26epage%3D2666" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit10b"><span><span class="NLM_contrib-group">Abou-Gharbia, M. A.; Yardley, J. P.; Childers, E.</span><div class="note"><p class="first last">(American Home Products Co., USA)</p></div><span> </span><span class="NLM_article-title">Aryl- and heteroaryl piperazinyl carboxamides having central nervous system activity</span>. U.S. Patent 5,380,725, <span class="NLM_month">January</span><span class="NLM_day">10</span>,<span class="NLM_x"> </span><span class="NLM_year">1995</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=1995&author=M.+A.+Abou-Gharbia&author=J.+P.+Yardley&author=E.+Childers&title=Aryl-+and+heteroaryl+piperazinyl+carboxamides+having+central+nervous+system+activity"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit10b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DAbou-Gharbia%26aufirst%3DM.%2BA.%26atitle%3DAryl-%2520and%2520heteroaryl%2520piperazinyl%2520carboxamides%2520having%2520central%2520nervous%2520system%2520activity%26date%3D1995" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group">Ballesteros, J.; Callado, L. F.</span><span> </span><span class="NLM_article-title">Effectiveness of pindolol plus serotonin uptake inhibitors in depression: a meta-analysis of early and late outcomes from randomised controlled trials</span>.  <span class="citation_source-journal">J. Affective Disord.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">79</span><span class="NLM_x">, </span> <span class="NLM_fpage">137</span><span class="NLM_x">â</span> <span class="NLM_lpage">147</span> and reference therein.</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Fjm200682b&amp;key=10.1016%2FS0165-0327%2802%2900404-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Fjm200682b&amp;key=15023488" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Fjm200682b&amp;key=1%3ACAS%3A528%3ADC%252BD2cXitFWkt7k%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=79&publication_year=2004&pages=137-147&author=J.+Ballesteros&author=L.+F.+Callado&title=Effectiveness+of+pindolol+plus+serotonin+uptake+inhibitors+in+depression%3A+a+meta-analysis+of+early+and+late+outcomes+from+randomised+controlled+trials"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Effectiveness of pindolol plus serotonin uptake inhibitors in depression: a meta-analysis of early and late outcomes from randomised controlled trials</span></div><div class="casAuthors">Ballesteros, Javier; Callado, Luis F.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Affective Disorders</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">79</span>
        (<span class="NLM_cas:issue">1-3</span>),
    <span class="NLM_cas:pages">137-147</span>CODEN:
                <span class="NLM_cas:coden">JADID7</span>;
        ISSN:<span class="NLM_cas:issn">0165-0327</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Background: Contradictory results on the efficacy of pindolol assocd. with selective serotonin reuptake inhibitors (SSRIs) in depressive illness have been published and no former review has produced an overall figure of its efficacy.This study aims to review the efficacy and tolerability of pindolol plus SSRIs in depressive illness.  Methods: A meta-anal. of randomised controlled trials (RCTs) comparing pindolol plus SSRIs with placebo plus SSRIs.  Results: Nine RCTs met inclusion criteria.  Outcome favored pindolol at 2 wk time (N=5; OR=2.8; 95% CI 1.4-5.7), but not at four to 6 wk (N=7; OR=1.4; 95% CI 0.8-2.7).  Results for early outcome studies were robust to sensitivity anal.  Nineteen more studies, averaging null results, would be needed to change the overall probability (P=0.0001) to a non-significant figure.  Conclusions: Pindolol seems to hasten the response to SSRIs in depression with a timing window circumscribed to the first weeks of treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq7KQryIvGRabVg90H21EOLACvtfcHk0ljUaw076eA1Fg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXitFWkt7k%253D&md5=cadc23327131671a25347a38abd3cc24</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1016%2FS0165-0327%2802%2900404-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0165-0327%252802%252900404-4%26sid%3Dliteratum%253Aachs%26aulast%3DBallesteros%26aufirst%3DJ.%26atitle%3DEffectiveness%2520of%2520pindolol%2520plus%2520serotonin%2520uptake%2520inhibitors%2520in%2520depression%253A%2520a%2520meta-analysis%2520of%2520early%2520and%2520late%2520outcomes%2520from%2520randomised%2520controlled%2520trials%26jtitle%3DJ.%2520Affective%2520Disord.%26date%3D2004%26volume%3D79%26spage%3D137%26epage%3D147" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group">Romeo, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arigas, F.</span><span> </span><span class="NLM_article-title">Preferential potentiation of the effects of serotonin uptake inhibitors by 5-HT<sub>1A</sub> receptor antagonists in the dorsal raphe pathway: Role of somatodendritic autoreceptors</span> <span class="citation_source-journal">J. Neurochem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1997</span><span class="NLM_x">, </span> <span class="NLM_volume">68</span><span class="NLM_x">, </span> <span class="NLM_fpage">2593</span><span class="NLM_x">â</span> <span class="NLM_lpage">2603</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Fjm200682b&amp;key=10.1046%2Fj.1471-4159.1997.68062593.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Fjm200682b&amp;key=9166757" title="">PubMed</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=68&publication_year=1997&pages=2593-2603&author=L.+Romeoauthor=F.+Arigas&title=Preferential+potentiation+of+the+effects+of+serotonin+uptake+inhibitors+by+5-HT1A+receptor+antagonists+in+the+dorsal+raphe+pathway%3A+Role+of+somatodendritic+autoreceptors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1046%2Fj.1471-4159.1997.68062593.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1046%252Fj.1471-4159.1997.68062593.x%26sid%3Dliteratum%253Aachs%26aulast%3DRomeo%26aufirst%3DL.%26aulast%3DArigas%26aufirst%3DF.%26atitle%3DPreferential%2520potentiation%2520of%2520the%2520effects%2520of%2520serotonin%2520uptake%2520inhibitors%2520by%25205-HT1A%2520receptor%2520antagonists%2520in%2520the%2520dorsal%2520raphe%2520pathway%253A%2520Role%2520of%2520somatodendritic%2520autoreceptors%26jtitle%3DJ.%2520Neurochem.%26date%3D1997%26volume%3D68%26spage%3D2593%26epage%3D2603" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group">Berman, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Anand, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cappiello, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miller, H. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, X. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oren, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Charney., D. S.</span><span> </span><span class="NLM_article-title">The use of pindolol with fluoxetine in the treatment of major depression: Final results from a double-blind, placebo-controlled trial</span> <span class="citation_source-journal">Biol. Psychiatry</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1999</span><span class="NLM_x">, </span> <span class="NLM_volume">45</span><span class="NLM_x">, </span> <span class="NLM_fpage">1170</span><span class="NLM_x">â</span> <span class="NLM_lpage">1177</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Fjm200682b&amp;key=10.1016%2FS0006-3223%2898%2900383-7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Fjm200682b&amp;key=10331109" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Fjm200682b&amp;key=1%3ACAS%3A528%3ADyaK1MXjsFeju78%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=45&publication_year=1999&pages=1170-1177&author=R.+M.+Bermanauthor=A.+Anandauthor=A.+Cappielloauthor=H.+L.+Millerauthor=X.+S.+Xuauthor=D.+A.+Orenauthor=D.+S.+Charney.&title=The+use+of+pindolol+with+fluoxetine+in+the+treatment+of+major+depression%3A+Final+results+from+a+double-blind%2C+placebo-controlled+trial"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">The use of pindolol with fluoxetine in the treatment of major depression: final results from a double-blind, placebo-controlled trial</span></div><div class="casAuthors">Berman, Robert M.; Anand, Amit; Cappiello, Angela; Miller, Helen L.; Hu, X. Sylvia; Oren, Dan A.; Charney, Dennis S.</div><div class="citationInfo"><span class="NLM_cas:title">Biological Psychiatry</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">45</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1170-1177</span>CODEN:
                <span class="NLM_cas:coden">BIPCBF</span>;
        ISSN:<span class="NLM_cas:issn">0006-3223</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Inc.</span>)
        </div><div class="casAbstract">Preliminary reports have suggested that concomitant institution of pindolol and serotonin reuptake inhibitors robustly hastens clin. response; however, contradictory evidence from a randomized double-blind, controlled trial was recently reported by this group in a population of depressed patients who were prescribed fluoxetine and pindolol.  Herein, we report final results from an extended sample size.  Drug-free outpatients with a major depressive episode were randomized in a double-blind manner to one of two treatment conditions: fluoxetine (20 mg daily) with pindolol (7.5 to 10 mg daily) or fluoxetine (20 mg daily) with placebo.  After 6 wk, patients were followed for 3 more weeks in a single-blind manner, on fluoxetine and placebo pindolol.  Eighty-six patients completed at least 1 or more weeks on protocol, with 45 and 41 patients randomized to the pindolol and placebo groups resp.  After 2 wk on protocol, partial remission (i.e., at least 50% decrease in depression rating scores from baseline) rates for pindolol (16%) and placebo (19%) groups were comparable.  By the study's end, a partial remission was achieved, at least transiently, for 67% of the pindolol group and 80% of the placebo group.  Pindolol treatment was assocd. with statistically significant redn. in blood pressure and pulse as compared to the control group.  The two groups did not have overall differences in rates of attrition, time to response, and side effects.  In accord with our previously published findings, these extended results do not support the efficacy of pindolol in hastening clin. response to fluoxetine in a patient population with predominantly chronic and recurrent depression.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq96N7R9EFBs7Vg90H21EOLACvtfcHk0lghE5dQxAOEqw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXjsFeju78%253D&md5=a38fd0eaa0ccda8a3c753ce88cbf0116</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1016%2FS0006-3223%2898%2900383-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0006-3223%252898%252900383-7%26sid%3Dliteratum%253Aachs%26aulast%3DBerman%26aufirst%3DR.%2BM.%26aulast%3DAnand%26aufirst%3DA.%26aulast%3DCappiello%26aufirst%3DA.%26aulast%3DMiller%26aufirst%3DH.%2BL.%26aulast%3DXu%26aufirst%3DX.%2BS.%26aulast%3DOren%26aufirst%3DD.%2BA.%26aulast%3DCharney.%26aufirst%3DD.%2BS.%26atitle%3DThe%2520use%2520of%2520pindolol%2520with%2520fluoxetine%2520in%2520the%2520treatment%2520of%2520major%2520depression%253A%2520Final%2520results%2520from%2520a%2520double-blind%252C%2520placebo-controlled%2520trial%26jtitle%3DBiol.%2520Psychiatry%26date%3D1999%26volume%3D45%26spage%3D1170%26epage%3D1177" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group">Pullar, I. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carney, S. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Colvin, E. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lucaites, V. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nelson, D. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wedley, S.</span><span> </span><span class="NLM_article-title">LY367265, an inhibitor of the 5-hydroxytryptamine transporter and 5-hydroxytryptamine<sub>2A</sub> receptor antagonist: A comparison with the antidepressant, nefazodone</span> <span class="citation_source-journal">Eur. J. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">407</span><span class="NLM_x">, </span> <span class="NLM_fpage">39</span><span class="NLM_x">â</span> <span class="NLM_lpage">46</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Fjm200682b&amp;key=10.1016%2FS0014-2999%2800%2900728-7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Fjm200682b&amp;key=11050288" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Fjm200682b&amp;key=1%3ACAS%3A528%3ADC%252BD3cXnsFWqt7o%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=407&publication_year=2000&pages=39-46&author=I.+A.+Pullarauthor=S.+L.+Carneyauthor=E.+M.+Colvinauthor=V.+L.+Lucaitesauthor=D.+L.+Nelsonauthor=S.+Wedley&title=LY367265%2C+an+inhibitor+of+the+5-hydroxytryptamine+transporter+and+5-hydroxytryptamine2A+receptor+antagonist%3A+A+comparison+with+the+antidepressant%2C+nefazodone"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">LY367265, an inhibitor of the 5-hydroxytryptamine transporter and 5-hydroxytryptamine2A receptor antagonist: a comparison with the antidepressant, nefazodone</span></div><div class="casAuthors">Pullar, I. A.; Carney, S. L.; Colvin, E. M.; Lucaites, V. L.; Nelson, D. L.; Wedley, S.</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">407</span>
        (<span class="NLM_cas:issue">1/2</span>),
    <span class="NLM_cas:pages">39-46</span>CODEN:
                <span class="NLM_cas:coden">EJPHAZ</span>;
        ISSN:<span class="NLM_cas:issn">0014-2999</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science B.V.</span>)
        </div><div class="casAbstract">The potential antidepressant, LY367265 (1-[2-[4-(6-fluoro-1H-indol-3-yl)-3,6-dihydro-1(2H)-pyridinyl]ethyl]-5,6-dihydro-1H,4H-[1,2,5]thiadiazolo[4.3.2-ij]quinoline-2,2,-dioxide) has been shown to have a higher affinity for the 5-hydroxytryptamine (5-HT) transporter (Ki=2.3 nM) and 5-HT2A (Ki=0.81 nM) receptor than the clin. effective antidepressant, nefazodone.  It is a potent inhibitor of [3H]5-HT uptake into rat cortical synaptosomes (IC50=3.1 nM) and shows selectivity over that for [3H]noradrenaline (IC50Â°1000 nM).  It potentiates potassium-induced [3H]5-HT outflow from prelabeled guinea pig cortical slices both in the presence (EC50=950 nM) and absence (EC50=250 nM) of a satg. concn. of the 5-HT transport inhibitor, paroxetine, indicating a low level of activity at the 5-HT1B/1D autoreceptor.  These studies indicate that LY367265 is a putative antidepressant which, because of its 5-HT2A receptor antagonist activity, has the potential to produce less sleep disturbance and sexual dysfunction than selective serotonin uptake inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrCax7sIb7CuLVg90H21EOLACvtfcHk0lghE5dQxAOEqw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXnsFWqt7o%253D&md5=f20cbf13b5c9d04cba0a86aeeed0eca2</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1016%2FS0014-2999%2800%2900728-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0014-2999%252800%252900728-7%26sid%3Dliteratum%253Aachs%26aulast%3DPullar%26aufirst%3DI.%2BA.%26aulast%3DCarney%26aufirst%3DS.%2BL.%26aulast%3DColvin%26aufirst%3DE.%2BM.%26aulast%3DLucaites%26aufirst%3DV.%2BL.%26aulast%3DNelson%26aufirst%3DD.%2BL.%26aulast%3DWedley%26aufirst%3DS.%26atitle%3DLY367265%252C%2520an%2520inhibitor%2520of%2520the%25205-hydroxytryptamine%2520transporter%2520and%25205-hydroxytryptamine2A%2520receptor%2520antagonist%253A%2520A%2520comparison%2520with%2520the%2520antidepressant%252C%2520nefazodone%26jtitle%3DEur.%2520J.%2520Pharmacol.%26date%3D2000%26volume%3D407%26spage%3D39%26epage%3D46" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group">Hatanaka, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nomura, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hidaka, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Takeuchi, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yatsugi, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fujii, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yamaguchi, T.</span><span> </span><span class="NLM_article-title">Biochemical profile of YM992, a novel selective serotonin reuptake inhibitor with 5-HT<sub>2A</sub> receptor antagonistic activity</span> <span class="citation_source-journal">Neuropharmacology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1997</span><span class="NLM_x">, </span> <span class="NLM_volume">35</span><span class="NLM_x">, </span> <span class="NLM_fpage">1621</span><span class="NLM_x">â</span> <span class="NLM_lpage">1626</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=35&publication_year=1997&pages=1621-1626&author=K.+Hatanakaauthor=T.+Nomuraauthor=K.+Hidakaauthor=H.+Takeuchiauthor=S.+Yatsugiauthor=M.+Fujiiauthor=T.+Yamaguchi&title=Biochemical+profile+of+YM992%2C+a+novel+selective+serotonin+reuptake+inhibitor+with+5-HT2A+receptor+antagonistic+activity"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DHatanaka%26aufirst%3DK.%26aulast%3DNomura%26aufirst%3DT.%26aulast%3DHidaka%26aufirst%3DK.%26aulast%3DTakeuchi%26aufirst%3DH.%26aulast%3DYatsugi%26aufirst%3DS.%26aulast%3DFujii%26aufirst%3DM.%26aulast%3DYamaguchi%26aufirst%3DT.%26atitle%3DBiochemical%2520profile%2520of%2520YM992%252C%2520a%2520novel%2520selective%2520serotonin%2520reuptake%2520inhibitor%2520with%25205-HT2A%2520receptor%2520antagonistic%2520activity%26jtitle%3DNeuropharmacology%26date%3D1997%26volume%3D35%26spage%3D1621%26epage%3D1626" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16a"><span><span class="NLM_contrib-group">Rush, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Armitage, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gillin, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yonkers, K. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Winokur, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moldofsky, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vogel, G. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kaplita, S. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fleming, J. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Montplaisir, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Erman, M. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Albala, B. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McQuade, R. D.</span><span> </span><span class="NLM_article-title">Comparative effects of nefazodone and fluoxetine on sleep in outpatients with major depressive disorder</span> <span class="citation_source-journal">Biol. Psychiatry</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1998</span><span class="NLM_x">, </span> <span class="NLM_volume">44</span><span class="NLM_x">, </span> <span class="NLM_fpage">3</span><span class="NLM_x">â</span> <span class="NLM_lpage">14</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16a&amp;dbid=16&amp;doi=10.1021%2Fjm200682b&amp;key=10.1016%2FS0006-3223%2898%2900092-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16a&amp;dbid=8&amp;doi=10.1021%2Fjm200682b&amp;key=9646878" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16a&amp;dbid=32&amp;doi=10.1021%2Fjm200682b&amp;key=1%3ACAS%3A528%3ADyaK1cXkt1Kjurg%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=44&publication_year=1998&pages=3-14&author=A.+J.+Rushauthor=R.+Armitageauthor=J.+C.+Gillinauthor=K.+A.+Yonkersauthor=A.+Winokurauthor=H.+Moldofskyauthor=G.+W.+Vogelauthor=S.+B.+Kaplitaauthor=J.+B.+Flemingauthor=J.+Montplaisirauthor=M.+K.+Ermanauthor=B.+J.+Albalaauthor=R.+D.+McQuade&title=Comparative+effects+of+nefazodone+and+fluoxetine+on+sleep+in+outpatients+with+major+depressive+disorder"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit16aR"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Comparative effects of nefazodone and fluoxetine on sleep in outpatients with major depressive disorder</span></div><div class="casAuthors">Rush, A. John; Armitage, Roseanne; Gillin, J. Christian; Yonkers, Kimberly A.; Winokur, Andrew; Moldofsky, Harvey; Vogel, Gerald W.; Kaplita, Stephen B.; Fleming, Jonathan B.; Montplaisir, Jacques; Erman, Milton K.; Albala, Bruce J.; Mcquade, Robert D.</div><div class="citationInfo"><span class="NLM_cas:title">Biological Psychiatry</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">44</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">3-14</span>CODEN:
                <span class="NLM_cas:coden">BIPCBF</span>;
        ISSN:<span class="NLM_cas:issn">0006-3223</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Inc.</span>)
        </div><div class="casAbstract">Sleep disturbances are common in major depressive disorder.  In previous open-label trials, nefazodone improved sleep continuity and increased rapid eye movement (REM) sleep, while not affecting stage 3/4 sleep or REM latency; in contrast, fluoxetine suppressed REM sleep.  This study compared the objective and subjective effects of nefazodone and fluoxetine on sleep.  This paper reports combined results of three identical, multisite, randomized, double-blind, 8-wk, acute-phase trials comparing nefazodone (n = 64) with fluoxetine (n = 61) in outpatients with nonpsychotic major depressive disorder and insomnia.  Sleep electroencephalog. (EEG) recordings were gathered at baseline and weeks 2, 4, and 8.  Clin. ratings were obtained at weeks 1-4, 6, and 8.  Nefazodone and fluoxetine were equally effective in reducing depressive symptoms; however, nefazodone differentially and progressively increased (while fluoxetine reduced) sleep efficiency and reduced (while fluoxetine increased) the no. of awakenings in a linear fashion over the 8-wk trial.  Fluoxetine, but not nefazodone, prolonged REM latency and suppressed REM sleep.  Nefazodone significantly increased total REM sleep time.  Clin. evaluations of sleep quality were significantly improved with nefazodone compared with fluoxetine.  Nefazodone and fluoxetine were equally effective antidepressants.  Nefazodone was assocd. with normal objective, and clinician- and patient-rated assessments of sleep when compared with fluoxetine.  These differential sleep EEG effects are consistent with the notion that nefazodone and fluoxetine may have somewhat different modes and spectra of action.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo-zPEkzYrEZrVg90H21EOLACvtfcHk0lghE5dQxAOEqw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXkt1Kjurg%253D&md5=c42a24385f0ade283a86f078467744aa</span></div><a href="/servlet/linkout?suffix=cit16a&amp;dbid=16384&amp;doi=10.1016%2FS0006-3223%2898%2900092-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0006-3223%252898%252900092-4%26sid%3Dliteratum%253Aachs%26aulast%3DRush%26aufirst%3DA.%2BJ.%26aulast%3DArmitage%26aufirst%3DR.%26aulast%3DGillin%26aufirst%3DJ.%2BC.%26aulast%3DYonkers%26aufirst%3DK.%2BA.%26aulast%3DWinokur%26aufirst%3DA.%26aulast%3DMoldofsky%26aufirst%3DH.%26aulast%3DVogel%26aufirst%3DG.%2BW.%26aulast%3DKaplita%26aufirst%3DS.%2BB.%26aulast%3DFleming%26aufirst%3DJ.%2BB.%26aulast%3DMontplaisir%26aufirst%3DJ.%26aulast%3DErman%26aufirst%3DM.%2BK.%26aulast%3DAlbala%26aufirst%3DB.%2BJ.%26aulast%3DMcQuade%26aufirst%3DR.%2BD.%26atitle%3DComparative%2520effects%2520of%2520nefazodone%2520and%2520fluoxetine%2520on%2520sleep%2520in%2520outpatients%2520with%2520major%2520depressive%2520disorder%26jtitle%3DBiol.%2520Psychiatry%26date%3D1998%26volume%3D44%26spage%3D3%26epage%3D14" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit16b"><span><span class="NLM_contrib-group">Avila, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vardona, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martin-Baranera, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maho, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sastre, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bello, J.</span><span> </span><span class="NLM_article-title">Does nefazodone improve both depression and Parkinson disease? A pilot randomized trial</span> <span class="citation_source-journal">J. Clin. Psychopharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">23</span><span class="NLM_x">, </span> <span class="NLM_fpage">509</span><span class="NLM_x">â</span> <span class="NLM_lpage">513</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16b&amp;dbid=16&amp;doi=10.1021%2Fjm200682b&amp;key=10.1097%2F01.jcp.0000088908.24613.db" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16b&amp;dbid=8&amp;doi=10.1021%2Fjm200682b&amp;key=14520130" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16b&amp;dbid=32&amp;doi=10.1021%2Fjm200682b&amp;key=1%3ACAS%3A528%3ADC%252BD3sXns12qu7w%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2003&pages=509-513&author=A.+Avilaauthor=X.+Vardonaauthor=M.+Martin-Baraneraauthor=P.+Mahoauthor=F.+Sastreauthor=J.+Bello&title=Does+nefazodone+improve+both+depression+and+Parkinson+disease%3F+A+pilot+randomized+trial"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit16bR"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Does Nefazodone Improves Both Depression and Parkinson Disease? A Pilot Randomized Trial</span></div><div class="casAuthors">Avila, Asuncion; Cardona, Xavier; Martin-Baranera, Montserrat; Maho, Placida; Sastre, Francesc; Bello, Juan</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Psychopharmacology</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">509-513</span>CODEN:
                <span class="NLM_cas:coden">JCPYDR</span>;
        ISSN:<span class="NLM_cas:issn">0271-0749</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">Some of the selective serotonin reuptake inhibitors (SSRI)-induced motor side effects are mediated by stimulating 5-HT2 receptors in the basal ganglia, probably because serotonin inhibits the subsequent neuronal dopamine release.  We hypothesized that nefazodone, a serotonin 2 antagonist/reuptake inhibitor (SARI) that selectively blocks 5-HT2 receptors, could disrupt the aforementioned inhibitory pathway.  Therefore, increased dopamine levels in the postsynaptic milieu and an improvement in the motor symptoms in depressed patients with Parkinson disease (PD) should be obsd.  This study was designed to det. whether nefazodone has a dual activity as an antidepressant and as an agent capable of reducing the extrapyramidal symptoms in depressed parkinsonian patients.  Depressed patients with PD were randomly assigned to 2 therapeutic groups: nefazodone or fluoxetine.  Patients were evaluated by a psychiatrist and were blindly assessed by a neurologist with an array of scales.  Patients on nefazodone (n = 9) showed a significant improvement over time in the total Unified Parkinson Disease Rating Scale score (UPDRS) (part II + part III) (P = 0.004) and in the UPDRS subscore part III (P = 0.003).  None of these scores changed over time in the fluoxetine group (n = 7).  Both, nefazodone and fluoxetine were equally effective as antidepressants: beck depression Inventory scores significantly improved (P < 0.001), with no significant differences between treatment groups (P = 0.97).If our results can be confirmed in a larger clin. trial, nefazodone ought to be considered over fluoxetine given its secondary beneficial effects regarding the redn. of extrapyramidal symptoms in depressed PD patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpCpklq8wnZtbVg90H21EOLACvtfcHk0lg6PMRmeONmbA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXns12qu7w%253D&md5=27b0e7a917af9fa7864b20b0e839fe1b</span></div><a href="/servlet/linkout?suffix=cit16b&amp;dbid=16384&amp;doi=10.1097%2F01.jcp.0000088908.24613.db&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252F01.jcp.0000088908.24613.db%26sid%3Dliteratum%253Aachs%26aulast%3DAvila%26aufirst%3DA.%26aulast%3DVardona%26aufirst%3DX.%26aulast%3DMartin-Baranera%26aufirst%3DM.%26aulast%3DMaho%26aufirst%3DP.%26aulast%3DSastre%26aufirst%3DF.%26aulast%3DBello%26aufirst%3DJ.%26atitle%3DDoes%2520nefazodone%2520improve%2520both%2520depression%2520and%2520Parkinson%2520disease%253F%2520A%2520pilot%2520randomized%2520trial%26jtitle%3DJ.%2520Clin.%2520Psychopharmacol.%26date%3D2003%26volume%3D23%26spage%3D509%26epage%3D513" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit16c"><span><span class="NLM_contrib-group">Greene, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barbhaiya, R. H.</span><span> </span><span class="NLM_article-title">Clinical pharmacokinetics of nefazodone</span> <span class="citation_source-journal">Clin. Pharmacokinet.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1997</span><span class="NLM_x">, </span> <span class="NLM_volume">33</span><span class="NLM_x">, </span> <span class="NLM_fpage">260</span><span class="NLM_x">â</span> <span class="NLM_lpage">275</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16c&amp;dbid=16&amp;doi=10.1021%2Fjm200682b&amp;key=10.2165%2F00003088-199733040-00002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16c&amp;dbid=8&amp;doi=10.1021%2Fjm200682b&amp;key=9342502" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16c&amp;dbid=32&amp;doi=10.1021%2Fjm200682b&amp;key=1%3ACAS%3A528%3ADyaK2sXntVGgtrk%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=33&publication_year=1997&pages=260-275&author=D.+Greeneauthor=R.+H.+Barbhaiya&title=Clinical+pharmacokinetics+of+nefazodone"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit16cR"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Clinical pharmacokinetics of nefazodone</span></div><div class="casAuthors">Greene, Douglas S.; Barbhaiya, Rashmi H.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Pharmacokinetics</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">33</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">260-275</span>CODEN:
                <span class="NLM_cas:coden">CPKNDH</span>;
        ISSN:<span class="NLM_cas:issn">0312-5963</span>.
    
            (<span class="NLM_cas:orgname">Adis</span>)
        </div><div class="casAbstract">A review with 51 refs.  Nefazodone is a new antidepressant drug, chem. unrelated to the tricyclic, tetracyclic or selective serotonin uptake inhibitors.  Nefazodone blocks the serotonin 5-HT2 receptors and reversibly inhibits serotonin reuptake in vivo.  Nefazodone is completely and rapidly absorbed after oral administration with a peak plasma concn. obsd. within 2 h of administration.  Nefazodone undergoes significant first-pass metab. resulting in an oral bioavailability of approx. 20%.  Although there is an 18% increase in nefazodone bioavailability with food, this increase is not clin. significant and nefazodone can be administered without regard to meals.  Three pharmacol. active nefazodone metabolites have been identified: hydroxy-nefazodone, triazoledione and m-chlorophenylpiperazine (mCPP).  The pharmacokinetics of nefazodone are nonlinear.  The increase in plasma concns. of nefazodone are greater than would be expected if they were proportional to increases in dose.  Steady-state plasma concns. of nefazodone are attained within 4 days of the commencement of administration.  The pharmacokinetics of nefazodone are not appreciably altered in patients with renal or mild-to-moderate hepatic impairment.  However, nefazodone plasma concns. are increased in severe hepatic impairment and in the elderly, esp. in elderly females.  Lower doses of nefazodone may be necessary in these groups.  Nefazodone is a weak inhibitor of cytochrome P 450 (CYP) 2D6 and does not inhibit CYP1A2.  It is not anticipated that nefazodone will interact with drugs cleared by these isoenzymes.  Indeed, nefazodone did not affect the pharmacokinetics of theophylline, a compd. cleared by CYP1A2.  Nefazodone is metabolized by and inhibits CYP3A4.  Clin. significant interactions have been obsd. between nefazodone and the benzodiazepines triazolam and alprazolam, cyclosporin and carbamazepine.  The potential for a clin. significant interaction between nefazodone and other drugs cleared by CYP3A4 (e.g. terfenadine) should be considered before the coadministration of these compds.  There was an increase in haloperidol plasma concns. when coadministered with nefazodone; nefazodone pharmacokinetics were not affected after coadministration.  No clin. significant interaction was obsd. when nefazodone was administered with lorazepam, lithium, alc., cimetidine, warfarin, theophylline or propranolol.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGowyKhx9mQWVrVg90H21EOLACvtfcHk0lg6PMRmeONmbA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXntVGgtrk%253D&md5=a5606549e2a64ad8d479197334bc3b65</span></div><a href="/servlet/linkout?suffix=cit16c&amp;dbid=16384&amp;doi=10.2165%2F00003088-199733040-00002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2165%252F00003088-199733040-00002%26sid%3Dliteratum%253Aachs%26aulast%3DGreene%26aufirst%3DD.%26aulast%3DBarbhaiya%26aufirst%3DR.%2BH.%26atitle%3DClinical%2520pharmacokinetics%2520of%2520nefazodone%26jtitle%3DClin.%2520Pharmacokinet.%26date%3D1997%26volume%3D33%26spage%3D260%26epage%3D275" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit16d"><span><span class="NLM_contrib-group">Kent, J. M.</span><span> </span><span class="NLM_article-title">SNaRIs, NaSSAs, and NaRIs: New agents for the treatment of depression</span> <span class="citation_source-journal">Lancet</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">355</span><span class="NLM_x">, </span> <span class="NLM_fpage">911</span><span class="NLM_x">â</span> <span class="NLM_lpage">918</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=355&publication_year=2000&pages=911-918&author=J.+M.+Kent&title=SNaRIs%2C+NaSSAs%2C+and+NaRIs%3A+New+agents+for+the+treatment+of+depression"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit16d&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DKent%26aufirst%3DJ.%2BM.%26atitle%3DSNaRIs%252C%2520NaSSAs%252C%2520and%2520NaRIs%253A%2520New%2520agents%2520for%2520the%2520treatment%2520of%2520depression%26jtitle%3DLancet%26date%3D2000%26volume%3D355%26spage%3D911%26epage%3D918" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17a"><span><span class="NLM_contrib-group">Lawler, C. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Prioleau, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lewis, M. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mak, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jian, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schetz, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gonzalez, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sibley, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mailman, R. B.</span><span> </span><span class="NLM_article-title">Interactions of the novel antipsychotic aripiprazole (OPC-14597) with dopamine and serotonin receptor subtypes</span> <span class="citation_source-journal">Neuropsychopahrmacology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1999</span><span class="NLM_x">, </span> <span class="NLM_volume">20</span><span class="NLM_x">, </span> <span class="NLM_fpage">612</span><span class="NLM_x">â</span> <span class="NLM_lpage">627</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17a&amp;dbid=16&amp;doi=10.1021%2Fjm200682b&amp;key=10.1016%2FS0893-133X%2898%2900099-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17a&amp;dbid=8&amp;doi=10.1021%2Fjm200682b&amp;key=10327430" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17a&amp;dbid=32&amp;doi=10.1021%2Fjm200682b&amp;key=1%3ACAS%3A528%3ADyaK1MXjsVamu7c%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=1999&pages=612-627&author=C.+P.+Lawlerauthor=C.+Prioleauauthor=M.+M.+Lewisauthor=C.+Makauthor=D.+Jianauthor=J.+A.+Schetzauthor=A.+M.+Gonzalezauthor=D.+R.+Sibleyauthor=R.+B.+Mailman&title=Interactions+of+the+novel+antipsychotic+aripiprazole+%28OPC-14597%29+with+dopamine+and+serotonin+receptor+subtypes"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit17aR"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Interactions of the novel antipsychotic aripiprazole (OPC-14597) with dopamine and serotonin receptor subtypes</span></div><div class="casAuthors">Lawler, Cindy P.; Prioleau, Cassandra; Lewis, Mechelle M.; Mak, Chun; Jiang, Dong; Schetz, John A.; Gonzalez, Antonio M.; Sibley, David R.; Mailman, Richard B.</div><div class="citationInfo"><span class="NLM_cas:title">Neuropsychopharmacology</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">612-627</span>CODEN:
                <span class="NLM_cas:coden">NEROEW</span>;
        ISSN:<span class="NLM_cas:issn">0893-133X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Inc.</span>)
        </div><div class="casAbstract">OPC-14597 {aripiprazole; 7- (4- (4-(2,3-dichlorophenyl) -1-piperazinyl) butyloxy) -3, 4-dihydro-2 (1H) -quinolinone} is a novel candidate antipsychotic that has high affinity for striatal dopamine D2-like receptors, but causes few extrapyramidal effects.  These studies characterized the mol. pharmacol. of OPC-14597, DM-1451 (its major rodent metabolite), and the related quinolinone deriv. OPC-4392 at each of the cloned dopamine receptors, and at serotonin 5HT6 and 5HT7 receptors.  All three compds. exhibited highest affinity for D2L and D2S receptors relative to the other cloned receptors examd.  Both OPC-4392 and OPC-14597 demonstrated dual agonist/antagonist actions at D2L receptors, although the metabolite DM-1451 behaved as a pure antagonist.  These data suggest that clin. atypicality can occur with drugs that exhibit selectivity for D2L/D2S rather than D3 or D4 receptors, and raise the possibility that the unusual profile of OPC-14597 in vivo (presynaptic agonist and postsynaptic antagonist) may reflect different functional consequences of this compd. interacting with a single dopamine receptor subtype (D2) in distinct cellular locales.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpFhC9HkOART7Vg90H21EOLACvtfcHk0lg6PMRmeONmbA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXjsVamu7c%253D&md5=6075301b17f119d4040742751425bb92</span></div><a href="/servlet/linkout?suffix=cit17a&amp;dbid=16384&amp;doi=10.1016%2FS0893-133X%2898%2900099-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0893-133X%252898%252900099-2%26sid%3Dliteratum%253Aachs%26aulast%3DLawler%26aufirst%3DC.%2BP.%26aulast%3DPrioleau%26aufirst%3DC.%26aulast%3DLewis%26aufirst%3DM.%2BM.%26aulast%3DMak%26aufirst%3DC.%26aulast%3DJian%26aufirst%3DD.%26aulast%3DSchetz%26aufirst%3DJ.%2BA.%26aulast%3DGonzalez%26aufirst%3DA.%2BM.%26aulast%3DSibley%26aufirst%3DD.%2BR.%26aulast%3DMailman%26aufirst%3DR.%2BB.%26atitle%3DInteractions%2520of%2520the%2520novel%2520antipsychotic%2520aripiprazole%2520%2528OPC-14597%2529%2520with%2520dopamine%2520and%2520serotonin%2520receptor%2520subtypes%26jtitle%3DNeuropsychopahrmacology%26date%3D1999%26volume%3D20%26spage%3D612%26epage%3D627" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit17b"><span><span class="NLM_contrib-group">Burstein, e. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ma, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wong, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gao, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pahrm., E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Knapp, A. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nash, N. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Olsson, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Davis, R. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hacksell, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weiner, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brann, M. R.</span><span> </span><span class="NLM_article-title">Intrinsic efficacy of antipsychotics at human D<sub>2</sub>, D<sub>3</sub>, and D<sub>4</sub> dopamine receptors: Identification of the clozapine metabolite <i>N</i>-desmethylclozapine as a D<sub>2</sub>/D<sub>3</sub> partial agonist</span> <span class="citation_source-journal">J. Pharmacol. Exp. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">315</span><span class="NLM_x">, </span> <span class="NLM_fpage">1278</span><span class="NLM_x">â</span> <span class="NLM_lpage">1287</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17b&amp;dbid=16&amp;doi=10.1021%2Fjm200682b&amp;key=10.1124%2Fjpet.105.092155" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17b&amp;dbid=8&amp;doi=10.1021%2Fjm200682b&amp;key=16135699" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17b&amp;dbid=32&amp;doi=10.1021%2Fjm200682b&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhtlalurnL" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=315&publication_year=2005&pages=1278-1287&author=e.+S.+Bursteinauthor=J.+Maauthor=S.+Wongauthor=Y.+Gaoauthor=E.+Pahrm.author=A.+E.+Knappauthor=N.+R.+Nashauthor=R.+Olssonauthor=R.+E.+Davisauthor=U.+Hacksellauthor=D.+M.+Weinerauthor=M.+R.+Brann&title=Intrinsic+efficacy+of+antipsychotics+at+human+D2%2C+D3%2C+and+D4+dopamine+receptors%3A+Identification+of+the+clozapine+metabolite+N-desmethylclozapine+as+a+D2%2FD3+partial+agonist"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit17bR"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Intrinsic efficacy of antipsychotics at human D2, D3, and D4 dopamine receptors: Identification of the clozapine metabolite N-desmethylclozapine as a D2/D3 partial agonist</span></div><div class="casAuthors">Burstein, E. S.; Ma, J.; Wong, S.; Gao, Y.; Pham, E.; Knapp, A. E.; Nash, N. R.; Olsson, R.; Davis, R. E.; Hacksell, U.; Weiner, D. M.; Brann, M. R.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">315</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">1278-1287</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Drugs that antagonize D2-like receptors are effective antipsychotics, but the debilitating movement disorder side effects assocd. with these drugs cannot be dissocd. from dopamine receptor blockade.  The "atypical" antipsychotics have a lower propensity to cause extrapyramidal symptoms (EPS), but the mol. basis for this is not fully understood nor is the impact of inverse agonism upon their clin. properties.  Using a cell-based functional assay, we demonstrate that overexpression of GÎ±o induces constitutive activity in the human D2-like receptors (D2, D3, and D4).  A large collection of typical and atypical antipsychotics was profiled for activity at these receptors.  Virtually all were D2 and D3 inverse agonists, whereas none was D4 inverse agonist, although many were potent D4 antagonists.  The inverse agonist activity of haloperidol at D2 and D3 receptors could be reversed by mesoridazine demonstrating that there were significant differences in the degrees of inverse agonism among the compds. tested.  Aripiprazole and the principle active metabolite of clozapine NDMC [8-chloro-11-(1-piperazinyl)-5H-dibenzo [b,e] [1,4] diazepine] were identified as partial agonists at D2 and D3 receptors, although clozapine itself was an inverse agonist at these receptors.  NDMC-induced functional responses could be reversed by clozapine.  It is proposed that the low incidence of EPS assocd. with clozapine and aripiprazole used may be due, in part, to these partial agonist properties of NDMC and aripiprazole and that bypassing clozapine blockade through direct administration of NDMC to patients may provide superior antipsychotic efficacy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpJpq7vgFnG8rVg90H21EOLACvtfcHk0lh4caYBSO-reA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhtlalurnL&md5=327fe47435bf8fa5215af0d2af4b3b40</span></div><a href="/servlet/linkout?suffix=cit17b&amp;dbid=16384&amp;doi=10.1124%2Fjpet.105.092155&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.105.092155%26sid%3Dliteratum%253Aachs%26aulast%3DBurstein%26aufirst%3De.%2BS.%26aulast%3DMa%26aufirst%3DJ.%26aulast%3DWong%26aufirst%3DS.%26aulast%3DGao%26aufirst%3DY.%26aulast%3DPahrm.%26aufirst%3DE.%26aulast%3DKnapp%26aufirst%3DA.%2BE.%26aulast%3DNash%26aufirst%3DN.%2BR.%26aulast%3DOlsson%26aufirst%3DR.%26aulast%3DDavis%26aufirst%3DR.%2BE.%26aulast%3DHacksell%26aufirst%3DU.%26aulast%3DWeiner%26aufirst%3DD.%2BM.%26aulast%3DBrann%26aufirst%3DM.%2BR.%26atitle%3DIntrinsic%2520efficacy%2520of%2520antipsychotics%2520at%2520human%2520D2%252C%2520D3%252C%2520and%2520D4%2520dopamine%2520receptors%253A%2520Identification%2520of%2520the%2520clozapine%2520metabolite%2520N-desmethylclozapine%2520as%2520a%2520D2%252FD3%2520partial%2520agonist%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2005%26volume%3D315%26spage%3D1278%26epage%3D1287" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group">Oshiro, Y.; Sato, S.; Kurahashi, N.</span> (<div class="note"><p class="first last">Otsuka Pharmaceutical Co., Japan</p></div>) <span> </span><span class="NLM_article-title">Carbostyril derivatives</span>. U.S. Patent 5,006,528, <span class="NLM_month">April</span><span class="NLM_day">9</span>,<span class="NLM_x"> </span><span class="NLM_year">1991</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=1991&author=Y.+Oshiro&author=S.+Sato&author=N.+Kurahashi&title=Carbostyril+derivatives"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DOshiro%26aufirst%3DY.%26atitle%3DCarbostyril%2520derivatives%26date%3D1991" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19a"><span><span class="NLM_contrib-group">Kang, S. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Park, E.-J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Park, W.-K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, H. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jeong, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jung, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Song, K.-S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, S. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Seo, H. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Han, H.-K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Son, E.-J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pae, A. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, J.</span><span> </span><span class="NLM_article-title">Arylpiperazine-containing pyrrole 3-carboxamide derivatives targeting serotonin 5-HT<sub>2A,</sub> 5-HT<sub>2c,</sub> and the serotonin transporter as a potential antidepressant</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">20</span><span class="NLM_x">, </span> <span class="NLM_fpage">1705</span><span class="NLM_x">â</span> <span class="NLM_lpage">1711</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2010&pages=1705-1711&author=S.+Y.+Kangauthor=E.-J.+Parkauthor=W.-K.+Parkauthor=H.+J.+Kimauthor=D.+Jeongauthor=M.+E.+Jungauthor=K.-S.+Songauthor=S.+H.+Leeauthor=H.+J.+Seoauthor=M.+J.+Kimauthor=M.+Leeauthor=H.-K.+Hanauthor=E.-J.+Sonauthor=A.+N.+Paeauthor=J.+Kimauthor=J.+Lee&title=Arylpiperazine-containing+pyrrole+3-carboxamide+derivatives+targeting+serotonin+5-HT2A%2C+5-HT2c%2C+and+the+serotonin+transporter+as+a+potential+antidepressant"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit19a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DKang%26aufirst%3DS.%2BY.%26aulast%3DPark%26aufirst%3DE.-J.%26aulast%3DPark%26aufirst%3DW.-K.%26aulast%3DKim%26aufirst%3DH.%2BJ.%26aulast%3DJeong%26aufirst%3DD.%26aulast%3DJung%26aufirst%3DM.%2BE.%26aulast%3DSong%26aufirst%3DK.-S.%26aulast%3DLee%26aufirst%3DS.%2BH.%26aulast%3DSeo%26aufirst%3DH.%2BJ.%26aulast%3DKim%26aufirst%3DM.%2BJ.%26aulast%3DLee%26aufirst%3DM.%26aulast%3DHan%26aufirst%3DH.-K.%26aulast%3DSon%26aufirst%3DE.-J.%26aulast%3DPae%26aufirst%3DA.%2BN.%26aulast%3DKim%26aufirst%3DJ.%26aulast%3DLee%26aufirst%3DJ.%26atitle%3DArylpiperazine-containing%2520pyrrole%25203-carboxamide%2520derivatives%2520targeting%2520serotonin%25205-HT2A%252C%25205-HT2c%252C%2520and%2520the%2520serotonin%2520transporter%2520as%2520a%2520potential%2520antidepressant%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2010%26volume%3D20%26spage%3D1705%26epage%3D1711" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit19b"><span><span class="NLM_contrib-group">Kang, S. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Park, E.-J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Park, W.-K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, H. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Choi, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jung, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Seo, H. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pae, A. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, J.</span><span> </span><span class="NLM_article-title">Further optimization of novel pyrrole 3-carboxamides for targeting serotonin 5-HT<sub>2A</sub>, 5-HT<sub>2c</sub>, and the serotonin transporter as a potential antidepressant</span> <span class="citation_source-journal">Bioorg. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">18</span><span class="NLM_x">, </span> <span class="NLM_fpage">6156</span><span class="NLM_x">â</span> <span class="NLM_lpage">6169</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2010&pages=6156-6169&author=S.+Y.+Kangauthor=E.-J.+Parkauthor=W.-K.+Parkauthor=H.+J.+Kimauthor=G.+Choiauthor=M.+E.+Jungauthor=H.+J.+Seoauthor=M.+J.+Kimauthor=A.+N.+Paeauthor=J.+Kimauthor=J.+Lee&title=Further+optimization+of+novel+pyrrole+3-carboxamides+for+targeting+serotonin+5-HT2A%2C+5-HT2c%2C+and+the+serotonin+transporter+as+a+potential+antidepressant"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit19b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DKang%26aufirst%3DS.%2BY.%26aulast%3DPark%26aufirst%3DE.-J.%26aulast%3DPark%26aufirst%3DW.-K.%26aulast%3DKim%26aufirst%3DH.%2BJ.%26aulast%3DChoi%26aufirst%3DG.%26aulast%3DJung%26aufirst%3DM.%2BE.%26aulast%3DSeo%26aufirst%3DH.%2BJ.%26aulast%3DKim%26aufirst%3DM.%2BJ.%26aulast%3DPae%26aufirst%3DA.%2BN.%26aulast%3DKim%26aufirst%3DJ.%26aulast%3DLee%26aufirst%3DJ.%26atitle%3DFurther%2520optimization%2520of%2520novel%2520pyrrole%25203-carboxamides%2520for%2520targeting%2520serotonin%25205-HT2A%252C%25205-HT2c%252C%2520and%2520the%2520serotonin%2520transporter%2520as%2520a%2520potential%2520antidepressant%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2010%26volume%3D18%26spage%3D6156%26epage%3D6169" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit19c"><span><span class="NLM_contrib-group">Kim, J. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kang, S. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Park, W.-K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, H. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jung, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Son, E.-J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pae, A. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, J.</span><span> </span><span class="NLM_article-title">Arylpiperazine-containing pyrimidine 4-carboxamide derivatives targeting serotonin 5-HT<sub>2A</sub>, 5-HT<sub>2c</sub>, and the serotonin transporter as a potential antidepressant</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">20</span><span class="NLM_x">, </span> <span class="NLM_fpage">6439</span><span class="NLM_x">â</span> <span class="NLM_lpage">6442</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2010&pages=6439-6442&author=J.+Y.+Kimauthor=D.+Kimauthor=S.+Y.+Kangauthor=W.-K.+Parkauthor=H.+J.+Kimauthor=M.+E.+Jungauthor=E.-J.+Sonauthor=A.+N.+Paeauthor=J.+Kimauthor=J.+Lee&title=Arylpiperazine-containing+pyrimidine+4-carboxamide+derivatives+targeting+serotonin+5-HT2A%2C+5-HT2c%2C+and+the+serotonin+transporter+as+a+potential+antidepressant"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit19c&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DKim%26aufirst%3DJ.%2BY.%26aulast%3DKim%26aufirst%3DD.%26aulast%3DKang%26aufirst%3DS.%2BY.%26aulast%3DPark%26aufirst%3DW.-K.%26aulast%3DKim%26aufirst%3DH.%2BJ.%26aulast%3DJung%26aufirst%3DM.%2BE.%26aulast%3DSon%26aufirst%3DE.-J.%26aulast%3DPae%26aufirst%3DA.%2BN.%26aulast%3DKim%26aufirst%3DJ.%26aulast%3DLee%26aufirst%3DJ.%26atitle%3DArylpiperazine-containing%2520pyrimidine%25204-carboxamide%2520derivatives%2520targeting%2520serotonin%25205-HT2A%252C%25205-HT2c%252C%2520and%2520the%2520serotonin%2520transporter%2520as%2520a%2520potential%2520antidepressant%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2010%26volume%3D20%26spage%3D6439%26epage%3D6442" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group">Lange, J. H. M.; Stuivenberg, H. H. V.; Vliet, B. J. V.</span> (<div class="note"><p class="first last">Solvay Pharmaceuticals</p></div>) <span> </span><span class="NLM_article-title">1<i>H</i>-imidazole derivatives as cannabinoid CB2 receptor modulators</span>. U.S. Patent Application 2006/0194779, <span class="NLM_month">August</span><span class="NLM_day">31</span>,<span class="NLM_x"> </span><span class="NLM_year">2006</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2006&author=J.+H.+M.+Lange&author=H.+H.+V.+Stuivenberg&author=B.+J.+V.+Vliet&title=1H-imidazole+derivatives+as+cannabinoid+CB2+receptor+modulators"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DLange%26aufirst%3DJ.%2BH.%2BM.%26atitle%3D1H-imidazole%2520derivatives%2520as%2520cannabinoid%2520CB2%2520receptor%2520modulators%26date%3D2006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21a"><span><span class="NLM_contrib-group">Lange, J. H. M.</span><span class="NLM_etal"></span><span> </span><span class="NLM_article-title">Bioisosteric replacements of the pyrazole moiety of rimonabant: Synthesis, biological properties, and molecular modeling investigations of thiazoles, triazoles, and imidazoles as potent and selective CB1 cannabinoid receptor antagonists</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">48</span><span class="NLM_x">, </span> <span class="NLM_fpage">1823</span><span class="NLM_x">â</span> <span class="NLM_lpage">1838</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm040843r" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref21/cit21a&amp;dbid=32&amp;doi=10.1021%2Fjm200682b&amp;key=1%3ACAS%3A528%3ADC%252BD2cXnvFSrsLg%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=2005&pages=1823-1838&author=J.+H.+M.+Lange&title=Bioisosteric+replacements+of+the+pyrazole+moiety+of+rimonabant%3A+Synthesis%2C+biological+properties%2C+and+molecular+modeling+investigations+of+thiazoles%2C+triazoles%2C+and+imidazoles+as+potent+and+selective+CB1+cannabinoid+receptor+antagonists"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit21aR"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Bioisosteric Replacements of the Pyrazole Moiety of Rimonabant: Synthesis, Biological Properties, and Molecular Modeling Investigations of Thiazoles, Triazoles, and Imidazoles as Potent and Selective CB1 Cannabinoid Receptor Antagonists</span></div><div class="casAuthors">Lange, Jos H. M.; van Stuivenberg, Herman H.; Coolen, Hein K. A. C.; Adolfs, Tiny J. P.; McCreary, Andrew C.; Keizer, Hiskias G.; Wals, Henri C.; Veerman, Willem; Borst, Alice J. M.; de Looff, Wouter; Verveer, Peter C.; Kruse, Chris G.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">48</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1823-1838</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Series of thiazoles, triazoles, and imidazoles were designed as bioisosteres, based on the 1,5-diarylpyrazole motif that is present in the potent CB1 receptor antagonist rimonabant.  A no. of target compds. were synthesized and evaluated in cannabinoid (hCB1 and hCB2) receptor assays.  The thiazoles, triazoles, and imidazoles elicited in vitro CB1 antagonistic activities and in general exhibited considerable CB1 vs CB2 receptor subtype selectivities, thereby demonstrating to be cannabinoid bioisosteres of the original diarylpyrazole class.  Some key representatives in the imidazole series showed potent pharmacol. in vivo activities after oral administration in both a CB agonist-induced hypotension model and a CB agonist-induced hypothermia model.  Mol. modeling studies showed a close three-dimensional structural overlap between the imidazole I and rimonabant.  A structure-activity relationship (SAR) study revealed a close correlation between the biol. results in the imidazole and pyrazole series.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp16SsR1EEEVbVg90H21EOLACvtfcHk0lijCkcksYFyIA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXnvFSrsLg%253D&md5=c3b80380a273d7f69a33c812a45e0154</span></div><a href="/servlet/linkout?suffix=cit21a&amp;dbid=16384&amp;doi=10.1021%2Fjm040843r&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm040843r%26sid%3Dliteratum%253Aachs%26aulast%3DLange%26aufirst%3DJ.%2BH.%2BM.%26atitle%3DBioisosteric%2520replacements%2520of%2520the%2520pyrazole%2520moiety%2520of%2520rimonabant%253A%2520Synthesis%252C%2520biological%2520properties%252C%2520and%2520molecular%2520modeling%2520investigations%2520of%2520thiazoles%252C%2520triazoles%252C%2520and%2520imidazoles%2520as%2520potent%2520and%2520selective%2520CB1%2520cannabinoid%2520receptor%2520antagonists%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2005%26volume%3D48%26spage%3D1823%26epage%3D1838" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit21b"><span><span class="NLM_contrib-group">Kim, J. Y.</span><span class="NLM_etal"></span><span> </span><span class="NLM_article-title">Diarylimidazolyl oxadiazole and thiadiazole derivatives as cannabinoid CB1 receptor antagonists</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x">, </span> <span class="NLM_fpage">142</span><span class="NLM_x">â</span> <span class="NLM_lpage">145</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2009&pages=142-145&author=J.+Y.+Kim&title=Diarylimidazolyl+oxadiazole+and+thiadiazole+derivatives+as+cannabinoid+CB1+receptor+antagonists"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit21b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DKim%26aufirst%3DJ.%2BY.%26atitle%3DDiarylimidazolyl%2520oxadiazole%2520and%2520thiadiazole%2520derivatives%2520as%2520cannabinoid%2520CB1%2520receptor%2520antagonists%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2009%26volume%3D19%26spage%3D142%26epage%3D145" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group">Smith, R. A.; OâConnor, S. J.; Wirtz, S.-N.; Wong, W. C.; Choi, S.; Kluender, H. C. E.; Su, N.; Wang, G.; Achebe, F.; Ying, S.</span> (<div class="note"><p class="first last">Bayer Pharmaceuticals Co.</p></div>) <span> </span><span class="NLM_article-title">Imidazole-4-carboxamide derivatives, preparation and use thereof for treatment of obesity</span>. WO 03/040107, <span class="NLM_month">May</span><span class="NLM_day">15</span>,<span class="NLM_x"> </span><span class="NLM_year">2003</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2003&author=R.+A.+Smith&author=S.+J.+O%E2%80%99Connor&author=S.-N.+Wirtz&author=W.+C.+Wong&author=S.+Choi&author=H.+C.+E.+Kluender&author=N.+Su&author=G.+Wang&author=F.+Achebe&author=S.+Ying&title=Imidazole-4-carboxamide+derivatives%2C+preparation+and+use+thereof+for+treatment+of+obesity"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DSmith%26aufirst%3DR.%2BA.%26atitle%3DImidazole-4-carboxamide%2520derivatives%252C%2520preparation%2520and%2520use%2520thereof%2520for%2520treatment%2520of%2520obesity%26date%3D2003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span class="NLM_contrib-group">Buettelmann, B.; Ceccarelli, S. M.; Jaeschke, G.; Kolczewski, S.; Porter, R. H. P.; Vieira, E.</span> (<div class="note"><p class="first last">F. Hoffmann-La Roche AG</p></div>) <span> </span><span class="NLM_article-title">Imidazole derivatives III</span>. WO 2005/003117, <span class="NLM_month">January</span><span class="NLM_day">13</span>,<span class="NLM_x"> </span><span class="NLM_year">2005</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2005&author=B.+Buettelmann&author=S.+M.+Ceccarelli&author=G.+Jaeschke&author=S.+Kolczewski&author=R.+H.+P.+Porter&author=E.+Vieira&title=Imidazole+derivatives+III"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DBuettelmann%26aufirst%3DB.%26atitle%3DImidazole%2520derivatives%2520III%26date%3D2005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><span class="NLM_contrib-group">Robarge, M. J.</span><span class="NLM_etal"></span><span> </span><span class="NLM_article-title">Design and synthesis of [(2,3-dichlorophenyl)piperazin-1-yl]alkylfluorenylcarboxamides as novel ligands selective for the dopamine D<sub>3</sub> receptor subtype</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">44</span><span class="NLM_x">, </span> <span class="NLM_fpage">3175</span><span class="NLM_x">â</span> <span class="NLM_lpage">3186</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm010146o" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=44&publication_year=2001&pages=3175-3186&author=M.+J.+Robarge&title=Design+and+synthesis+of+%5B%282%2C3-dichlorophenyl%29piperazin-1-yl%5Dalkylfluorenylcarboxamides+as+novel+ligands+selective+for+the+dopamine+D3+receptor+subtype"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1021%2Fjm010146o&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm010146o%26sid%3Dliteratum%253Aachs%26aulast%3DRobarge%26aufirst%3DM.%2BJ.%26atitle%3DDesign%2520and%2520synthesis%2520of%2520%255B%25282%252C3-dichlorophenyl%2529piperazin-1-yl%255Dalkylfluorenylcarboxamides%2520as%2520novel%2520ligands%2520selective%2520for%2520the%2520dopamine%2520D3%2520receptor%2520subtype%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2001%26volume%3D44%26spage%3D3175%26epage%3D3186" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25"><span><span class="NLM_contrib-group">Park, W.-K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jeong, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cho, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cha, M. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pae, A. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Choi, K. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koh, H. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kong, J. Y.</span><span> </span><span class="NLM_article-title">KKHA-761, a potent D<sub>3</sub> receptor antagonist with high 5-HT<sub>1A</sub> receptor affinity, exhibits antipsychotic properties in animal models of schizophrenia</span> <span class="citation_source-journal">Pharmacol., Biochem. Behav.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">82</span><span class="NLM_x">, </span> <span class="NLM_fpage">361</span><span class="NLM_x">â</span> <span class="NLM_lpage">372</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=82&publication_year=2005&pages=361-372&author=W.-K.+Parkauthor=D.+Jeongauthor=H.+Choauthor=S.+J.+Leeauthor=M.+Y.+Chaauthor=A.+N.+Paeauthor=K.+I.+Choiauthor=H.+Y.+Kohauthor=J.+Y.+Kong&title=KKHA-761%2C+a+potent+D3+receptor+antagonist+with+high+5-HT1A+receptor+affinity%2C+exhibits+antipsychotic+properties+in+animal+models+of+schizophrenia"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DPark%26aufirst%3DW.-K.%26aulast%3DJeong%26aufirst%3DD.%26aulast%3DCho%26aufirst%3DH.%26aulast%3DLee%26aufirst%3DS.%2BJ.%26aulast%3DCha%26aufirst%3DM.%2BY.%26aulast%3DPae%26aufirst%3DA.%2BN.%26aulast%3DChoi%26aufirst%3DK.%2BI.%26aulast%3DKoh%26aufirst%3DH.%2BY.%26aulast%3DKong%26aufirst%3DJ.%2BY.%26atitle%3DKKHA-761%252C%2520a%2520potent%2520D3%2520receptor%2520antagonist%2520with%2520high%25205-HT1A%2520receptor%2520affinity%252C%2520exhibits%2520antipsychotic%2520properties%2520in%2520animal%2520models%2520of%2520schizophrenia%26jtitle%3DPharmacol.%252C%2520Biochem.%2520Behav.%26date%3D2005%26volume%3D82%26spage%3D361%26epage%3D372" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit26"><span><span class="NLM_contrib-group">Chiu, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marcoe, K. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bounds, S. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, C. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Feng, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cheng, F. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Crumb, W. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mitchell, R.</span><span> </span><span class="NLM_article-title">Validation of a [<sup>3</sup>H]Astemizole binding assay in HEK293 cells expressing HERG K<sup>+</sup> channels</span> <span class="citation_source-journal">J. Pharmacol. Sci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">95</span><span class="NLM_x">, </span> <span class="NLM_fpage">311</span><span class="NLM_x">â</span> <span class="NLM_lpage">319</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Fjm200682b&amp;key=10.1254%2Fjphs.FPE0040101" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Fjm200682b&amp;key=15272206" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Fjm200682b&amp;key=1%3ACAS%3A528%3ADC%252BD2cXmtFeksbs%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=95&publication_year=2004&pages=311-319&author=P.+J.+Chiuauthor=K.+F.+Marcoeauthor=S.+E.+Boundsauthor=C.+H.+Linauthor=J.+J.+Fengauthor=A.+Linauthor=F.+C.+Chengauthor=W.+J.+Crumbauthor=R.+Mitchell&title=Validation+of+a+%5B3H%5DAstemizole+binding+assay+in+HEK293+cells+expressing+HERG+K%2B+channels"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Validation of a [3H]astemizole binding assay in HEK293 cells expressing HERG K+ channels</span></div><div class="casAuthors">Chiu, Peter J. S.; Marcoe, Karen F.; Bounds, Sidney E.; Lin, Chun-Hsiung; Feng, Jin-Jye; Lin, Atsui; Cheng, Fong-Chi; Crumb, William J.; Mitchell, Richard</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacological Sciences (Tokyo, Japan)</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">95</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">311-319</span>CODEN:
                <span class="NLM_cas:coden">JPSTGJ</span>;
        ISSN:<span class="NLM_cas:issn">1347-8613</span>.
    
            (<span class="NLM_cas:orgname">Japanese Pharmacological Society</span>)
        </div><div class="casAbstract">A radioligand binding assay for the HERG (human ether-a-go-go-related gene) K+ channel was developed to identify compds. which may have inhibitory activity and potential cardiotoxicity.  Pharmacol. characterization of the [3H]astemizole binding assay for HERG K+ channels was performed using HERG-expressing HEK293 cells.  The assay conditions employed yielded 90% specific binding using 10 Î¼g/well of membrane protein with 1.5 nM of [3H]astemizole at 25Â°.  The Kd and Bmax values were 5.91Â±0.81 nM and 6.36Â±0.26 pmol/mg, resp.  The intraassay and interassay variations were 11.4% and 14.9%, resp.  Binding affinities for 32 ref. compds. (including dofetilide, cisapride, and terfenadine) with diverse structures demonstrated a similar potency rank order for HERG inhibition to that reported in the literature.  Moreover, the [3H]astemizole binding data demonstrated a rank order of affinity that was highly correlated to that of inhibitory potency in the electrophysiol. studies for HERG in HEK293 (rSP=0.91, P<0.05).  In conclusion, the [3H]astemizole binding assay is rapid and capable of detecting HERG inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrGxk529fo22rVg90H21EOLACvtfcHk0lg9qZ_YQ5YPgw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXmtFeksbs%253D&md5=2e75917b530755e7c039c22deff36908</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1254%2Fjphs.FPE0040101&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1254%252Fjphs.FPE0040101%26sid%3Dliteratum%253Aachs%26aulast%3DChiu%26aufirst%3DP.%2BJ.%26aulast%3DMarcoe%26aufirst%3DK.%2BF.%26aulast%3DBounds%26aufirst%3DS.%2BE.%26aulast%3DLin%26aufirst%3DC.%2BH.%26aulast%3DFeng%26aufirst%3DJ.%2BJ.%26aulast%3DLin%26aufirst%3DA.%26aulast%3DCheng%26aufirst%3DF.%2BC.%26aulast%3DCrumb%26aufirst%3DW.%2BJ.%26aulast%3DMitchell%26aufirst%3DR.%26atitle%3DValidation%2520of%2520a%2520%255B3H%255DAstemizole%2520binding%2520assay%2520in%2520HEK293%2520cells%2520expressing%2520HERG%2520K%252B%2520channels%26jtitle%3DJ.%2520Pharmacol.%2520Sci.%26date%3D2004%26volume%3D95%26spage%3D311%26epage%3D319" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit27a"><span><span class="NLM_contrib-group">Ostroff, R. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nelson, J. C.</span><span> </span><span class="NLM_article-title">Risperidone augmentation of selective serotonin reuptake inhibitors in major depression</span> <span class="citation_source-journal">J. Clin. Psychiatry</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1999</span><span class="NLM_x">, </span> <span class="NLM_volume">60</span><span class="NLM_x">, </span> <span class="NLM_fpage">256</span><span class="NLM_x">â</span> <span class="NLM_lpage">259</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27a&amp;dbid=16&amp;doi=10.1021%2Fjm200682b&amp;key=10.4088%2FJCP.v60n0410" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27a&amp;dbid=8&amp;doi=10.1021%2Fjm200682b&amp;key=10221288" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27a&amp;dbid=32&amp;doi=10.1021%2Fjm200682b&amp;key=1%3ACAS%3A528%3ADyaK1MXivFekuro%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=1999&pages=256-259&author=R.+B.+Ostroffauthor=J.+C.+Nelson&title=Risperidone+augmentation+of+selective+serotonin+reuptake+inhibitors+in+major+depression"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit27aR"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Risperidone augmentation of selective serotonin reuptake inhibitors in major depression</span></div><div class="casAuthors">Ostroff, Robert B.; Nelson, J. Craig</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Psychiatry</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">256-259</span>CODEN:
                <span class="NLM_cas:coden">JCLPDE</span>;
        ISSN:<span class="NLM_cas:issn">0160-6689</span>.
    
            (<span class="NLM_cas:orgname">Physicians Postgraduate Press, Inc.</span>)
        </div><div class="casAbstract">Background: At low doses, risperidone acts as a 5-HT2 antagonist.  Preclin. data suggest 5-HT2 antagonists may enhance the action of serotonin.  This report examines the clin. use of risperidone to augment selective serotonin reuptake inhibitor (SSRI) antidepressants in patients who have not responded to SSRI therapy.  Method: In 8 patients with major depressive disorder without psychotic features (DSM-IV) who had not responded to an SSRI, risperidone was added to the ongoing SSRI treatment.  Hamilton Rating Scale for Depression scores were obtained before and after the addn. of risperidone.  Results: These 8 patients remitted within 1 wk of the addn. of risperidone.  Risperidone also appeared to have beneficial effects on sleep disturbance and sexual dysfunction.  Conclusion: Risperidone may be a useful adjunct to SSRIs in the treatment of depression.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoESVKe73GdRLVg90H21EOLACvtfcHk0lg9qZ_YQ5YPgw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXivFekuro%253D&md5=a438999ad3a5c6cf6d8a432f533d7d6d</span></div><a href="/servlet/linkout?suffix=cit27a&amp;dbid=16384&amp;doi=10.4088%2FJCP.v60n0410&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4088%252FJCP.v60n0410%26sid%3Dliteratum%253Aachs%26aulast%3DOstroff%26aufirst%3DR.%2BB.%26aulast%3DNelson%26aufirst%3DJ.%2BC.%26atitle%3DRisperidone%2520augmentation%2520of%2520selective%2520serotonin%2520reuptake%2520inhibitors%2520in%2520major%2520depression%26jtitle%3DJ.%2520Clin.%2520Psychiatry%26date%3D1999%26volume%3D60%26spage%3D256%26epage%3D259" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit27b"><span><span class="NLM_contrib-group">Shelton, R. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tollefson, G. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tohen, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stahl, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gannon, K. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jacobs, T. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buras, W. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bymaster, F. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Spencer, K. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Feldman, P. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meltzer, H. Y.</span><span> </span><span class="NLM_article-title">A novel augmentation strategy for treating resistant major depression</span> <span class="citation_source-journal">Am. J. Psychiatry.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">158</span><span class="NLM_x">, </span> <span class="NLM_fpage">131</span><span class="NLM_x">â</span> <span class="NLM_lpage">134</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27b&amp;dbid=16&amp;doi=10.1021%2Fjm200682b&amp;key=10.1176%2Fappi.ajp.158.1.131" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27b&amp;dbid=8&amp;doi=10.1021%2Fjm200682b&amp;key=11136647" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27b&amp;dbid=32&amp;doi=10.1021%2Fjm200682b&amp;key=1%3ACAS%3A280%3ADC%252BD3M7isVCgsw%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=158&publication_year=2001&pages=131-134&author=R.+C.+Sheltonauthor=G.+D.+Tollefsonauthor=M.+Tohenauthor=S.+Stahlauthor=K.+S.+Gannonauthor=T.+G.+Jacobsauthor=W.+R.+Burasauthor=F.+P.+Bymasterauthor=W.+Zhangauthor=K.+A.+Spencerauthor=P.+D.+Feldmanauthor=H.+Y.+Meltzer&title=A+novel+augmentation+strategy+for+treating+resistant+major+depression"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit27bR"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">A novel augmentation strategy for treating resistant major depression</span></div><div class="casAuthors">Shelton R C; Tollefson G D; Tohen M; Stahl S; Gannon K S; Jacobs T G; Buras W R; Bymaster F P; Zhang W; Spencer K A; Feldman P D; Meltzer H Y</div><div class="citationInfo"><span class="NLM_cas:title">The American journal of psychiatry</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">158</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">131-4</span>
        ISSN:<span class="NLM_cas:issn">0002-953X</span>.
    </div><div class="casAbstract">OBJECTIVE:  Treatment-resistant depression is a significant public health concern; drug switching or augmentation often produce limited results.  The authors hypothesized that fluoxetine could be augmented with olanzapine to successfully treat resistant depression.  METHOD:  An 8-week double-blind study was conducted with 28 patients who were diagnosed with recurrent, nonbipolar, treatment-resistant depression without psychotic features.  Subjects were randomly assigned to one of three groups: olanzapine plus placebo, fluoxetine plus placebo, or olanzapine plus fluoxetine.  RESULTS:  Fluoxetine monotherapy produced minimal improvement on various scales that rate severity of depression.  The benefits of olanzapine monotherapy were modest.  Olanzapine plus fluoxetine produced significantly greater improvement than either monotherapy on one measure and significantly greater improvement than olanzapine monotherapy on the other measures after 1 week.  There were no significant differences between treatment groups on extrapyramidal measures nor significant adverse drug interactions.  CONCLUSIONS:  Olanzapine plus fluoxetine demonstrated superior efficacy for treating resistant depression compared to either agent alone.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTbFiAxqdsjlHp3bfzSLaX5fW6udTcc2eay9AMaQNpVELntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD3M7isVCgsw%253D%253D&md5=d6138dcb65d8be1b2dc6d67e34af364e</span></div><a href="/servlet/linkout?suffix=cit27b&amp;dbid=16384&amp;doi=10.1176%2Fappi.ajp.158.1.131&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1176%252Fappi.ajp.158.1.131%26sid%3Dliteratum%253Aachs%26aulast%3DShelton%26aufirst%3DR.%2BC.%26aulast%3DTollefson%26aufirst%3DG.%2BD.%26aulast%3DTohen%26aufirst%3DM.%26aulast%3DStahl%26aufirst%3DS.%26aulast%3DGannon%26aufirst%3DK.%2BS.%26aulast%3DJacobs%26aufirst%3DT.%2BG.%26aulast%3DBuras%26aufirst%3DW.%2BR.%26aulast%3DBymaster%26aufirst%3DF.%2BP.%26aulast%3DZhang%26aufirst%3DW.%26aulast%3DSpencer%26aufirst%3DK.%2BA.%26aulast%3DFeldman%26aufirst%3DP.%2BD.%26aulast%3DMeltzer%26aufirst%3DH.%2BY.%26atitle%3DA%2520novel%2520augmentation%2520strategy%2520for%2520treating%2520resistant%2520major%2520depression%26jtitle%3DAm.%2520J.%2520Psychiatry.%26date%3D2001%26volume%3D158%26spage%3D131%26epage%3D134" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit27c"><span><span class="NLM_contrib-group">Carpenter, L. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yasmin, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Price, L. H.</span><span> </span><span class="NLM_article-title">A double-blind, placebo-controlled study of antidepressant augmentation with mirtazapine</span> <span class="citation_source-journal">Biol. Psychiatry</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">51</span><span class="NLM_x">, </span> <span class="NLM_fpage">183</span><span class="NLM_x">â</span> <span class="NLM_lpage">188</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27c&amp;dbid=16&amp;doi=10.1021%2Fjm200682b&amp;key=10.1016%2FS0006-3223%2801%2901262-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27c&amp;dbid=8&amp;doi=10.1021%2Fjm200682b&amp;key=11822997" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27c&amp;dbid=32&amp;doi=10.1021%2Fjm200682b&amp;key=1%3ACAS%3A528%3ADC%252BD38Xos1CitA%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2002&pages=183-188&author=L.+L.+Carpenterauthor=S.+Yasminauthor=L.+H.+Price&title=A+double-blind%2C+placebo-controlled+study+of+antidepressant+augmentation+with+mirtazapine"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit27cR"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">A double-blind, placebo-controlled study of antidepressant augmentation with Mirtazapine</span></div><div class="casAuthors">Carpenter, Linda L.; Yasmin, Sarah; Price, Lawrence H.</div><div class="citationInfo"><span class="NLM_cas:title">Biological Psychiatry</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">51</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">183-188</span>CODEN:
                <span class="NLM_cas:coden">BIPCBF</span>;
        ISSN:<span class="NLM_cas:issn">0006-3223</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Inc.</span>)
        </div><div class="casAbstract">Background: A previous pilot study of open-label mirtazapine augmentation conducted by the authors in 20 depressed patients yielded a 55% response rate at week 4.  A double-blind controlled trial was undertaken to further elucidate the efficacy of this intervention.  Methods: 26 adult outpatients with persistent major depression despite adequate antidepressant monotherapy were randomized to receive 4 wk of mirtazapine or placebo augmentation.  Mirtazapine was begun at 15 mg at bedtime, with possible titrn. to 30 mg at bedtime per physician's discretion after week 1.  Results: Categorical pos. response rate at end point was 64% for active drug and 20% for placebo.  Remission rates were 45.4% and 13.3% for active drug and placebo groups, resp., Mirtazapine demonstrated statistically significant superiority to placebo on most major outcome measures, and was assocd. with improvement in overall functioning and quality of life.  There were no significant group differences with regard to emergent side effects, wt. change, or serum concns. of primary antidepressants.  Conclusions: Mirtazapine appears safe and effective for short-term antidepressant augmentation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp1FktNE8OvDbVg90H21EOLACvtfcHk0lgt-1UgwLRraw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38Xos1CitA%253D%253D&md5=1a2e576459c244a9d8d39b1f9442ba2e</span></div><a href="/servlet/linkout?suffix=cit27c&amp;dbid=16384&amp;doi=10.1016%2FS0006-3223%2801%2901262-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0006-3223%252801%252901262-8%26sid%3Dliteratum%253Aachs%26aulast%3DCarpenter%26aufirst%3DL.%2BL.%26aulast%3DYasmin%26aufirst%3DS.%26aulast%3DPrice%26aufirst%3DL.%2BH.%26atitle%3DA%2520double-blind%252C%2520placebo-controlled%2520study%2520of%2520antidepressant%2520augmentation%2520with%2520mirtazapine%26jtitle%3DBiol.%2520Psychiatry%26date%3D2002%26volume%3D51%26spage%3D183%26epage%3D188" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref28"><div class="reference"><strong class="refLabel"><a href="#ref28" class="rightTabRefNumLink">28</a></strong><div class="NLM_citation" id="rightTab-cit28"><span><span class="NLM_contrib-group">Marek, G. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carpenter, L. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McDougle, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Price, L. H.</span><span> </span><span class="NLM_article-title">Synergistic action of 5-HT<sub>2A</sub> antagonists and selective serotonin reuptake inhibitors in neuropsychiatric disorders</span> <span class="citation_source-journal">Neuropsychopharmacology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">28</span><span class="NLM_x">, </span> <span class="NLM_fpage">402</span><span class="NLM_x">â</span> <span class="NLM_lpage">412</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2003&pages=402-412&author=G.+J.+Marekauthor=L.+L.+Carpenterauthor=C.+J.+McDougleauthor=L.+H.+Price&title=Synergistic+action+of+5-HT2A+antagonists+and+selective+serotonin+reuptake+inhibitors+in+neuropsychiatric+disorders"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMarek%26aufirst%3DG.%2BJ.%26aulast%3DCarpenter%26aufirst%3DL.%2BL.%26aulast%3DMcDougle%26aufirst%3DC.%2BJ.%26aulast%3DPrice%26aufirst%3DL.%2BH.%26atitle%3DSynergistic%2520action%2520of%25205-HT2A%2520antagonists%2520and%2520selective%2520serotonin%2520reuptake%2520inhibitors%2520in%2520neuropsychiatric%2520disorders%26jtitle%3DNeuropsychopharmacology%26date%3D2003%26volume%3D28%26spage%3D402%26epage%3D412" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref29"><div class="reference"><strong class="refLabel"><a href="#ref29" class="rightTabRefNumLink">29</a></strong><div class="NLM_citation" id="rightTab-cit29"><span><span class="NLM_contrib-group">Porsolt, R. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bertin, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jalfre, M.</span><span> </span><span class="NLM_article-title">âBehavioural despairâ in rats and mice: Strain differences and the effects of imipramine</span> <span class="citation_source-journal">Eur. J. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1978</span><span class="NLM_x">, </span> <span class="NLM_volume">51</span><span class="NLM_x">, </span> <span class="NLM_fpage">291</span><span class="NLM_x">â</span> <span class="NLM_lpage">294</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Fjm200682b&amp;key=10.1016%2F0014-2999%2878%2990414-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Fjm200682b&amp;key=568552" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Fjm200682b&amp;key=1%3ACAS%3A528%3ADyaE1MXkvVCksg%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=1978&pages=291-294&author=R.+D.+Porsoltauthor=A.+Bertinauthor=M.+Jalfre&title=%E2%80%9CBehavioural+despair%E2%80%9D+in+rats+and+mice%3A+Strain+differences+and+the+effects+of+imipramine"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">"Behavioral despair" in rats and mice:  strain differences and the effects of imipramine</span></div><div class="casAuthors">Porsolt, Roger D.; Bertin, Anne; Jalfre, Maurice</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Pharmacology</span>
        (<span class="NLM_cas:date">1978</span>),
    <span class="NLM_cas:volume">51</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">291-4</span>CODEN:
                <span class="NLM_cas:coden">EJPHAZ</span>;
        ISSN:<span class="NLM_cas:issn">0014-2999</span>.
    </div><div class="casAbstract">Imipramine-HCl (I-HCl)  [113-52-0] dose-dependently decreased the immobility of Sprague-Dawley and Wistar/Charles River strains of rats forced to swim in a restricted space; I, however, had no effects on the immobility in Wistar/Iffa Credo rats.  I decreased the immobility in 3 different strain of mice, although a significant base-line strain difference was obsd. with the 3 strains without I pretreatment.  The results are discussed with regard to possible strain differences in the behavioral effects of pharmacol. agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrMNU10A5PpWLVg90H21EOLACvtfcHk0lgt-1UgwLRraw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaE1MXkvVCksg%253D%253D&md5=629df41e4ba1ea421f084411086a7f57</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1016%2F0014-2999%2878%2990414-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0014-2999%252878%252990414-4%26sid%3Dliteratum%253Aachs%26aulast%3DPorsolt%26aufirst%3DR.%2BD.%26aulast%3DBertin%26aufirst%3DA.%26aulast%3DJalfre%26aufirst%3DM.%26atitle%3D%25E2%2580%259CBehavioural%2520despair%25E2%2580%259D%2520in%2520rats%2520and%2520mice%253A%2520Strain%2520differences%2520and%2520the%2520effects%2520of%2520imipramine%26jtitle%3DEur.%2520J.%2520Pharmacol.%26date%3D1978%26volume%3D51%26spage%3D291%26epage%3D294" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li><li id="pane-m3" aria-labelledby="pane-m3" class="tab__pane tab__pane-suppInfo empty"><h2 class="supp-info-label">Supporting Information</h2><div class="article_supporting-info" id="rightTab-notes-1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-rightTab-_i45"><a href="/doi/suppl/10.1021/jm200682b">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a class="" href="#"><span>Jump To</span><i class="icon-angle-down"></i></a><div class="dropBlock__holder" data-db-target-of="sectionsDB_10137"></div></div></div></div></div><hr /></hr><p class="last">Experimental procedures for molecules not described in main paper text and <sup>1</sup>H NMR, <sup>13</sup>C NMR, and HPLC spectrum data for compounds <b>57</b>, <b>68</b>, <b>70</b>, <b>71</b>, <b>100</b>, <b>131</b>, <b>143</b>, and <b>145</b>. This material is available free of charge via the Internet at <a class="extLink" href="http://pubs.acs.org">http://pubs.acs.org</a>.</p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/jm200682b/suppl_file/jm200682b_si_001.pdf">jm200682b_si_001.pdf (7.74 MB)</a></li></ul></div></div><div id="rightTab-figshare-widget"></div><br /></br><div class="TermsAndConditionsDropzoneRight" data-pb-dropzone="TermsAndConditionsDropzoneRight"><div data-widget-def="UX3HTMLWidget" data-widget-id="b84e6b6c-b4d0-4427-b286-3cf14d52d013" class="mb-4">
        



        
        <h2 style="font-size: 1rem;margin-bottom: 10px;">Terms & Conditions</h2>
<p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system:
<a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div></div></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Fjm200682b&amp;pbContext=%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Barticle%3Aarticle%3A10.1021%2Fjm200682b%3Bwgroup%3Astring%3AACHS+website+Group%3Bwebsite%3Awebsite%3Aacspubs%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2011.54.issue-18%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Supporting Information" data-slide-target=".tab__pane-suppInfo" class="w-slide__btn slide-active"><i class="icon-supporting-info"></i><span>Supporting Information</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/jm200682b" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                2MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright Â© 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">Youâve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"679916379917d1ef","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.7.0","si":10}'></script>
</body>
</html>
